tvty-10q_20200630.htm

0001564590-20-038169.txt : 20200807 0001564590-20-038169.hdr.sgml : 20200807 20200807114842 ACCESSION NUMBER: 0001564590-20-038169 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 86 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200807 DATE AS OF CHANGE: 20200807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TIVITY HEALTH, INC. CENTRAL INDEX KEY: 0000704415 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 621117144 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19364 FILM NUMBER: 201084491 BUSINESS ADDRESS: STREET 1: 701 COOL SPRINGS BOULEVARD CITY: FRANKLIN STATE: TN ZIP: 37067 BUSINESS PHONE: 6156144929 MAIL ADDRESS: STREET 1: 701 COOL SPRINGS BOULEVARD CITY: FRANKLIN STATE: TN ZIP: 37067 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHWAYS, INC. DATE OF NAME CHANGE: 20170104 FORMER COMPANY: FORMER CONFORMED NAME: TIVITY HEALTH, INC DATE OF NAME CHANGE: 20161230 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHWAYS, INC DATE OF NAME CHANGE: 20060201 10-Q 1 tvty-10q_20200630.htm 10-Q tvty-10q_20200630.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Quarterly Period Ended June 30, 2020

☐Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from _____ to _____

Commission file number 000-19364

TIVITY HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware		62-1117144
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

701 Cool Springs Boulevard, Franklin, TN 37067

(Address of principal executive offices) (Zip code)

(800) 869-5311

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock - $.001 par value		TVTY		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒

No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒

No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐	Smaller reporting company	☐
Non-accelerated filer	☐			Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐

No ☒

As of August 4, 2020, there were outstanding 48,560,369 shares of the registrant’s common stock, par value $.001 per share (“Common Stock”).

Tivity Health, Inc.

Form 10-Q

Table of Contents

			Page
Part I
	Item 1.	Financial Statements	3
	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	28
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	45
	Item 4.	Controls and Procedures	46

Part II
	Item 1.	Legal Proceedings	47
	Item 1A.	Risk Factors	47
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	62
	Item 6.	Exhibits	63

PART I

Item 1. Financial Statements

TIVITY HEALTH, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

(Unaudited)

	June 30, 2020			December 31, 2019
Current assets:
Cash and cash equivalents	$	60,274		$	2,486
Accounts receivable, net		36,339			97,596
Inventories		22,088			36,407
Prepaid expenses		15,058			18,255
Other current assets		8,110			6,993
Total current assets		141,869			161,737

Property and equipment, net of accumulated depreciation of $53,525 and $42,510 respectively		52,436			52,909
Right-of-use assets, operating leases		35,300			41,518
Right-of-use assets, finance leases		1,356			1,680
Intangible assets, net		593,520			689,686
Goodwill, net		535,135			654,635
Other assets		21,554			23,740
Total assets	$	1,381,170		$	1,625,905

Current liabilities:
Accounts payable	$	35,492		$	46,480
Accrued salaries and benefits		10,539			13,071
Accrued liabilities		42,020			55,663
Deferred revenue		12,440			12,037
Income taxes payable		7,835			405
Current portion of operating lease liabilities		13,157			13,131
Current portion of finance lease liabilities		644			624
Current portion of long-term debt		9,775			—
Current portion of other long-term liabilities		15,664			4,947
Total current liabilities		147,566			146,358

Long-term debt		1,002,547			1,048,127
Long-term operating lease liabilities		23,515			30,321
Long-term finance lease liabilities		753			1,080
Long-term deferred tax liability		137,205			160,846
Other long-term liabilities		31,863			12,263

Commitments and contingent liabilities

Stockholders' equity:
Preferred stock $.001 par value, 5,000,000 shares authorized, none outstanding		—			—
Common Stock $.001 par value, 120,000,000 shares authorized, 48,548,741 and 48,156,786 shares outstanding, respectively		48			48
Additional paid-in capital		505,760			504,419
Accumulated deficit		(406,840	)		(237,284	)
Treasury stock, at cost, 2,254,953 shares in treasury		(28,182	)		(28,182	)
Accumulated other comprehensive loss		(33,065	)		(12,091	)
Total stockholders' equity		37,721			226,910
Total liabilities and stockholders' equity	$	1,381,170		$	1,625,905

See accompanying notes to the consolidated financial statements.

TIVITY HEALTH, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except earnings per share data)

(Unaudited)

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020			2019
Revenues:
Services	$	79,856	$	157,481	$	239,548		$	314,008
Products		182,742		182,896		360,705			240,463
Total revenues		262,598		340,377		600,253			554,471

Cost of revenue:
Services (exclusive of depreciation of $2,240, $1,503, $4,071, and $2,859, respectively, included below)		31,886		111,073		147,034			224,916
Products (exclusive of depreciation and amortization of $8,587, $5,861, $19,280, and $7,488, respectively, included below)		86,355		83,685		170,363			110,181
Total cost of revenue		118,241		194,758		317,397			335,097

Marketing expenses		51,105		54,603		138,177			78,751
Selling, general and administrative expenses		23,471		29,667		51,480			56,852
Depreciation and amortization		12,919		9,084		27,682			12,666
Impairment loss		—		—		199,500			—
Restructuring and related charges		1,009		2,352		1,752			3,943
Operating income (loss)		55,853		49,913		(135,735	)		67,162

Interest expense		21,235		23,661		42,898			31,328
Income (loss) before income taxes		34,618		26,252		(178,633	)		35,834

Income tax expense (benefit)		6,107		8,115		(9,038	)		13,483
Net income (loss)		28,511		18,137		(169,595	)		22,351

Earnings (loss) per share:
Basic	$	0.59	$	0.38	$	(3.49	)	$	0.49
Diluted ⁽¹⁾	$	0.58	$	0.37	$	(3.49	)	$	0.49

Comprehensive income (loss)	$	27,366	$	5,901	$	(190,569	)	$	10,115

Weighted average common shares and equivalents:
Basic		48,711		47,790		48,662			45,165
Diluted ⁽¹⁾		48,794		48,461		48,662			45,719

(1)

The impact of potentially dilutive securities for the six months ended June 30, 2020 was not considered because the impact would be anti-dilutive.

See accompanying notes to the consolidated financial statements.

TIVITY HEALTH, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Net income (loss)	$	28,511		$	18,137		$	(169,595	)	$	22,351
Net change in fair value of interest rate swaps, net of income tax benefit of $393, $4,068, $7,195, and $4,068, respectively		(1,145	)		(12,236	)		(20,974	)		(12,236	)
Comprehensive income (loss)	$	27,366		$	5,901		$	(190,569	)	$	10,115

See accompanying notes to the consolidated financial statements.

TIVITY HEALTH, INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

For the Three and Six Months Ended June 30, 2020 and 2019

(In thousands)

(Unaudited)

	Preferred Stock		Common Stock		Additional Paid-in Capital			Retained Earnings (Accumulated Deficit)			Treasury Stock			Accumulated Other Comprehensive Loss			Total
Balance, March 31, 2019	$	—	$	47	$	491,548		$	53,751		$	(28,182	)	$	—		$	517,164
Comprehensive income (loss)		—		—		—			18,137			—			(12,236	)		5,901
Exercise of stock options		—		—		137			—			—			—			137
Tax withholding for share-based compensation		—		—		(794	)		—			—			—			(794	)
Share-based employee compensation expense		—		—		6,898			—			—			—			6,898
Balance, June 30, 2019	$	—	$	47	$	497,789		$	71,888		$	(28,182	)	$	(12,236	)	$	529,306

Balance, December 31, 2018	$	—	$	41	$	347,487		$	49,655		$	(28,182	)	$	—		$	369,001
Comprehensive income (loss)		—		—		—			22,351			—			(12,236	)		10,115
Issuance of Common Stock in connection with Merger		—		6		132,832			—			—			—			132,838
Share-based compensation replacement awards related to Merger and attributable to pre- combination services		—		—		9,107			—			—			—			9,107
Exercise of stock options		—		—		370			—			—			—			370
Tax withholding for share-based compensation		—		—		(1,135	)		—			—			—			(1,135	)
Share-based employee compensation expense		—		—		9,257			—			—			—			9,257
Other		—		—		(129	)		(118	)		—			—			(247	)
Balance, June 30, 2019	$	—	$	47	$	497,789		$	71,888		$	(28,182	)	$	(12,236	)	$	529,306

Balance, March 31, 2020	$	—	$	48	$	503,049		$	(435,371	)	$	(28,182	)	$	(31,920	)	$	7,624
Comprehensive income (loss)		—		—		—			28,511			—			(1,145	)		27,366
Tax withholding for share-based compensation		—		—		(154	)		—			—			—			(154	)
Share-based employee compensation expense		—		—		2,865			—			—			—			2,865
Other		—		—		—			20			—			—			20
Balance, June 30, 2020	$	—	$	48	$	505,760		$	(406,840	)	$	(28,182	)	$	(33,065	)	$	37,721

Balance, December 31, 2019	$	—	$	48	$	504,419		$	(237,284	)	$	(28,182	)	$	(12,091	)	$	226,910
Comprehensive income (loss)		—		—		—			(169,595	)		—			(20,974	)		(190,569	)
Exercise of stock options		—		—		601			—			—			—			601
Tax withholding for share-based compensation		—		—		(2,949	)		—			—			—			(2,949	)
Share-based employee compensation expense		—		—		3,689			—			—			—			3,689
Other		—		—		—			39			—			—			39
Balance, June 30, 2020	$	—	$	48	$	505,760		$	(406,840	)	$	(28,182	)	$	(33,065	)	$	37,721

See accompanying notes to the consolidated financial statements.

TIVITY HEALTH, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Six Months Ended June 30,
	2020			2019
Cash flows from operating activities:
Net income (loss)	$	(169,595	)	$	22,351
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization		27,682			12,666
Amortization and write-off of deferred loan costs		2,315			3,073
Amortization of debt discount		2,049			389
Share-based employee compensation expense		3,689			9,257
Impairment of goodwill and intangible assets		199,500			—
Deferred income taxes		(16,447	)		10,789
Decrease (increase) in accounts receivable, net		61,257			(3,754	)
Decrease in inventory		14,319			8,719
Decrease in other current assets		1,363			1,057
Increase (decrease) in accounts payable		9,411			(5,872	)
(Decrease) increase in accrued salaries and benefits		(2,532	)		570
Decrease in other current liabilities		(5,925	)		(8,266	)
Increase (decrease) in deferred revenue		403			(2,725	)
Other		3,454			1,345
Net cash flows provided by operating activities	$	130,943		$	49,599

Cash flows from investing activities:
Acquisition of property and equipment	$	(10,362	)	$	(8,918	)
Business acquisitions, net of cash acquired		—			(1,062,818	)
Net cash flows used in investing activities	$	(10,362	)	$	(1,071,736	)

Cash flows from financing activities:
Proceeds from issuance of long-term debt	$	196,525		$	1,399,945
Payments of long-term debt		(236,375	)		(347,879	)
Payments related to tax withholding for share-based compensation		(2,949	)		(1,135	)
Exercise of stock options		601			370
Deferred loan costs		—			(30,189	)
Principal payments related to financing leases		(306	)		(22	)
Change in cash overdraft and other		(20,289	)		3,530
Net cash flows (used in) provided by financing activities	$	(62,793	)	$	1,024,620

Effect of exchange rate changes on cash	$	—		$	(12	)

Net increase in cash and cash equivalents	$	57,788		$	2,471

Cash and cash equivalents, beginning of period	$	2,486		$	1,933

Cash and cash equivalents, end of period	$	60,274		$	4,404

See accompanying notes to the consolidated financial statements.

TIVITY HEALTH, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1.	Basis of Presentation and Recent Developments

Our financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In our opinion, the accompanying consolidated financial statements of Tivity Health^®, Inc. and its wholly-owned subsidiaries, including the results of Nutrisystem^®, Inc. (“Nutrisystem”) acquired on March 8, 2019 (collectively, “Tivity Health,” the “Company,” or such terms as “we,” “us,” or “our”) reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement. In preparing our consolidated financial statements in conformity with U.S. GAAP, management must make estimates and assumptions that affect: (1) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements; and (2) the reported amounts of revenues and expenses during the reporting period. By their nature, estimates are subject to an inherent degree of uncertainty. Due to the significant uncertainty relating to the potential future impacts of the coronavirus pandemic on our business and the overall market, actual results could differ from those estimates, including, but not limited to, estimates of fair value of goodwill and indefinite-lived intangible assets, allowances for doubtful accounts, and valuation allowances on deferred tax assets. Our consolidated statements of operations include results of Nutrisystem from March 8, 2019 forward. We have reclassified certain items in prior periods to conform to current classifications.

Following the acquisition of Nutrisystem (the “Merger”), we organize and manage our operations within two reportable segments, based on the types of products and services they offer: Healthcare and Nutrition. The Healthcare segment is comprised of our legacy business and includes SilverSneakers^® senior fitness, Prime^® Fitness, WholeHealth Living^®and Wisely Well^TM. The Nutrition segment is comprised of Nutrisystem’s legacy business and includes the Nutrisystem^® and the South Beach Diet^®programs.

We have omitted certain financial information that is normally included in financial statements prepared in accordance with U.S. GAAP but that is not required for interim reporting purposes. You should read the accompanying consolidated financial statements in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019.

Recent Developments

In January 2020, the Secretary of the U.S. Department of Health and Human Services (“HHS”) declared a national public health emergency due to a novel strain of coronavirus, which causes the disease known as “COVID-19”. In March 2020, the World Health Organization characterized the outbreak of COVID-19 as a global pandemic, and COVID-19 continues to spread throughout the United States and other countries. Many state and local governments, together with public health officials, have recommended and mandated precautions to mitigate the spread of COVID-19, including ordering closure of certain businesses and imposing stay-at-home orders and social distancing guidelines for individuals. Such measures have resulted in significantly reduced demand for many businesses that have continued in operation.

By March 31, 2020, substantially all of the fitness centers in our national network were temporarily closed, which had an adverse impact on the results of operations in our Healthcare segment for the first quarter of 2020 because a significant portion of our Healthcare segment revenues from our SilverSneakers program is based on member visits to a fitness partner location. A substantial number of our fitness partner locations remained closed through April, with some locations reopening in May and additional locations reopening in June. For the month of June 2020, approximately 66% of our fitness partner locations reported at least one visit from our SilverSneakers program. For the second quarter of 2020, the average monthly total participation levels of our SilverSneakers members were significantly below historical levels, and we also experienced a decline in paid subscribers for Prime Fitness, each of which adversely impacted revenues in our Healthcare segment.

We do not believe that COVID-19-related developments had a material impact on the results of operations or cash flows of our Nutrition segment for the first or second quarters of 2020. While overall we did not experience any significant disruptions, interruptions, or increased costs related to our supply chain, inventory, or distribution channels as a result of COVID-19, we experienced delays in fulfilling orders for our Nutrition segment’s products at certain of our warehouses due to some employees of our fulfillment provider testing positive for COVID-19. As a result, we incurred incremental expense of $1.3 million in the second quarter related to increased labor rates and

overtime for employees of our fulfillment provider as well as additional shipping and related charges as we transferred the fulfillment of certain orders to other warehouses that were farther from the customer’s delivery destination.

We have taken a number of actions in response to the pandemic, including the following:

•

Given the continued uncertainty surrounding COVID-19, in March 2020, we borrowed $75 million under our Revolving Credit Facility as a precautionary measure to increase our cash position and maintain financial flexibility. We repaid such $75 million in full in June 2020. As of June 30, 2020, outstanding debt under our credit agreement was $1,012.3 million, and we had $60.3 million of cash and cash equivalents. In July 2020, we repaid $24.8 million of principal on the term loans under our credit agreement, resulting in our next required quarterly installment being due in December 2021. As of June 30, 2020, we had a working capital deficit of $5.7 million. While the COVID-19 pandemic has created significant uncertainty as to general economic and market conditions for the remainder of 2020 and beyond, as of the date of this report, we believe our cash on hand, expected cash flows from operations, and anticipated available credit under the Credit Agreement (as defined below) will be sufficient to fund our operations, principal and interest payments, and capital expenditures for the next 12 months.

•

We are taking a variety of measures to ensure the availability and functioning of our critical infrastructure, to promote the safety and security of our employees and to support the communities in which we operate. These measures include implementing remote working arrangements for employees where practicable. We are following public and private sector policies and initiatives to reduce the transmission of COVID-19, such as the imposition of travel restrictions, the promotion of social distancing, and the adoption of work-from-home arrangements.

•

We are focused on preserving our liquidity and managing our cash flow, including, but not limited to, managing our working capital, optimizing tax savings under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) and other COVID-19-related legislation, curtailing capital expenditures, reducing discretionary spending, and reducing compensation costs.

In April 2020, we furloughed 13% of our approximately 1,000 employees. In June 2020, some of these furloughed employees’ positions were eliminated (in addition to other position eliminations, resulting in approximately 8% of our employees being terminated), and we extended the furlough for substantially all of the remaining furloughed employees through the end of 2020. Also in June 2020, we placed an additional 2% of our total employees on furlough through the end of 2020.

Also in April 2020, the Compensation Committee of the Company’s Board of Directors (the “Board”) approved a 25% reduction in base salary for the Company’s executive officers and certain other employees for the period from April 20, 2020 through August 23, 2020. In June 2020, the Compensation Committee determined to extend such reductions in base salary through December 31, 2020. Additionally, the Board approved a 100% reduction in the annual cash retainer and annual committee retainers payable to non-management members of the Board who stood for reelection at the 2020 Annual Meeting of Stockholders (except for Daniel G. Tully who does not receive compensation for his service on the Board) for a period of four months, beginning May 1, 2020 or as soon thereafter as reasonably practicable. In June 2020, the Board determined to extend such reduction in cash compensation to the Board through December 31, 2020.

Effective at the end of July 2020, the Compensation Committee suspended the Company matching contribution to the Company’s 401(k) plan.

Nutrition business unit as well as the fair value of the Nutrisystem tradename were below their carrying amounts, and we recorded an impairment loss of $199.5 million, including $80.0 million related to the Nutrisystem tradename and $119.5 million related to goodwill allocated to the Nutrition segment. There were no impairment triggers during the second quarter of 2020 related to our goodwill or indefinite-lived intangible assets.

2.	Recent Relevant Accounting Standards

In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-04, “Reference Rate Reform (“ASC 848”): Facilitation of the Effects of Reference Rate Reform on Financial Reporting”. ASC 848 contains temporary optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform, such as a transition away from the use of LIBOR. ASC 848 was effective for the Company as of January 1, 2020. The provisions of ASC 848 are available through December 31, 2022, at which time the reference rate replacement activity is expected to have been completed. The provisions of ASC 848 must be applied at a Topic, Subtopic or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. The accounting relief provided by ASC 848 is applicable only to legacy contracts if the amendments made to the agreements are solely for reference rate reform activities. Modifications that are unrelated to reference rate reform will scope out a given contract. ASC 848 allows for different elections to be made at different points in time, and the timing of those elections will be documented as applicable. For the avoidance of doubt, we intend to reassess the elections of optional expedients and exceptions included within ASC 848 related to our hedging activities and will document the election of these items on a quarterly basis. In March 2020, we elected the expedient that allows us to assume that our hedged interest payments are probable of occurring regardless of any expected modification in their terms related to reference rate reform. In addition, we have the option to change the method of assessing effectiveness upon a change in the critical terms of the derivative or the hedged transactions and upon the end of relief under ASC 848. In June 2020, we elected to (i) continue the method of assessing effectiveness as documented in the original hedge documentation and (ii) apply the expedient wherein the reference rate on the hypothetical derivative matches the reference rate on the hedging instrument. We will also apply the aforementioned elections to any future designated cash flow hedging relationship.

In October 2018, the FASB issued ASU 2018-16, "Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (“SOFR”) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes" (“ASU 2018-16”), which adds the OIS rate based on SOFR as a U.S. benchmark interest rate to facilitate the LIBOR to SOFR transition and provide lead time for entities to prepare for changes to interest rate risk hedging strategies. ASU 2018-16 is effective for fiscal years beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. As of March 31, 2020, the benchmark interest rate in our existing interest rate swap agreements is LIBOR. The adoption of this standard did not have an impact on our financial position, results of operations, or cash flows.

In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other” (“ASU 2017-04”), which simplifies the subsequent measurement of goodwill by eliminating step two from the goodwill impairment test. ASU 2017-04 is effective for annual and interim impairment tests in fiscal years beginning after December 15, 2019 and is required to be applied prospectively. Early adoption is allowed for annual goodwill impairment tests performed on testing dates after January 1, 2017. We adopted ASU 2017-04 on October 1, 2019. As further discussed in Note 12, we recorded impairment losses related to goodwill during the fourth quarter of 2019 and the first quarter of 2020.

In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”), which changes the fair value measurement disclosure requirements of ASC 820. ASU 2018-13 is effective for fiscal years beginning on or after December 15, 2019, including interim periods therein, and is generally required to be applied retrospectively, except for certain components that are to be applied prospectively. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

In August 2018, the FASB issued ASU No. 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract,” which requires implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the arrangement, if those costs would be capitalized by the customer in a software licensing arrangement. This standard is effective for annual periods beginning after December 15, 2019, and interim periods within those fiscal

years. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), which requires companies to measure credit losses for financial assets held at the reporting date utilizing a methodology that reflects current expected credit losses over the lifetime of such assets. ASU 2016-13 was effective for the Company on January 1, 2020 and is generally required to be applied using the modified retrospective approach, with limited exceptions for specific instruments. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

3.	Revenue Recognition

We account for revenue from contracts with customers in accordance with Accounting Standards Codification (“ASC”) Topic 606. The unit of account in ASC Topic 606 is a performance obligation, which is a promise in a contract to transfer to a customer either a distinct good or service (or bundle of goods or services) or a series of distinct goods or services provided over a period of time. ASC Topic 606 requires that a contract's transaction price, which is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, is to be allocated to each performance obligation in the contract based on relative standalone selling prices and recognized as revenue when or as the performance obligation is satisfied.

Healthcare Segment

Our Healthcare segment earns revenue from three programs, SilverSneakers senior fitness, Prime Fitness and WholeHealth Living. We provide the SilverSneakers senior fitness program to members of Medicare Advantage and Medicare Supplement plans through our contracts with such plans. We offer Prime Fitness, a fitness facility access program, through contracts with commercial health plans, employers, and other sponsoring organizations that allow their members to individually purchase the program. We sell our WholeHealth Living program primarily to health plans.

Except for Prime Fitness, our Healthcare segment’s customer contracts generally have initial terms of approximately three years. Some contracts allow the customer to terminate early and/or determine on an annual basis to which of their members they will offer our programs. For Prime Fitness, our contracts with commercial health plans, employers, and other sponsoring organizations generally have initial terms of approximately three years, while individuals who purchase the Prime Fitness program through these organizations may cancel at any time (on a monthly basis) after an initial period of one to three months. The significant majority of our Healthcare segment’s customer contracts contain one performance obligation - to stand ready to provide access to our network of fitness locations and fitness programming - which is satisfied over time as services are rendered each month over the contract term. There are generally no performance obligations that are unsatisfied at the end of a particular month. There was no material revenue recognized during the three and six months ended June 30, 2020 from performance obligations satisfied in a prior period.

Our fees within the Healthcare segment are variable month to month and are generally billed per member per month (“PMPM”) or billed based on a combination of PMPM and member visits to a network location. We bill PMPM fees by multiplying the contractually negotiated PMPM rate by the number of members eligible for or receiving our services during the month. We bill for member visits approximately one month in arrears once actual member visits are known. Payments from customers are typically due within 30 days of invoice date. When material, we capitalize costs to obtain contracts with customers and amortize them over the expected recovery period. At June 30, 2020 and December 31, 2019, $0.7 million and $0.5 million, respectively, of such costs were capitalized. During the three and six months ended June 30, 2020 and 2019, the amortization of such capitalized costs was immaterial.

Our Healthcare segment’s customer contracts include variable consideration, which is allocated to each distinct month over the contract term based on eligible members and/or member visits each month. The allocated consideration corresponds directly with the value to our customers of our services completed for the month. Under the majority of our Healthcare segment’s contracts, we recognize revenue each month using the practical expedient available under ASC 606-10-55-18, which provides that revenue is recognized in the amount for which we have the right to invoice. ASC 606-10-50-14(b) provides an optional exemption, which we have elected to apply, from disclosing remaining performance obligations when revenue is recognized from the satisfaction of the performance obligation in accordance with the “right to invoice” practical expedient.

The following table sets forth Healthcare revenue disaggregated by program. Revenue from our SilverSneakers program is predominantly contracted with Medicare Advantage and Medicare Supplement plans.

(In thousands)	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
SilverSneakers	$	49,157	$	122,899	$	170,764	$	245,922
Prime Fitness		19,047		29,751		51,858		58,494
WholeHealth Living		4,747		4,467		9,796		9,041
Other ⁽¹⁾		8,972		364		9,197		551
	$	81,923	$	157,481	$	241,615	$	314,008

(1)

For the three and six months ended June 30, 2020, other revenue in the table above includes $6.8 million from a well-being program with a large employer as well as $2.1 million of Wisely Well revenue.

Sales and usage-based taxes are excluded from revenues.

Nutrition Segment

Our Nutrition segment earns revenue from four sources: direct to consumer, retail, QVC and other. Revenue is measured based on the consideration specified in a contract with a customer and excludes any sales incentives and amounts collected on behalf of third parties. As explained in more detail below, revenue is recognized upon satisfaction of the performance obligation by transferring control over a product to a Nutrition segment customer. Direct-mail advertising costs are expensed as incurred. We recognize an asset for the carrying amount of product to be returned and for costs to obtain a contract if the amortization is more than one year in duration. We expense costs to obtain a contract as incurred if the amortization period is less than one year.

We sell pre-packaged foods directly to weight loss program participants primarily through the Internet and telephone (referred to as the direct to consumer channel), through QVC (a television shopping network), and select retailers. Pre-packaged foods include both frozen and non-frozen (ready-to-go), shelf-stable products.

Products sold through the direct to consumer channel, both frozen and non-frozen, may be sold separately (a la carte) or as part of a packaged monthly meal plan for which Nutrition segment customers pay at the point of sale. Products sold through QVC are payable by QVC upon our shipment of the product to the end consumer. For both the direct to consumer channel and QVC, we recognize revenue at a point in time, i.e., at the shipping point. Direct to consumer customers may return unopened ready-to-go Nutrisystem products within 30 days after purchase in order to receive a refund or credit. Frozen Nutrisystem products are refundable only if the order is canceled within 14 days after delivery. South Beach Diet products are not refundable.

Products sold to retailers include both frozen and non-frozen products and are payable by the retailer upon receipt. We recognize revenue at a point in time, i.e., when the retailers take possession of the product. Certain retailers have the right to return unsold products.

We account for the shipment of frozen and non-frozen, ready-to-go products as separate performance obligations. The consideration, including variable consideration for product returns, is allocated between frozen and non-frozen products based on their standalone selling prices. The amount of revenue recognized is adjusted for expected returns, which are estimated based on historical data.

In addition to our pre-packaged foods, we sell prepaid gift cards through a wholesaler that are redeemable through the Internet or telephone. Prepaid gift cards represent grants of rights to goods to be provided in the future to gift card buyers. The wholesaler has the right to return all unsold prepaid gift cards. The wholesaler’s retail selling price of the gift cards is deferred in the balance sheet and recognized as revenue when we have satisfied our performance obligation, i.e., when a gift card holder redeems the gift card with us. We recognize breakage amounts (the estimated amount of unused gift cards) as revenue, in proportion to the actual gift card redemptions exercised by gift card holders in relation to the total expected redemptions of gift cards. We utilize historical experience in estimating the total expected breakage and period over which the gift cards will be redeemed.

Sales and other taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a Nutrition segment customer are excluded from revenue and presented on a net basis. After control over a product has transferred to a Nutrition segment customer, shipping and handling costs associated with outbound freight are accounted for as a fulfillment cost and are included in revenue and cost of revenue in the accompanying consolidated statements of operations. Revenue from shipping and handling charges was $6.5 million and $13.0 million for the three and six months ended June 30, 2020, respectively, and $6.3 million and $8.1 million for the three and six months ended June 30, 2019 (from March 8, 2019 forward), respectively.

The following table sets forth Nutrition segment revenue, from March 8, 2019 forward, disaggregated by the source of revenue:

(In thousands)	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Nutrisystem direct to consumer	$	165,118	$	155,976	$	320,509	$	203,977
South Beach Diet direct to consumer		8,650		14,464	$	21,414		19,118
Retail		3,902		8,728		9,350		13,032
QVC		2,901		3,522		7,088		4,044
Other		104		206		277		292
	$	180,675	$	182,896	$	358,638	$	240,463

The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:

(In thousands)	June 30, 2020		December 31, 2019
Contract assets	$	243	$	95
Contract liabilities	$	10,937	$	10,911

The contract assets primarily relate to unbilled accounts receivable and are included as other current assets in the accompanying consolidated balance sheet. The contract liabilities (deferred revenue) primarily relate to sale of prepaid gift cards and unshipped foods, which are deferred until such time as the Company has satisfied its performance obligations.

Significant changes in the contract liabilities (deferred revenue) balance during the period are as follows:

	Three Months Ended June 30,			Six Months Ended June 30,
(In thousands)	2020			2020
Revenue recognized that was included in the contract liability (deferred revenue) balance on January 1, 2020	$	(2,395	)	$	(8,112	)
Increases due to cash received for prepaid gift cards sold or unshipped food, excluding amounts recognized as revenue, and (decreases) due to returns	$	(71	)	$	8,138

The following table includes estimated revenue from the prepaid gift cards expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) at the end of the reporting period:

(In thousands)
Remaining 2020	$	1,789
2021		1,901
2022		1,192
2023		468
2024		297
2025		220
	$	5,867

We apply the practical expedient in subtopic ASC 606-10-50-14 and do not disclose information about remaining performance obligations that have original expected durations of one year or less.

We review the reserves for our Nutrition segment customer returns at each reporting period and adjust them to reflect data available at that time. To estimate reserves for returns, we consider actual return rates in preceding periods and changes in product offerings or marketing methods that might impact returns going forward. To the extent the estimate of returns changes, we will adjust the reserve, which will impact the amount of revenue recognized in the period of the adjustment. The provision for estimated returns for the three and six months ended June 30, 2020 was $4.1 million and $9.3 million, respectively, and $5.6 million and $7.0 million for the three and six months ended June 30, 2019 (from March 8, 2019 forward), respectively. At June 30, 2020 and December 31, 2019, the reserve for estimated returns incurred but not received and processed was $1.4 million and $0.8 million, respectively, and has been included in accrued liabilities in the accompanying consolidated balance sheet.

4.	Inventories

Inventories consist principally of packaged food held in external fulfillment locations. We value inventories at the lower of cost or net realizable value, with cost determined using the first-in, first-out method. We continually assess quantities of inventory on hand to identify excess or obsolete inventory and record a provision for any estimated loss. We estimate the reserve for excess and obsolete inventory primarily on forecasted demand and/or our ability to sell the products, our ability to introduce new products, future production requirements, and changes in consumer behavior. The reserve for excess and obsolete inventory was $2.0 million and $1.8 million at June 30, 2020 and December 31, 2019, respectively.

5.	Intangible Assets and Goodwill

The COVID-19 pandemic has had and is having an adverse impact on the overall economy, resulting in rapidly changing market and economic conditions that have impacted the Company. In March 2020, we experienced a significant decline in the Company’s market capitalization and in the actual and forecasted operating results of our Healthcare segment, in addition to the unfavorable change in market conditions. As a result, management concluded that there were triggering events during the first quarter of 2020 necessitating an impairment evaluation of our goodwill and indefinite-lived intangible assets. Through this evaluation, management concluded that the fair value of goodwill allocated to the Nutrition business unit as well as the fair value of the Nutrisystem tradename were below their carrying amounts, and in the first quarter of 2020, we recorded impairment losses of $80.0 million and $119.5 million related to the Nutrisystem tradename and goodwill, respectively (see Note 12). A reconciliation of our goodwill balance is as follows:

(In thousands)	Healthcare		Nutrition			Consolidated
Balance, January 1, 2020	$	334,680	$	319,955		$	654,635
Impairment loss		—		(119,500	)	$	(119,500	)
Balance, June 30, 2020	$	334,680	$	200,455		$	535,135

At June 30, 2020 and December 31, 2019, intangible assets not subject to amortization consist of tradenames of $509.0 million and $589.0 million, respectively.

6.	Marketing Expenses

Marketing expense includes media, advertising production, marketing and promotional expenses and payroll-related expenses, including share-based payment arrangements, for personnel engaged in these activities. Media expense was $45.1 million and $122.4 million for the three and six months ended June 30, 2020, respectively, and $47.3 million and $67.5 million for the three and six months ended June 30, 2019 (from March 8, 2019 forward), respectively. Internet advertising expense is recorded based on either the rate of delivery of a guaranteed number of impressions over the advertising contract term or on the cost per customer acquired, depending upon the terms. All other advertising costs are charged to expense as incurred or the first time the advertising takes place. At June 30, 2020 and December 31, 2019, $0.3 million and $5.0 million, respectively, of costs have been prepaid for future advertisements and promotions.

7.	Share-Based Compensation

We currently have five types of share-based awards outstanding to our employees and directors: stock options, restricted stock awards, restricted stock units, performance-based stock units, and market stock units. We believe that our share-based awards align the interests of our employees and directors with those of our stockholders. Vesting terms for each of these award types generally range from one to four years.

We recognize share-based compensation expense for the market stock units if the requisite service period is rendered, even if the market condition is never satisfied. For the three and six months ended June 30, 2020, we recognized total share-based compensation costs of $2.9 million and $3.7 million, respectively. For the three and six months ended June 30, 2019, we recognized total share-based compensation costs of $6.9 million and $9.3 million, respectively, including $0.5 million and $0.6 million, respectively, recorded to restructuring and related charges. We account for forfeitures as they occur.

8.	Income Taxes

For the three months ended June 30, 2020 and 2019, we had an effective income tax rate of 17.6% and 30.9%, respectively. During the second quarter of 2020, our effective income tax rate was lower than our statutory rate, primarily due to a change in the estimated annual effective income tax rate. During the second quarter of 2019, we had nondeductible expenses related to the acquisition of Nutrisystem that caused an increase in our effective income tax rate.

For the six months ended June 30, 2020 and 2019, we had an effective tax benefit rate of 5.1% and an effective income tax rate of 37.6%, respectively. For the six months ended June 30, 2020, our effective tax benefit rate was lower than our statutory benefit rate primarily due to the nondeductible goodwill impairment loss of $119.5 million recorded during the first quarter. For the six months ended June 30, 2019, our effective income tax rate increased due to nondeductible expenses related to the acquisition of Nutrisystem as well as two adjustments related to the acquisition that collectively increased our income tax expense for such period by approximately $2.7 million: (i) we evaluated the realizability of beginning-of-the-year deferred tax assets and increased the valuation allowance on deferred tax assets related to state net operating loss carryforwards by $1.8 million, and (ii) we recorded a $0.9 million reduction in deferred tax assets related to state income tax credits.

We file income tax returns in the U.S. Federal jurisdiction and in various state and foreign jurisdictions. Tax years remaining subject to examination in the U.S. Federal jurisdiction include 2016 to present.

Leases

We maintain lease agreements principally for our office spaces and certain equipment. In addition, certain of our contracts, such as those with our fulfillment vendor related to our warehouse space or contracts with certain equipment vendors, contain embedded leases. We maintain three sublease agreements with respect to two of our office locations, each of which continues through the initial term of our master lease agreement. Such sublease income and payments, while they reduce our rent expense, are not considered in the value of the right-of-use asset or lease liability. With the exception of two finance leases related to a network server and office equipment, all of our leases are classified as operating leases. In the aggregate, our leases generally have remaining lease terms of one to five years, some of which include options to extend the lease for additional periods.

The following table shows the components of lease expense for the three and six months ended June 30, 2020 and 2019:

	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)	2020			2019			2020			2019
Finance lease cost:
Amortization of leased assets	$	162		$	12		$	324		$	24
Interest of lease liabilities		22			2			47			4
Operating lease cost		3,675			3,804			7,350			6,520
Short-term lease cost		137			116			266			149
Total lease cost before subleases	$	3,996		$	3,934		$	7,987		$	6,697
Sublease income		(1,363	)		(1,356	)		(2,764	)		(2,700	)
Total lease cost, net	$	2,633		$	2,578		$	5,223		$	3,997

Supplemental cash flow information related to leases is as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)	2020			2019			2020			2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flow attributable to operating leases	$	(2,545	)	$	(3,561	)	$	(5,611	)	$	(5,108	)
Operating cash flow attributable to finance leases		(22	)		(2	)		(47	)		(4	)
Financing cash flow attributable to finance leases		(155	)		(11	)		(306	)		(22	)

Supplemental noncash information:
Right-of-use assets obtained in exchange for operating lease liabilities ⁽¹⁾		—			—			—			48,972
Right-of-use assets obtained in exchange for finance lease liabilities ⁽¹⁾		—			—			—			181

(1)

No new leases were entered into during the six months ended June 30, 2019. Amounts shown are due to the adoption of ASC 842 and reflect balances as of January 1, 2019 for the Healthcare segment and as of March 8, 2019 for the Nutrition segment (i.e., the date of our acquisition of Nutrisystem).

10.

Debt

The Company's debt, net of unamortized deferred loan costs and original issue discount, consisted of the following at June 30, 2020 and December 31, 2019:

(In thousands)	June 30, 2020			December 31, 2019
Term Loan A	$	280,000		$	288,750
Term Loan B		775,000			786,250
Revolving Credit Facility		—			19,850
		1,055,000			1,094,850
Less: deferred loan costs and original issue discount		(42,678	)		(46,723	)
Total debt		1,012,322			1,048,127
Less: current portion		(9,775	)		—
Total non-current portion of debt	$	1,002,547		$	1,048,127

Credit Facility

In connection with the consummation of the Merger, on March 8, 2019, we entered into a new Credit and Guaranty Agreement (the “Credit Agreement”) with a group of lenders, Credit Suisse AG, Cayman Islands Branch, as general administrative agent, term facility agent and collateral agent, and SunTrust Bank, as revolving facility agent and swingline lender. The Credit Agreement provides us with (i) a $350.0 million term loan A facility (“Term Loan A”), (ii) an $830.0 million term loan B facility (“Term Loan B” and, together with Term Loan A, the “Term Loans”), (iii) a $125.0 million revolving credit facility that includes a $35.0 million sublimit for swingline loans and a $50.0 million sublimit for letters of credit (the “Revolving Credit Facility”; Term Loan A, Term Loan B and the Revolving Credit Facility are sometimes herein referred to collectively as the “Credit Facilities”), and (iv) uncommitted incremental accordion facilities in an aggregate amount at any date equal to the greater of $125.0 million or 50% of our consolidated EBITDA for the then-preceding four fiscal quarters, plus additional amounts based on, among other things, satisfaction of certain financial ratio requirements. As of June 30, 2020, outstanding debt under the Credit Agreement was $1,012 million, and availability under the Revolving Credit Facility totaled $124.5 million as calculated under the most restrictive covenant.

We are required to repay Term Loan A loans in consecutive quarterly installments, each in the amount of 2.50% of the aggregate initial amount of such loans, payable beginning on June 30, 2019 and on the last day of each succeeding quarter thereafter until maturity on March 8, 2024, at which time the entire outstanding principal balance of such loans is due and payable in full. We are required to repay Term Loan B loans in consecutive quarterly installments, each in the amount of 0.75% of the aggregate initial amount of such loans, payable beginning on June 30, 2019 and on the last day of each succeeding quarter thereafter until maturity on March 8, 2026, at which time the entire outstanding principal balance of such loans is due and payable in full. We are permitted to make voluntary prepayments of borrowings under the Term Loans at any time without penalty. From March 8, 2019 through June 30, 2020, we made payments of $125.0 million on the Term Loans, which included prepayments of all amounts due through March 31, 2021, excluding any Excess Cash Flow Payments that may be required, as described below. We are required to repay in full any outstanding swingline loans and revolving loans under the Revolving Credit Facility on March 8, 2024. In addition, the Credit Agreement contains provisions that, beginning with fiscal 2019, may require annual excess cash flow (as defined in the Credit Agreement and generally designed to equal cash generated by our business in excess of cash used in the business) to be applied towards the Term Loans. We are required to make prepayments on the Term Loans equal to our excess cash flow for a given fiscal year multiplied by the following excess cash flow percentages (such resulting payment an “Excess Cash Flow Payment”) based on our Net Leverage Ratio (as defined below) on the last day of such fiscal year: (a) 75% if the Net Leverage Ratio is greater than 3.75:1, (b) 50% if the Net Leverage Ratio is equal to or less than 3.75:1 but greater than 3.25:1 (c) 25% if the Net Leverage Ratio is equal to or less than 3.25:1 but greater than 2.75:1, and (d) 0% if the Net Leverage Ratio is equal to or less than 2.75:1. Any such potential mandatory prepayments are reduced by voluntary prepayments. We were not required to make an Excess Cash Flow Payment for fiscal 2019.

The Credit Agreement contains a financial covenant that requires us to maintain maximum ratios or levels of consolidated total net debt to consolidated adjusted EBITDA, calculated as provided in the Credit Agreement (the “Net Leverage Ratio”), of 5.75:1.00 for all test dates occurring on or after December 31, 2019 but prior to December 31, 2020, 5.25:1.00 for all test dates occurring on or after December 31, 2020 but prior to December 31, 2021, and 4.75:1.00 for all test dates occurring on or after December 31, 2021. As of June 30, 2020, we were in compliance with all of the covenant requirements of the Credit Agreement, and our Net Leverage Ratio was equal to 4.08.

Based on our current assumptions with respect to the COVID-19 pandemic, including, among other things, the duration of the temporary closures of our fitness partner locations and the average monthly total participation levels of our members after such locations reopen, we currently believe we will be in compliance with the Net Leverage Ratio covenant over the next 12 months; however, given the significant uncertainty relating to the potential impacts of the COVID-19 pandemic on our business going forward, there are potential scenarios under which we could fail to comply with the Net Leverage Ratio covenant. Our failure to comply with the Net Leverage Ratio covenant would result in an event of default that, if not waived, could have a material adverse effect on our financial condition, results of operations or debt service capability. We will continue to monitor our projected ability to comply with all covenants under the Credit Agreement, including the Net Leverage Ratio, which could include seeking an amendment to or waiver of the Net Leverage Ratio covenant if necessary.

Borrowings under the Credit Agreement bear interest at variable rates based on a margin or spread in excess of either (1) one-month, two-month, three-month or six-month LIBOR (or, with the approval of all lenders holding the particular class of loans, 12-month LIBOR), which may not be less than zero, or (2) the greatest of (a) the prime lending rate of the agent bank for the particular facility, (b) the federal funds rate plus 0.50%, and (c) one-month LIBOR plus 1.00% (the “Base Rate”), as selected by the Company. The LIBOR margin for Term Loan A loans is 4.25%, the LIBOR margin for Term Loan B loans is 5.25% and the LIBOR margin for revolving loans varies between 3.75% and 4.25%, depending on our total Net Leverage Ratio. The Base Rate margin for Term Loan A loans is 3.25%, the Base Rate margin for Term Loan B loans is 4.25% and the Base Rate margin for revolving loans varies between 2.75% and 3.25%, depending on our total Net Leverage Ratio. In May 2019, we entered into eight amortizing interest rate swap agreements, each of which matures in May 2024. Under these agreements, we receive a variable rate of interest based on LIBOR, and we pay a fixed rate of interest equal to approximately 2.2% plus a spread, as described in the preceding sentences. As of June 30, 2020, these interest rate swap agreements had current notional amounts totaling $800.0 million.

The Credit Agreement also provides for annual commitment fees ranging between 0.250% and 0.500% of the unused commitments under the Revolving Credit Facility, depending on our total Net Leverage Ratio, and annual letter of credit fees on the daily outstanding availability under outstanding letters of credit at the applicable LIBOR margin for the Revolving Credit Facility, depending on our total Net Leverage Ratio.

Extensions of credit under the Credit Agreement are secured by guarantees from substantially all of the Company’s active material domestic subsidiaries and by security interests in substantially all of Company’s and such subsidiaries’ assets.

The Credit Agreement contains a financial covenant that requires us to maintain specified maximum ratios or levels of consolidated total net debt to EBITDA, calculated as provided in the Credit Agreement. The Credit Agreement also contains various other affirmative and negative covenants customary for financings of this type that, subject to certain exceptions, impose restrictions and limitations on the Company and certain of the Company’s subsidiaries with respect to, among other things, indebtedness; liens; negative pledges; restricted payments (including dividends, distributions, buybacks, redemptions, repurchases with respect to equity interests, and payments, redemptions, retirements, purchases, acquisitions, defeasance, exchange, conversion, cancellation or termination with respect to junior lien, subordinated or unsecured debt); restrictions on subsidiary distributions; loans, advances, guarantees, acquisitions and other investments; mergers and other fundamental changes; sales and other dispositions of assets (including equity interests in subsidiaries); sale/leaseback transactions; transactions with affiliates; conduct of business; amendments and waivers of organizational documents and material junior debt agreements; and changes to fiscal year.

11.	Commitments and Contingencies

Shareholder Lawsuits: Weiner Lawsuit, Consolidated Derivative Lawsuit, and Witmer Lawsuit

On November 6, 2017, United Healthcare issued a press release announcing expansion of its fitness benefits (“United Press Release”), and the market price of the Company's shares of common stock, par value $.001 per

share (“Common Stock”) dropped on that same day. In connection with the United Press Release, four lawsuits were filed against the Company. As further described below, three of the four lawsuits have been dismissed. We are currently not able to predict the probable outcome of the remaining matter or to reasonably estimate a range of potential loss, if any. We intend to vigorously defend ourselves against the remaining complaint.

On November 20, 2017, Eric Weiner, claiming to be a stockholder of the Company, filed a complaint on behalf of stockholders who purchased Common Stock between February 24, 2017 and November 3, 2017 (“Weiner Lawsuit”). The Weiner Lawsuit was filed as a class action in the U.S. District Court for the Middle District of Tennessee, naming as defendants the Company, the Company's chief executive officer, chief financial officer and a former executive who served as both chief accounting officer and interim chief financial officer. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Rule 10b-5 promulgated under the Exchange Act in making false and misleading statements and omissions related to the United Press Release. The complaint seeks monetary damages on behalf of the purported class. On April 3, 2018, the Court entered an order appointing the Oklahoma Firefighters Pension and Retirement System as lead plaintiff, designated counsel for the lead plaintiff, and established certain deadlines for the case. On June 4, 2018, plaintiff filed a first amended complaint. The Court denied the Company’s Motion to Dismiss on March 18, 2019 and the Company’s Motion to Reconsider on May 22, 2019. On January 29, 2020, the Court granted lead plaintiff’s motion to certify the class. On July 23, 2020, the United States Court of Appeals for the Sixth Circuit denied the Company’s application for permission to appeal the class certification ruling. The case is currently set for trial on May 18, 2021.

On January 26, 2018 and August 24, 2018, individuals claiming to be stockholders of the Company filed shareholder derivative actions, on behalf of the Company, in the U.S. District Court for the Middle District of Tennessee, naming the Company as a nominal defendant and certain current and former executives and directors as defendants. On October 15, 2018, the two complaints were consolidated (the “Consolidated Derivative Lawsuit”). On May 15, 2019, a consolidated amended complaint was filed. The consolidated amended complaint asserts claims for violation of Section 10(b), 14(a), and 29(b) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, and unjust enrichment. Plaintiffs seek to recover damages on behalf of the Company, certain corporate governance and internal procedural reforms, and other equitable relief. On June 14, 2019, the defendants filed a Motion to Dismiss all claims and the plaintiffs filed their opposition to the Motion to Dismiss on July 17, 2019. On October 22, 2019, the Consolidated Derivative Lawsuit was dismissed with prejudice. On November 20, 2019, plaintiffs filed a notice of appeal with the United States Circuit Court for the Sixth Circuit. The parties have entered into a Memorandum of Understanding (“MOU”) to resolve the Consolidated Derivative Lawsuit, and on May 19, 2020, the case was remanded to the District Court to review for approval a forthcoming stipulation of settlement based on the terms set forth in the MOU.

Shareholder Lawsuits: Strougo, Cobb, and Delaware Lawsuits

On February 25, 2020, Robert Strougo, claiming to be a stockholder of the Company, filed a complaint on behalf of stockholders who purchased Common Stock between March 8, 2019 and February 19, 2020 (the "Strougo Lawsuit"). The Strougo Lawsuit was filed as a class action in the U.S. District Court for the Middle District of Tennessee, naming the Company, the Company's chief financial officer and former chief executive officer as defendants. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated under the Exchange Act in making false and misleading statements and omissions related to the performance of the Nutrisystem business that the Company acquired on March 8, 2019. The complaint seeks monetary damages on behalf of the purported class. Three parties have filed a motion seeking to be appointed lead plaintiff and counsel, but the Court has not ruled on those motions. Given the uncertainty of litigation and the preliminary stage of the case, we are currently not able to predict the probable outcome of the matter or to reasonably estimate a range of potential loss, if any.

On April 9, 2020, John Cobb, claiming to be a stockholder of the Company, filed a derivative complaint in the United States District Court for the Middle District of Tennessee naming the Company as a nominal defendant and certain directors and the Company’s former chief executive officer and current chief financial officer as defendants (the “Cobb Lawsuit”). The complaint asserted claims for breach of Section 14(a) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, failure of internal controls, and unjust enrichment, largely tracking the factual allegations in the Strougo Lawsuit. The plaintiff seeks monetary damages on behalf of the Company, restitution, and certain corporate governance and internal procedural reforms. On June 9, 2020, the United States Magistrate Judge approved the parties’ stipulation to a stay the case pending the resolution of defendants’ anticipated motion to dismiss in the Strougo case. Given the uncertainty of litigation and the preliminary stage of the case, we are currently not able to predict the probable outcome of the matter or to reasonably estimate a range of potential loss, if any.

In July 2020, three putative derivative complaints were filed in the United States District Court for the District of Delaware by the following individuals claiming to be stockholders of the Company: Patrick Yerby, Thomas R. Conte, Melvyn Klein, and Mark Ridendour (the “Delaware Derivative Lawsuits”). The complaints largely track the allegations, named defendants, asserted claims, and requested relief of the Cobb Lawsuit. Once the Delaware Derivative Lawsuits are consolidated by the District Court, the Company intends to seek a stay similar to that entered in the Cobb Lawsuit.

Given the uncertainty of litigation and the preliminary stage of the case, we are not currently able to predict the probable outcome of the matter or to reasonably estimate a range of potential loss, if any. We intend to vigorously defend ourselves against the Strougo Lawsuit, Cobb Lawsuit, and Delaware Derivative Lawsuit.

Trademark Lawsuit: Pacific Packaging Lawsuit

On May 31, 2019, Pacific Packaging Concepts, Inc. (“Pacific Packaging”) filed a complaint in the U.S. District Court for the Central District of California, Western Division, naming as defendants two subsidiaries of the Company; Nutrisystem, Inc. and Nutri/System IPHC, Inc. In its complaint, Pacific Packaging alleged that the defendants’ use of Pacific Packaging’s federally registered trademark, Fresh Start, in advertisements for its weight management program and shakes constitutes federal trademark infringement, counterfeit trademark infringement, false designation of origin, federal trademark dilution, unfair competition, false advertising, common law unfair competition, and common law trademark infringement. The complaint seeks injunctive relief and monetary damages in an unspecified amount. On August 29, 2019, the defendants filed their Answer to Complaint. Given the uncertainty of litigation and the preliminary stage of the case, we are currently not able to predict the probable outcome of the matter or to reasonably estimate a range of potential loss, if any. We intend to vigorously defend ourselves against this complaint.

Other

Additionally, from time to time, we are subject to contractual disputes, claims and legal proceedings that arise in the ordinary course of our business. Some of the legal proceedings pending against us as of the date of this report are expected to be covered by insurance policies. As these matters are subject to inherent uncertainties, our view of these matters may change in the future. We expense legal costs as incurred.

12.	Fair Value Measurements

We account for certain assets and liabilities at fair value. Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability.

Fair Value Hierarchy

The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

Level 1:

Quoted prices in active markets for identical assets or liabilities;

Level 2:

Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-based valuation techniques in which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

Level 3:

Unobservable inputs that are supported by little or no market activity and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table presents our assets and liabilities measured at fair value on a recurring basis at June 30, 2020 and December 31, 2019.

	Level 2
(In thousands)	June 30, 2020		December 31, 2019
Liabilities:
Interest rate swap agreements	$	44,407	$	16,238

The fair values of interest rate swap agreements are primarily determined based on the present value of future cash flows using internal models and third-party pricing services with observable inputs, including interest rates, yield curves and applicable credit spreads.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

We measure certain assets at fair value on a nonrecurring basis in the fourth quarter of each year, including the following:

•

reporting units measured at fair value as part of a goodwill impairment test; and

•

indefinite-lived intangible assets measured at fair value for impairment assessment.

Each of these assets above is classified as Level 3 within the fair value hierarchy. The COVID-19 pandemic has had and is having an adverse impact on the overall economy, resulting in rapidly changing market and economic conditions that have impacted the Company. In March 2020, we experienced a significant decline in the Company’s market capitalization and in the actual and forecasted operating results of our Healthcare segment, in addition to the unfavorable change in market conditions. As a result, management concluded that there were triggering events during the first quarter of 2020 necessitating an impairment evaluation of our goodwill (for each of our reporting units) and indefinite-lived intangible assets (which consist of the Nutrisystem tradename and the SilverSneakers tradename).

We estimated the fair value of each reporting unit using a combination of a discounted cash flow model and a market-based approach, and we reconciled the aggregate fair value of our reporting units to our consolidated market capitalization. Estimating fair value requires significant judgments, including management’s estimate of future cash flows of each reporting unit (which is dependent on internal forecasts of projected income), estimation of the long-term growth rates of future revenues for our reporting units, the terminal growth rate of revenue, the tax rate, and determination of the weighted average cost of capital, as well as relevant comparable company revenue and earnings multiples and market participant acquisition premium for the market-based approaches. Changes in these estimates and assumptions could materially affect the estimate of fair value and goodwill impairment for each reporting unit. There is significant uncertainty relating to the potential future impacts of the COVID-19 pandemic on our business and the overall market.

Certain significant inputs used in the estimation of fair value were adversely impacted by the changing market and economic conditions discussed above, most notably the weighted average cost of capital, resulting in a lower estimated fair value for each of our reporting units. Before we performed the impairment analysis during the first quarter, the estimated fair value of the Nutrition reporting unit was equal to its carrying value due to an impairment loss we recorded in the fourth quarter of 2019. Because there was no excess of estimated fair value over carrying value (“headroom”) for the Nutrition reporting unit at the beginning of 2020, the decrease in the estimated fair value of the Nutrition reporting unit during the first quarter of 2020 resulted in an impairment of the carrying value of

goodwill for the Nutrition reporting unit, and we recorded a $119.5 million goodwill impairment loss. None of the impaired goodwill is deductible for tax purposes, and there is no cash tax benefit related to the impairment. For the Healthcare reporting unit, the fair value of the reporting unit exceeded its carrying amount, and we determined that the carrying value of goodwill was not impaired.

Also during the first quarter of 2020, we estimated the fair value of indefinite-lived intangible assets, which consisted of two tradenames (the Nutrisystem tradename and the SilverSneakers tradename), using the relief-from-royalty method, which required significant assumptions such as the long-term growth rate of future revenues, the royalty rate for such revenue, and a discount rate. Changes in these estimates and assumptions could materially affect the estimate of fair value for the tradenames. Similar to the goodwill impairment analysis described above, the discount rate used in the estimation of fair value of the tradenames was adversely impacted by the changing market and economic conditions discussed above, resulting in a lower estimated fair value for each tradename.

Due to an impairment loss recorded in the fourth quarter of 2019 related to the Nutrisystem tradename and goodwill, the estimated fair value of the Nutrisystem tradename was equal to its carrying value at the beginning of 2020. The decrease in the estimated fair value of the Nutrisystem tradename during the first quarter of 2020 resulted in an impairment of tradename, and we recorded an $80.0 million impairment loss related to the Nutrisystem tradename. None of this impairment loss is deductible for tax purposes, and there is no cash tax benefit related to the impairment. Based on our impairment assessment of the SilverSneakers tradename, we determined that the carrying value of the tradename was not impaired as of the measurement date.

There were no impairment triggers during the second quarter of 2020 related to our goodwill or indefinite-lived intangible assets.

Fair Value of Other Financial Instruments

The estimated fair value of each class of financial instruments at June 30, 2020 was as follows:

Cash and cash equivalents – The carrying amount of $60.3 million approximates fair value due to the short maturity of those instruments (less than three months).

Debt – The estimated fair value of outstanding borrowings under the Credit Agreement, which includes term loan facilities and a revolving credit facility (see Note 10), is determined based on the fair value hierarchy as discussed above.

The Term Loans are actively traded and therefore are classified as Level 1 valuations. The estimated fair value is based on quotes as of June 30, 2020 from dealers who stand ready and willing to transact at those prices. The Revolving Credit Facility is not actively traded and therefore is classified as a Level 2 valuation based on the market for similar instruments. The estimated fair value and carrying amount of outstanding borrowings under the Term Loans at June 30, 2020 were $921.2 million and $1,012.3 million, respectively. There were no outstanding borrowings under the Revolving Credit Facility at June 30, 2020.

13.	Derivative Instruments and Hedging Activities

We use derivative instruments to manage differences in the amount, timing, and duration of our known or expected cash payments related to our outstanding debt (i.e., interest rate risk). These derivatives are designated and qualify as a hedge of the exposure to variability in expected future cash flows and are therefore considered cash flow hedges. We account for derivatives in accordance with FASB ASC Topic 815, which establishes accounting and reporting standards requiring that derivative instruments be recorded on the balance sheet at fair value as either an asset or liability. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether we have elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. We classify cash flows from settlement of our cash flow hedges in the same category as the cash flows from the related hedged items, generally within the operating activities in the consolidated statements of cash flows. We do not use derivatives for trading or speculative purposes and currently do not have any derivatives that are not designated as hedges.

Cash Flow Hedges of Interest Rate Risk

Our objectives in using interest rate derivatives are to add stability to interest expense and to manage our exposure to interest rate movements. To accomplish this objective, we primarily use interest rate swaps as part of our interest rate risk management strategy. The counterparties to the interest rate swap agreements expose us to credit risk in the event of nonperformance by such counterparties. However, at June 30, 2020, we do not anticipate nonperformance by these counterparties. Our interest rate swap agreements with each of the counterparties contain a provision whereby if we either default or are capable of being declared in default on any of our indebtedness, whether or not such default results in repayment of the indebtedness being accelerated by the lender, then we could also be declared in default on our derivative obligations.

Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for our making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. In May 2019, we entered into eight amortizing interest rate swap agreements, each of which matures in May 2024. Under these agreements, we receive a variable rate of interest based on LIBOR, and we pay a fixed rate of interest equal to approximately 2.2% plus a spread (see Note 10). As of June 30, 2020, these interest rate swap agreements had current notional amounts totaling $800.0 million.

We record derivatives that are designated and qualify as cash flow hedges at estimated fair value in the consolidated balance sheet, with the related gains and losses recorded in accumulated other comprehensive income or loss ("accumulated OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as we make interest payments on our variable-rate debt. As of June 30, 2020, we expect to reclassify $15.8 million from accumulated OCI as an increase to interest expense within the next 12 months due to the scheduled payment of interest associated with our debt.

The estimated gross fair values of derivative instruments and their classification on the consolidated balance sheet at June 30, 2020 and December 31, 2019 were as follows:

(In thousands)	June 30, 2020		December 31, 2019
Liabilities:
Derivatives designated as hedging instruments:
Current portion of long-term liabilities	$	15,664	$	4,947
Other long-term liabilities		28,743		11,291
	$	44,407	$	16,238

The following table presents the effect of cash flow hedge accounting on accumulated OCI as of June 30, 2020 and 2019:

(In thousands)	For the Three Months Ended					For the Six Months Ended
Derivatives in Cash Flow Hedging Relationships	June 30, 2020			June 30, 2019		June 30, 2020			June 30, 2019
Loss related to effective portion of derivatives recognized in accumulated OCI, gross of tax effect	$	5,020		$	16,144	$	32,772		$	16,144
Gain (loss) related to effective portion of derivatives reclassified from accumulated OCI to interest expense, gross of tax effect	$	(3,482	)	$	160	$	(4,603	)	$	160

14. Earnings (Loss) Per Share

We use the two-class method to calculate earnings per share as the unvested restricted stock awards outstanding under our equity incentive plan are participating shares with nonforfeitable rights to dividends. Under the two-class method, we compute earnings per share of Common Stock by dividing the sum of distributed earnings to common stockholders (currently not applicable as we do not pay dividends) and undistributed earnings allocated to common stockholders by the weighted average number of outstanding shares of Common Stock for the period. In applying the two-class method, we allocate undistributed earnings to both shares of Common Stock and participating securities based on the number of weighted average shares outstanding during the period. Any undistributed losses are not allocated to unvested restricted stock as the restricted stockholders are not obligated to share in the losses. Following is a reconciliation of the numerator and denominator of basic and diluted earnings (loss) per share for the three and six months ended June 30, 2020 and 2019:

(In thousands except per share data)	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Numerator:
Net income (loss)	$	28,511		$	18,137		$	(169,595	)	$	22,351
Net income allocated to unvested restricted stock		(20	)		(93	)		—			(77	)
Net income (loss) allocated to shares of Common Stock	$	28,491		$	18,044		$	(169,595	)	$	22,274

Denominator:
Shares used for basic income (loss) per share		48,711			47,790			48,662			45,165
Effect of dilutive stock options and restricted stock units outstanding:
Non-qualified stock options		8			93			—			110
Restricted stock units		75			578			—			444
Shares used for diluted income (loss) per share ⁽¹⁾		48,794			48,461			48,662			45,719

Earnings (loss) per share:
Basic	$	0.59		$	0.38		$	(3.49	)	$	0.49
Diluted ⁽¹⁾	$	0.58		$	0.37		$	(3.49	)	$	0.49

Dilutive securities outstanding not included in the computation of earnings per share because their effect is anti-dilutive:
Non-qualified stock options		235			71			202			76
Restricted stock units		750			288			544			172
Restricted stock awards		32			128			35			64
Performance-based stock units		95			—			64			—
Market-based stock units		49			—			25			—

(1)

The impact of potentially dilutive securities for the six months ended June 30, 2020 was not considered because the impact would be anti-dilutive.

Market stock units and performance stock units outstanding are considered contingently issuable shares, and certain of these stock units were excluded from the calculations of diluted earnings per share for all periods presented as the performance criteria had not been met as of the end of the reporting periods.

15. Accumulated OCI

The following tables summarize the changes in accumulated OCI, net of tax, for the six months ended June 30, 2020:

(In thousands)	Net Change in Fair Value of Interest Rate Swaps
Accumulated OCI, net of tax, as of January 1, 2020	$	(12,091	)
Other comprehensive income (loss) before reclassifications, net of tax of $8,370		(24,402	)
Amounts reclassified from accumulated OCI, net of tax of $1,175		3,428
Accumulated OCI, net of tax, as of June 30, 2020	$	(33,065	)

The following table presents details about reclassifications out of accumulated OCI for the six months ended June 30, 2020:

(In thousands)	Six Months Ended June, 2020			Statement of Operations Classification
Interest rate swaps	$	4,603		Interest expense
		(1,175	)	Income tax expense
	$	3,428		Net of tax

See Note 13 for a further discussion of our interest rate swaps.

16. Segment Disclosures and Concentrations of Risk

Background and Basis of Organization

Following the acquisition of Nutrisystem in March 2019, we organize and manage our operations within two reportable segments, based on the types of products and services they offer: Healthcare and Nutrition. The Healthcare segment derives its revenues from SilverSneakerssenior fitness, Prime Fitness and WholeHealth Living. The Nutrition segment provides weight management products and services and derives its revenues from Nutrisystem and South Beach Diet products. Prior to the acquisition of Nutrisystem, we had one reportable segment.

Segment Revenues, Profit or Loss, and Assets

Our chief operating decision maker evaluates performance and allocates resources based on each segment’s EBITDA excluding acquisition and integration costs, impairment loss, restructuring and related charges, CEO transition costs, and direct, incremental costs related to COVID-19. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. Transactions between the segments primarily consist of payments made by one segment on behalf of the other segment, which are recorded as current assets and eliminated in consolidation. Intersegment revenues and costs related to Wisely Well totaled $1.9 million for the three and six months ended June 30, 2020. The following tables present information about reported segment revenues and profit or loss, net of intersegment eliminations, as well as reconciliations of each such amount to consolidated totals:

(In thousands)
	Three Months Ended June 30,
	2020						2019
	Healthcare		Nutrition		Total Segments		Healthcare		Nutrition		Total Segments
Revenues	$	81,923	$	180,675	$	262,598	$	157,481	$	182,896	$	340,377	(1)

Consolidated income before income taxes					$	34,618					$	26,252

Acquisition and integration costs						2,049						8,999
Impairment loss						—						—
CEO transition costs						1,745						—
COVID-19 costs						1,260						—
Restructuring and related charges						1,009						2,352
Interest expense						21,235						23,661
Depreciation and amortization						12,919						9,084
Adjusted EBITDA	$	41,472	$	33,363	$	74,835	$	35,681	$	34,667	$	70,348

(In thousands)
	Six Months Ended June 30,
	2020							2019
	Healthcare		Nutrition		Total Segments			Healthcare		Nutrition		Total Segments
Revenues	$	241,615	$	358,638	$	600,253		$	314,008	$	240,463	$	554,471	(1)

Consolidated income (loss) before income taxes					$	(178,633	)					$	35,834

Acquisition and integration costs						4,844							26,049
Impairment loss						199,500							—
CEO transition costs						4,332							—
COVID-19 costs						1,260							—
Restructuring and related charges						1,752							3,943
Interest expense						42,898							31,328
Depreciation and amortization						27,682							12,666
Adjusted EBITDA	$	71,719	$	31,916	$	103,635		$	61,810	$	48,010	$	109,820

(1)

The figure for total segments equals the consolidated figure for such item.

Our total assets by segment were as follows:

(In thousands)	June 30, 2020		December 31, 2019
Healthcare	$	527,353	$	526,013
Nutrition		853,817		1,099,892
Total assets	$	1,381,170	$	1,625,905

Concentrations of Risk

As of June 30, 2020, we were subject to concentration of revenue risk related to the services that we provide. For the three and six months ended June 30, 2020, a significant portion (19% and 28%, respectively) of our consolidated revenues was derived from our SilverSneakerssenior fitness offering, in which a meaningful amount of our fees is earned based on member visits to fitness partner locations. Due to widespread closures of our partner locations beginning in March 2020 related to the COVID-19 pandemic, there was a significant decrease in member participation and the related revenues during March 2020, with visits decreasing sharply by the end of March. A substantial number of our fitness partner locations remained closed for at least a portion of the second quarter. During the second quarter of 2020, the average monthly total participation levels of our SilverSneakers members were significantly below historical levels, and we also experienced a decline in paid subscribers for Prime Fitness, each of which adversely impacted revenues in our Healthcare segment. These adverse impacts to revenue were somewhat mitigated by a reduction in cost of services as our visit costs decreased in a corresponding manner.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

As used throughout this Quarterly Report on Form 10-Q, unless the context otherwise indicates, the terms “we,” “us,” “our,” “Tivity Health,” or the “Company” refer collectively to Tivity Health, Inc. and its wholly-owned subsidiaries. Please read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes included under Item 1. “Financial Statements” of this report.

Recent Developments

In January 2020, the Secretary of HHS declared a national public health emergency due to a novel strain of coronavirus, which causes the disease known as “COVID-19”. In March 2020, the World Health Organization characterized the outbreak of COVID-19 as a global pandemic, and COVID-19 continues to spread throughout the United States and other countries. Many state and local governments, together with public health officials, have recommended and mandated precautions to mitigate the spread of COVID-19, including ordering closure of certain businesses and imposing stay-at-home orders and social distancing guidelines for individuals. Such measures have resulted in significantly reduced demand for many businesses that have continued in operation.

We have taken a number of actions in response to the pandemic, including the following:

•

Given the continued uncertainty surrounding COVID-19, in March 2020, we borrowed $75 million under our Revolving Credit Facility as a precautionary measure to increase our cash position and maintain financial flexibility. We repaid such $75 million in full in June 2020. As of June 30, 2020, outstanding debt under our Credit Agreement was $1,012.3 million, and we had $60.3 million of cash and cash equivalents. In July 2020, we repaid $24.8 million of principal on the term loans under our Credit Agreement, resulting in our next required quarterly installment being due in December 2021. While the COVID-19 pandemic has created significant uncertainty as to general economic and market conditions for the remainder of 2020 and beyond, as of the date of this report, we believe our cash on hand, expected cash flows from operations, and anticipated available credit under the Credit Agreement will be sufficient to fund our operations, principal and interest payments, and capital expenditures for the next 12 months.

•

transmission of COVID-19, such as the imposition of travel restrictions, the promotion of social distancing, and the adoption of work-from-home arrangements, and all of these policies and initiatives could impact our operations.

•

We are focused on preserving our liquidity and managing our cash flow, including, but not limited to, managing our working capital, optimizing tax savings under the CARES Act, curtailing capital expenditures, reducing discretionary spending, and reducing compensation costs.

Also in April 2020, the Compensation Committee of the Company’s Board approved a 25% reduction in base salary for the Company’s executive officers and certain other employees for the period from April 20, 2020 through August 23, 2020. In June 2020, the Compensation Committee determined to extend such reductions in base salary through December 31, 2020. Additionally, the Board approved a 100% reduction in the annual cash retainer and annual committee retainers payable to non-management members of the Board who stood for reelection at the 2020 Annual Meeting of Stockholders (except for Daniel G. Tully who does not receive compensation for his service on the Board) for a period of four months, beginning May 1, 2020 or as soon thereafter as reasonably practicable. In June 2020, the Board determined to extend such reduction in cash compensation to the Board through December 31, 2020.

Effective at the end of July 2020, the Compensation Committee suspended the Company matching contribution to the Company’s 401(k) plan.

The CARES Act contains modifications on the limitation of business interest for tax years beginning in 2019 and 2020. The modifications to Section 163(j) of the Internal Revenue Code increase the allowable business interest deduction from 30% of adjusted taxable income to 50% of adjusted taxable income. This modification significantly increases the Company’s allowable interest expense deduction and results in significantly less taxable income for the years ended 2019 and 2020, resulting in less cash taxes owed for these years. In addition, the CARES Act allows net operating losses (“NOLs”) incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. In July 2020, we filed a refund claim of $8.2 million under such NOL carryback provision.

As a result of the COVID-19 pandemic, in March 2020, we experienced a significant decline in the Company’s market capitalization and in the actual and forecasted operating results of our Healthcare segment, in addition to the unfavorable change in market conditions. As a result, management concluded that there were triggering events during the first quarter of 2020 necessitating an impairment evaluation of our goodwill and indefinite-lived intangible assets. Through this evaluation, management concluded that the fair value of goodwill allocated to the Nutrition business unit as well as the fair value of the Nutrisystem tradename were below their carrying amounts, and we recorded an impairment loss of $199.5 million, including $80.0 million related to the Nutrisystem tradename and $119.5 million related to goodwill allocated to the Nutrition segment. There were no impairment triggers during the second quarter of 2020 related to our goodwill or indefinite-lived intangible assets.

Overview

Tivity Health, Inc., founded and incorporated in Delaware in 1981, is a leading provider of healthy life-changing solutions, including SilverSneakers, Nutrisystem, Prime Fitness, Wisely Well, South Beach Diet, and WholeHealth Living. On March 8, 2019, we completed our acquisition of Nutrisystem, Inc. (“Nutrisystem”), a provider of weight management products and services, including nutritionally balanced weight loss programs sold primarily through the Internet and telephone and multi-day kits and single items (a la carte) available at select retail locations.

Following the acquisition of Nutrisystem, we organize and manage our operations within two reportable segments, based on the types of products and services they offer: Healthcare and Nutrition. The Healthcare segment is comprised of our legacy business and includes SilverSneakers, Prime Fitness, WholeHealth Living, and Wisely Well. The Nutrition segment is comprised of Nutrisystem’s legacy business and includes Nutrisystem and the South Beach Diet.

On May 6, 2020, we announced that the Board has decided to explore strategic alternatives with respect to our Nutrition business unit, including a possible transaction. We can give no assurance as to whether we will be able to identify any strategic alternatives that are likely to increase value to our stockholders.

As part of our Healthcare segment, SilverSneakers is offered to members of Medicare Advantage and Medicare Supplement plans. We also offer Prime Fitness, a fitness facility access program, through commercial health plans, employers, and other sponsoring organizations. Our national network of fitness centers delivers both SilverSneakers and Prime Fitness. Our fitness networks encompass more than 16,000 partner locations and approximately 1,000 alternative virtual and physical locations that provide classes outside of traditional fitness centers. Through our WholeHealth Living program, which we sell primarily to health plans, we offer a continuum of services related to complementary, alternative, and physical medicine. Our WholeHealth Living network includes relationships with approximately 24,000 complementary, alternative, and physical medicine practitioners to serve individuals through health plans and employers who seek health services such as chiropractic care, acupuncture, physical therapy, occupational therapy, massage therapy, and more.

Our Nutrition segment includes Nutrisystem and the South Beach Diet. Typically, our Nutrition segment customers purchase monthly food packages containing a four-week meal plan consisting of breakfasts, lunches, dinners, snacks and flex meals, which they supplement, depending on the program they are following, with items such as fresh fruits, fresh vegetables, lean protein and dairy. Most Nutrition segment customers order on auto-delivery, which means we send a four-week meal plan on an ongoing basis until notified of a customer’s cancellation. Auto-delivery customers are offered savings off of our regular one-time rate with each order. Monthly notifications are also sent to remind customers to update order preferences. We offer pre-selected favorites or customers may personalize their meal plan by selecting their entire menu or by customizing plans to their specific tastes or dietary preference. In total, our plans feature approximately 250 food options including frozen and unfrozen ready-to-go entrees, snacks, and shakes, at different price points. Additionally, we offer unlimited counseling from our trained weight loss counselors, registered dietitians and certified diabetes educators at no cost. Counselors are available as needed, seven days a week throughout an extended day, with further support provided through our digital tools. The Nutrition segment also offers its products through select retailers and QVC, a television shopping network.

Forward-Looking Statements

This report contains forward-looking statements, which are based upon current expectations, involve a number of risks and uncertainties, and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and those regarding the intent, belief, or expectations of the Company, including, without limitation, all statements regarding the Company's future earnings, revenues, and results of operations. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary from those in the forward-looking statements as a result of various factors, including, but not limited to:

•

impacts from the COVID-19 pandemic (including the response of governmental authorities to combat and contain the pandemic, the closure of fitness centers in our national network (or operational restrictions imposed on such fitness centers), and potential reclosures as a result of recent surges in positive COVID-19 cases) on our business, operations or liquidity;

•

the risk that the significant indebtedness incurred in connection with the acquisition of Nutrisystem may limit our ability to adapt to changes in the economy or market conditions, expose us to interest rate risk for the variable rate indebtedness and require a substantial portion of cash flows from operations to be dedicated to the payment of indebtedness;

•

our ability to service our debt, make principal and interest payments as those payments become due, and remain in compliance with our debt covenants;

•

the risks associated with changes in macroeconomic conditions (including the impacts of any recession or changes in consumer spending resulting from the COVID-19 pandemic), widespread epidemics, pandemics (such as the current COVID-19 pandemic) or other outbreaks of disease, geopolitical turmoil, and the continuing threat of domestic or international terrorism;

•

our ability to collect accounts receivable from our customers and amounts due under our sublease agreements;

•

the market’s acceptance of our new products and services;

•

our ability to develop and implement effective strategies and to anticipate and respond to strategic changes, opportunities, and emerging trends in our industry and/or business, as well as to accurately forecast the related impact on our revenues and earnings;

•

the risk that our exploration of strategic alternatives for our Nutrition business unit will be unsuccessful in identifying or consummating any strategic alternative that yields additional value for our stockholders, or that such exploration adversely affects the Nutrition business unit or the Company as a whole;

•

the risk that we are unable to achieve the strategic benefits, synergies and growth opportunities that were anticipated in connection with the acquisition of Nutrisystem, either in a timely manner or at all;

•

counterparty risk associated with our interest rate swap agreements;

•

our ability to obtain adequate financing to provide the capital that may be necessary to support our current or future operations;

•

the impact of any additional impairment of our goodwill, intangible assets, or other long-term assets;

•

the risks associated with potential failures of our information systems;

•

the risks associated with data privacy or security breaches, computer hacking, network penetration and other illegal intrusions of our information systems or those of third-party vendors or other service providers, which may result in unauthorized access by third parties, loss, misappropriation, disclosure or corruption of customer, employee or our information, or other data subject to privacy laws and may lead to a disruption in our business, costs to modify, enhance, or remediate our cybersecurity measures, enforcement actions, fines or litigation against us, or damage to our business reputation;

•

the impact of any new or proposed legislation, regulations and interpretations relating to Medicare, Medicare Advantage, Medicare Supplement, e-commerce, advertising, and privacy and security laws;

•

our ability to attract, hire, or retain key personnel or other qualified employees and to control labor costs;

•

the risks associated with changes to traditional office-centered business processes and/or conducting operations out of the office in a work-from-home or remote model during adverse situations (e.g., during a crisis, disaster, or pandemic), which may result in additional costs and/or may negatively impact productivity and cause other disruptions to our business;

•

the effectiveness of the reorganization of our business (including the 2020 COVID Restructuring Plan) and our ability to realize the anticipated benefits;

•

our ability to effectively compete against other entities, whose financial, research, staff, and marketing resources may exceed our resources;

•

the impact of legal proceedings involving us and/or our subsidiaries, products, or services, including any claims related to intellectual property rights;

•

our ability to enforce our intellectual property rights;

•

the risks associated with deriving a significant concentration of our revenues from a limited number of our Healthcare segment customers, many of whom are health plans;

•

our ability and/or the ability of our Healthcare segment customers to enroll participants and to accurately forecast their level of enrollment and participation in our programs in a manner and within the timeframe we anticipate;

•

our ability to sign, renew and/or maintain contracts with our Healthcare segment customers and/or our fitness partner locations under existing terms or to restructure these contracts on terms that would not have a material negative impact on our results of operations;

•

the impact of a reduction in Medicare Advantage health plan reimbursement rates or changes in plan design;

•

the ability of our Healthcare segment health plan customers to maintain the number of covered lives enrolled in those health plans during the terms of our agreements;

•

our ability to add and/or retain paid subscribers in our Prime Fitness program;

•

the impact of severe or adverse weather conditions, the current COVID-19 pandemic, and the potential emergence of additional health pandemics or infectious disease outbreaks on member participation in our Healthcare segment programs;

•

the impact of healthcare reform on our business;

•

the effectiveness of our marketing and advertising programs;

•

loss of, or disruption in the business of, any of our food suppliers or our fulfillment provider, or disruptions in the shipping of our food products for our Nutrition segment (including as a result of the COVID-19 pandemic);

•

the impact of claims that our Nutrition segment personnel are unqualified to provide proper weight loss advice;

•

the impact of health- or advertising-related claims by our Nutrition segment customers or competitors;

•

competition from other weight management industry participants or the development of more effective or more favorably perceived weight management methods;

•

loss of any of our Nutrition segment third-party retailer agreements and any obligations associated with such loss;

•

our ability to continue to develop innovative weight loss programs and enhance our existing programs, or the failure of our programs to continue to appeal to the market;

•

the impact of claims from our Nutrition segment competitors regarding advertising or other marketing practices;

•

our ability to develop and commercially introduce new products and services;

•

our ability to receive referrals for sales of our programs in the Nutrition segment from existing Nutrition segment customers, a decline in which could adversely impact our customer acquisition costs;

•

failure to attract spokespersons or negative publicity with respect to any of our spokespersons;

•

our ability to anticipate change and respond to emerging trends for customer preferences and the impact of the same on demand for our services and products;

•

the seasonality of the business of our Nutrition segment, particularly with respect to diet season;

•

negative publicity with respect to the weight loss industry;

•

the impact of increased governmental regulation on our Nutrition segment;

•

a significant portion of our Nutrition segment revenue depends on our ability to sustain subscriptions of our Nutrition segment’s programs, and cancellations could impact our future operating results;

•

claims arising from the sale of ingested products; and

•

other risks detailed in this report and our other filings with the Securities and Exchange Commission.

We undertake no obligation to update or revise any such forward-looking statements.

Business Strategy

Tivity Health’s integrated portfolio of healthy life-changing solutions supports overall health and wellness programs, which we believe are critical to our health plan and employer-based customers. On May 6, 2020, we announced that the Board has decided to explore strategic alternatives with regard to our Nutrition business unit, including a possible transaction. We can give no assurance as to whether we will be able to identify any strategic alternatives that are likely to increase value to our stockholders. In the event that we determine to pursue a sale of the Nutrition business unit, we may be unable to secure a buyer or, if we do so, such sale transaction may not be at a price that is favorable to us. Speculation regarding any developments related to the review of strategic alternatives for our Nutrition business unit and perceived uncertainties related to the future of the Company could cause our stock price to fluctuate significantly. We have not set a specific timetable for the conclusion of this process. Notwithstanding the exploration of strategic alternatives, our near-term strategy for the Nutrition business unit is to maximize opportunities to better serve our customers and grow our business as well as prepare for a successful 2021 diet season. For the Healthcare business unit, we will continue to focus on adding new members, building engagement and participation among current eligible members (including expansion and enhancement of our digital offerings and virtual exercise classes during and beyond the duration of the COVID-19 pandemic), and collaborating with health plans and other partners to introduce new products and services. In addition, we expect that the Healthcare business unit will continue to use the Wisely Well brand and to support our health plan partners with nutrition offerings such as home meal delivery to seniors or members recently discharged from the hospital as well as nutritional support for members with chronic conditions.

Critical Accounting Policies

We describe our significant accounting policies in Note 1 to the consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (“2019 Form 10-K”). We prepare the consolidated financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”), which requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and related disclosures at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.

We believe the following accounting policies are the most critical in understanding the estimates and judgments that are involved in preparing our financial statements and the uncertainties that could impact our results of operations, financial condition and cash flows.

Excess and Obsolete Inventory

We continually assess the quantities of inventory on hand to identify excess or obsolete inventory and record a provision for any estimated loss. We estimate the reserve for excess and obsolete inventory based primarily on our forecasted demand and/or our ability to sell the products, introduction of new products, future production requirements and changes in our customers’ behavior. The reserve for excess and obsolete inventory was $2.0 million and $1.8 million at June 30, 2020 and December 31, 2019, respectively.

Acquisition Accounting

In connection with any acquisitions, we allocate the purchase price to the assets and liabilities we acquire, such as net tangible assets, deferred revenue, identifiable intangible assets such as trade names, customer lists, and customer relationships, and goodwill. We apply significant judgments and estimates in determining the fair market value of the assets acquired and their useful lives. For example, we estimated the fair value of existing definite-lived customer lists based on the multi-period excess earnings method under the income approach, which involved applying an attrition rate to the estimated net future cash flows from the customers that existed as of the acquisition date. We estimated the fair values of the tradenames using the relief-from-royalty method, which required significant assumptions such as the long-term growth rates of future revenues, the royalty rate for such revenue, the terminal growth rate of revenue, the tax rate, and a discount rate. Different estimates and assumptions in valuing acquired assets could yield materially different results.

Impairment of Intangible Assets and Goodwill

We review goodwill for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis (during the fourth quarter of our fiscal year) or more frequently whenever events or circumstances indicate that the carrying value may not be recoverable. Following the acquisition of Nutrisystem in March 2019, we have two reporting units: Healthcare and Nutrition. Prior to such acquisition, we had one reporting unit. As further described below under “Impairment Loss,” in March 2020, we experienced a significant decline in the Company’s market capitalization and in the actual and forecasted operating results of our Healthcare segment, in addition to the unfavorable change in market conditions. As a result, management concluded that there were triggering events during the first quarter of 2020 necessitating an impairment evaluation of our goodwill and indefinite-lived intangible assets. Through this evaluation, management concluded that the fair value of goodwill allocated to the Nutrition business unit as well as the fair value of the Nutrisystem tradename were below their carrying amounts, and during the first quarter of 2020, we recorded an impairment loss of $199.5 million, including $80.0 million related to the Nutrisystem tradename and $119.5 million related to goodwill allocated to the Nutrition segment. See Note 12 of the notes to consolidated financial statements included in this report.

As part of the annual impairment test, we may elect to perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If we elect not to perform a qualitative assessment or we determine that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we perform a quantitative review as described below.

During a quantitative review of goodwill, we estimate the fair value of each reporting unit based on a discounted cash flow model or a combination of a discounted cash flow model and market-based approaches, and we reconcile the aggregate fair value of our reporting units to our consolidated market capitalization. If the fair value of the reporting unit exceeds its carrying amount, no impairment is indicated. If the fair value of the reporting unit is less than its carrying amount, impairment of goodwill is measured as the excess of the carrying amount over fair value. Estimating fair value requires significant judgments, including management's estimate of future cash flows of each reporting unit (which is dependent on internal forecasts of projected income), estimation of the long-term growth rates of future revenues for our reporting units, the terminal growth rate of revenue, the tax rate, and determination of the weighted average cost of capital, as well as relevant comparable company revenue and earnings multiples and market participant acquisition premium for the market-based approaches. Changes in these estimates and assumptions could materially affect the estimate of fair value and potential goodwill impairment for each reporting unit.

Except for two tradenames that have an indefinite life and are not subject to amortization, we amortize identifiable intangible assets over their estimated useful lives on a straight-line or accelerated basis based on the period for which the economic benefits of the asset are expected to be realized. We assess the potential impairment of intangible assets subject to amortization whenever events or changes in circumstances indicate that

the carrying values may not be recoverable. If we determine that the carrying value of other identifiable intangible assets may not be recoverable, we calculate any impairment using an estimate of the asset's fair value based on the estimated price that would be received to sell the asset in an orderly transaction between market participants.

We review indefinite-lived intangible assets for impairment on an annual basis (during the fourth quarter of our fiscal year) or more frequently whenever events or circumstances indicate that the carrying value may not be recoverable. We estimate the fair value of our indefinite-lived tradenames using the relief-from-royalty method, which requires us to estimate significant assumptions such as the long-term growth rates of future revenues associated with the tradename, the royalty rate for such revenue, the terminal growth rate of revenue, the tax rate, and a discount rate. Changes in these estimates and assumptions could materially affect the estimates of fair values for the tradenames.

Revenue Recognition

We account for revenue from contracts with customers in accordance with Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers” (“ASC Topic 606”). The unit of account in ASC Topic 606 is a performance obligation, which is a promise in a contract to transfer to a customer either a distinct good or service (or bundle of goods or services) or a series of distinct goods or services provided over a period of time. ASC Topic 606 requires that a contract’s transaction price, which is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, is to be allocated to each performance obligation in the contract based on relative standalone selling prices and recognized as revenue when or as the performance obligation is satisfied.

Healthcare Segment

Our Healthcare segment earns revenue from our three programs, SilverSneakers senior fitness, Prime Fitness and WholeHealth Living. We provide the SilverSneakers senior fitness program to members of Medicare Advantage and Medicare Supplement plans through our contracts with those plans. We offer Prime Fitness, a fitness facility access program, through contracts with commercial health plans, employers, and other sponsoring organizations that allow their members to individually purchase the program. We sell our WholeHealth Living program primarily to health plans.

The significant majority of our Healthcare segment’s customer contracts contain one performance obligation - to stand ready to provide access to our network of fitness locations and fitness programming - which is satisfied over time as services are rendered each month over the contract term. There are generally no performance obligations that are unsatisfied at the end of a particular month. There was no material revenue recognized during the three and six months ended June 30, 2020 from performance obligations satisfied in a prior period.

Our fees within our Healthcare segment are variable month to month and are generally billed per member per month (“PMPM”) or billed based on a combination of PMPM and member visits to a network location. We bill PMPM fees by multiplying the contractually negotiated PMPM rate by the number of members eligible for or receiving our services during the month. We bill for member visits approximately one month in arrears once actual member visits are known. Payments from customers are typically due within 30 days of invoice date. When material, we capitalize costs to obtain contracts with customers and amortize them over the expected recovery period.

Although we evaluate our financial performance and make resource allocation decisions based upon the results of our two reportable segments, we believe the following information depicts how our Healthcare segment revenues and cash flows are affected by economic factors. For the three and six months ended June 30, 2020, revenue from our SilverSneakers program, which is predominantly contracted with Medicare Advantage and Medicare

Supplement plans, comprised approximately 60% and 71%, respectively, of revenues in the Healthcare segment, while revenue from our Prime Fitness program comprised approximately 23% and 21%, respectively of revenues in the Healthcare segment, and our WholeHealth Living program comprised approximately 6% and 4%, respectively, of revenues in the Healthcare segment. Other revenues, which were earned from health plans and a large employer, comprised 11% and 4% of our revenues for the three and six months ended June 30, 2020, respectively.

Sales and usage-based taxes are excluded from revenues.

Nutrition Segment

Our Nutrition segment earns revenue from four sources: direct to consumer, retail, QVC and other. Revenue is measured based on the consideration specified in a contract with a customer and excludes any sales incentives and amounts collected on behalf of third parties. As explained in more detail below, revenue is recognized upon satisfaction of the performance obligation by transferring control over a product to a Nutrition segment customer. The estimated breakage of gift cards (estimated amount of unused gift cards) is recognized over the pattern of redemption of the gift cards, and direct-mail advertising costs are expensed as incurred. We recognize an asset for the carrying amount of product to be returned and for costs to obtain a contract if the amortization is more than one year in duration. We expense costs to obtain a contract as incurred if the amortization period is less than one year.

We sell pre-packaged foods directly to weight loss program participants primarily through the Internet and telephone (referred to as the direct to consumer channel), through QVC (a television shopping network), and select retailers. Pre-packaged foods are comprised of both frozen and non-frozen (ready-to-go), shelf-stable products.

Products sold through the direct to consumer channel, both frozen and non-frozen, may be sold separately (a la carte) or as part of a packaged monthly meal plan for which Nutrition segment customers pay at the point of sale. Products sold through QVC are payable by QVC upon our shipment of the product to the end consumer. For both the direct to consumer channel and QVC, we recognize revenue at a point in time, i.e., at the shipping point. Direct to consumer customers may return unopened ready-to-go Nutrisystem products within 30 days after purchase in order to receive a refund or credit. Frozen Nutrisystem products are non-returnable and non-refundable unless the order is canceled within 14 days after delivery. South Beach Diet products are not refundable.

We review the reserves for our Nutrition segment customer returns at each reporting period and adjust them to reflect data available at that time. To estimate reserves for returns, we consider actual return rates in preceding periods and changes in product offerings or marketing methods that might impact returns going forward. To the extent the estimate of returns changes, we will adjust the reserve, which will impact the amount of revenue recognized in the period of the adjustment. The provision for estimated returns for the three and six months ended June 30, 2020 was $4.1 million and $9.3 million, respectively. The provision for estimated returns for the three and six months ended June 30, 2019 was $5.6 million and $7.0 million, respectively. The reserve for estimated returns incurred but not received and processed was $1.4 million and $0.8 million at June 30, 2020 and December 31, 2019, respectively, and has been included in accrued liabilities in the accompanying consolidated balance sheet.

Key Performance Indicators

In managing our business, we regularly review and analyze a number of key performance indicators (“KPIs”), including revenues by segment, adjusted EBITDA by segment (both in dollars and as a percentage of revenues), and free cash flow. Free cash flow is not calculated in accordance with U.S. GAAP (“non-GAAP”). These KPIs help us monitor our performance, identify trends affecting our business, determine the allocation of resources, and assess the quality and potential variability of our cash flows and earnings. We believe they are useful to investors in evaluating and understanding our business.

	Three Months Ended June 30,						Six Months Ended June 30,
(In $000s)	2020			2019			2020			2019
Healthcare segment:
Revenues	$	81,923		$	157,481		$	241,615		$	314,008
Adjusted EBITDA		41,472			35,681			71,719			61,810
Adjusted EBITDA as a percentage of revenues		50.6	%		22.7	%		29.7	%		19.7	%
Nutrition segment:
Revenues	$	180,675		$	182,896		$	358,638		$	240,463
Adjusted EBITDA		33,363			34,667			31,916			48,010
Adjusted EBITDA as a percentage of revenues		18.5	%		19.0	%		8.9	%		20.0	%

•

Revenues – we review year-over-year changes in revenue by segment as a key measure of our success in growing our business. In addition to measuring revenue by segment, we also measure and report revenue by program type or source of revenue, as detailed in Note 3 of the notes to the consolidated financial statements included in this report, i.e., SilverSneakers, Prime Fitness, WholeHealth Living, Other, Nutrisystem direct to consumer, South Beach Diet direct to consumer, retail, and QVC. Evaluating revenue by program type or source helps us identify and address changes in product mix, broad market factors that may affect our revenues, and opportunities for future growth.

•

Adjusted EBITDA is defined as described in Note 16, “Segment Disclosures and Concentrations of Risk”, of the notes to the consolidated financial statements included in this report. We believe adjusted EBITDA provides investors a helpful measure for comparing our operating performance with our historical operating results as well as the performance of other companies that may have different financing and capital structures or tax rates. We believe it is a useful indicator of the operational strength and performance of our business without regard to items such as amortization of intangible assets, which can vary substantially from company to company depending upon the nature and extent of acquisitions. Adjusted EBITDA is not considered a non-GAAP measure in the context of ASC 280, “Segment Reporting”, which requires disclosure of the metrics that the chief operating decision maker uses to evaluate performance and allocate resources. Because adjusted EBITDA may be defined differently by other companies in our industry, the financial measure presented herein may not be comparable to similarly titled measures of other companies.

•

Free cash flow is a non-GAAP measure and is defined by the Company as net cash flows provided by operating activities less acquisition of property and equipment. We believe free cash flow is useful to management and investors to measure (i) our performance, (ii) the strength of the Company and its ability to generate cash, and (iii) the amount of cash that is available to repay debt or make other investments. A reconciliation of free cash flow to cash flows from operating activities (the most comparable U.S. GAAP measure) is set forth below.

	Six Months Ended June 30,
(In thousands)	2020			2019
Net cash flows provided by operating activities	$	130,943		$	49,599
Acquisition of property and equipment		(10,362	)		(8,918	)
Free cash flow	$	120,581		$	40,681

Outlook

Although there is significant uncertainty relating to the potential impacts of the COVID-19 pandemic on our business going forward, including the duration of the outbreak, the timing and duration of our fitness partner locations being open, the impact on member participation in our SilverSneakers programs, and the ultimate medium- and long-term impact of the pandemic on the global economy, we expect our results of operations for the short term to be adversely impacted by COVID-19, primarily in our Healthcare segment, when compared to the same periods in the prior year and to our expectations at the beginning of 2020. For the Nutrition segment, we expect revenues for the third quarter of 2020 to decrease compared to the second quarter of 2020 due to normal seasonality in this business.

Executive Overview of Results

The key financial results for the three and six months ended June 30, 2020 are:

•

Revenues of $262.6 million for the three months ended June 30, 2020, including $81.9 million from the Healthcare segment and $180.7 million from the Nutrition segment, compared to revenues of $340.4 million for the three months ended June 30, 2019, including $157.5 million from the Healthcare segment and $182.9 million from the Nutrition segment.

•

Revenues of $600.3 million for the six months ended June 30, 2020, including $241.6 million from the Healthcare segment and $358.6 million from the Nutrition segment, compared to revenues of $554.5 million for the six months ended June 30, 2019, including $314.0 million from the Healthcare segment and $240.5 million from the Nutrition segment.

•

Pre-tax income of $34.6 million for the three months ended June 30, 2020 compared to $26.3 million for the three months ended June 30, 2019. Pre-tax income for the three months ended June 30, 2020 includes:

$51.1 million of marketing expenses, including $50.3 million attributable to the Nutrition segment, compared to $54.6 million for the same period in 2019, which included $50.6 million attributable to the Nutrition segment;

$21.2 million of interest expense compared to $23.7 million for the same period in 2019;

$7.1 million of amortization expense compared to $4.4 million for the same period in 2019;

$2.0 million of transition, acquisition, and integration costs compared to $9.0 million for the same period in 2019;

$1.7 million of CEO transition costs compared to $0 for the same period in 2019;

$1.3 million of COVID-19 costs compared to $0 for the same period in 2019; and

$1.0 million of restructuring and related charges compared to $2.4 million for the same period in 2019.

•

Pre-tax loss of ($178.6) million for the six months ended June 30, 2020 compared to pre-tax income of $35.8 million for the six months ended June 30, 2019. Pre-tax loss for the six months ended June 30, 2020 includes:

$199.5 million of impairment loss, all of which was attributable to the Nutrition segment, compared to $0 for the same period in 2019;

$138.2 million of marketing expenses, including $130.1 million attributable to the Nutrition segment, compared to $78.8 million for the same period in 2019, which included $65.5 million attributable to the Nutrition segment;

$42.9 million of interest expense compared to $31.3 million for the same period in 2019;

$16.2 million of amortization expense compared to $5.8 million for the same period in 2019;

$4.8 million of transition, acquisition, and integration costs compared to $26.0 million for the same period in 2019;

$4.3 million of CEO transition costs compared to $0 for the same period in 2019;

$1.8 million of restructuring and related charges compared to $3.9 million for the same period in 2019; and

$1.3 million of COVID-19 costs compared to $0 for the same period in 2019.

Results of Operations

The following table sets forth the components of the consolidated statements of operations for the three and six months ended June 30, 2020 and 2019 expressed as a percentage of revenues from continuing operations.

	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Revenues		100.0	%		100.0	%		100.0	%		100.0	%
Cost of revenue (exclusive of depreciation and amortization included below)		45.0	%		57.2	%		52.9	%		60.4	%
Marketing expenses		19.5	%		16.0	%		23.0	%		14.2	%
Selling, general and administrative expenses		8.9	%		8.7	%		8.6	%		10.3	%
Depreciation and amortization		4.9	%		2.7	%		4.6	%		2.3	%
Impairment loss		—			—			33.2	%		—
Restructuring and related charges		0.4	%		0.7	%		0.3	%		0.7	%
Operating income (loss) ⁽¹⁾		21.3	%		14.7	%		(22.6	)%		12.1	%

Interest expense		8.1	%		7.0	%		7.1	%		5.7	%
Income (loss) before income taxes ⁽¹⁾		13.2	%		7.7	%		(29.8	)%		6.5	%
Income tax expense		2.3	%		2.4	%		(1.5	)%		2.4	%
Net income (loss) ⁽¹⁾		10.9	%		5.3	%		(28.3	)%		4.0	%

(1)

Figures may not add due to rounding.

Revenues

Revenues were $262.6 million for the second quarter of 2020 compared to $340.4 million for the second quarter of 2019, including the following revenues by segment:

•

Healthcare segment revenues were $81.9 million for the second quarter of 2020 compared to $157.5 million for the second quarter of 2019, a decrease of $75.6 million, primarily as a result of a net decrease in SilverSneakers revenue of $73.7 million driven by a decrease in revenue-generating visits for the second quarter of 2020 due to the COVID-19 pandemic, which resulted in the closure of substantially all of our fitness partner locations beginning in March 2020. While some of these locations reopened in May and additional locations reopened in June of 2020, the average monthly total participation levels of our members after such locations reopened were significantly lower than in the second quarter of 2019. As a result, revenues from PMPM fees represented 88% of SilverSneakers revenue for the second quarter of 2020, compared to 33% for the second quarter of 2019. In addition, revenue from Prime Fitness decreased by $10.7 million due to a decrease in paid subscribers for the second quarter of 2020 compared to the second quarter of 2019. These decreases were partially offset by an increase of $6.8 million during the second quarter of 2020 from a program with a large employer seeking to improve its employees’ well-being during the COVID-19 pandemic. We do not expect revenue from this program to recur at this level in future quarters.

•

Nutrition segment revenues were $180.7 million for the second quarter of 2020 compared to $182.9 million for the second quarter of 2019, a decrease of $2.2 million, primarily due to decreases in revenue from South Beach Diet and retail of $5.8 million and $4.8 million, respectively, mostly offset by an increase in Nutrisystem direct to consumer revenue of $9.1 million, primarily driven by higher revenue from new customers in their initial diet cycle ($11.5 million), partially offset by lower revenue from reactivation of former customers ($2.4 million).

Revenues were $600.3 million for the six months ended June 30, 2020 compared to $554.5 million for the six months ended June 30, 2019, including the following revenues by segment:

•

Healthcare segment revenues were $241.6 million for the six months ended June 30, 2020 compared to $314.0 million for the six months ended June 30, 2019, a decrease of $72.4 million, primarily as a result of a net decrease in SilverSneakers revenue of $75.2 million driven by a decrease in revenue-generating visits in 2020 due to the COVID-19 pandemic, which resulted in the closure of substantially all of our fitness partner locations beginning in March 2020. While some of these locations reopened in May and additional locations reopened in June of 2020, the average participation level of our members after such locations reopened was significantly lower than in the comparable period in 2019. As a result, revenues from PMPM fees represented 51% of SilverSneakers revenue for the six months ended June 30, 2020, compared to 33% for the same period in 2019. In addition, revenue from Prime Fitness decreased by $6.6 million due to a decrease in paid subscribers for the six months ended June 30, 2020 compared to the six months ended June 30, 2019. These decreases were partially offset by an increase of $6.8 million during the second quarter of 2020 from a program with a large employer seeking to improve its employees’ well-being during the COVID-19 pandemic. We do not expect revenue from this program to recur at this level in future quarters.

•

Nutrition segment revenues were $358.6 million for the six months ended June 30, 2020 compared to $240.5 million for the second quarter of 2019, primarily due to the acquisition of Nutrisystem on March 8, 2019.

Cost of Revenue

Cost of revenue (excluding depreciation and amortization) (“Cost of Revenue”) was $118.2 million, or 45.0% of revenues, for the second quarter of 2020 compared to $194.8 million, or 57.2% of revenues, for the second quarter of 2019, including the following Cost of Revenue by segment:

•

For the Healthcare segment, Cost of Revenue was $33.8 million, or 41.3% of revenues, for the second quarter of 2020 compared to $111.1 million, or 70.5% of revenues, for the second quarter of 2019, primarily due to a higher mix of revenues from PMPM fees in the second quarter of 2020, as noted above, coupled with a decrease in visit costs due to the temporary closure of fitness partner locations and a decline in average monthly total participation levels (compared to the same period in 2019) after such locations reopened.

•

For the Nutrition segment, Cost of Revenue was $84.4 million, or 46.7% of revenues, for the second quarter of 2020 compared to $83.7 million, or 45.8% of revenues, for the second quarter of 2019, primarily due to (i) incremental expense due to the COVID-19 pandemic as discussed under “Recent Developments” and (ii) increased food costs and changes in program mix to more premium products. These increases were partially offset by a decrease in acquisition and integration costs.

Cost of Revenue was $317.4 million, or 52.9% of revenues, for the six months ended June 30, 2020 compared to $335.1 million, or 60.4% of revenues, for the six months ended June 30, 2019, including the following Cost of Revenue by segment:

•

For the Healthcare segment, Cost of Revenue was $149.0 million, or 61.6% of revenues, for the six months ended June 30, 2020 compared to $224.9 million, or 71.6% of revenues, for the six months ended June 30, 2019, primarily due to a higher mix of revenues from PMPM fees in 2020, as noted above, coupled with a decrease in visit costs due to the temporary closure of fitness partner locations and a decline in average monthly total participation levels (compared to the same period in 2019) after such locations reopened.

•

For the Nutrition segment, Cost of Revenue was $168.4 million, or 47.0% of revenues, for the six months ended June 30, 2020 compared to $110.2 million, or 45.8% of revenues, for the six months ended June 30, 2019, primarily due to (i) incremental expense due to the COVID-19 pandemic as discussed under “Recent Developments”, (ii) increased food costs and changes in program mix to more premium products, and (iii) promotional activity. These increases were partially offset by a decrease in acquisition and integration costs.

Marketing Expenses

Marketing expenses were $51.1 million, or 19.4% of revenues, for the second quarter of 2020 compared to $54.6 million, or 16.0% of revenues, for the second quarter of 2019, including the following marketing expenses by segment:

•

For the Healthcare segment, marketing expenses were $0.8 million, or 0.9% of revenues, for the second quarter of 2020 compared to $4.0 million, or 2.5% of revenues, for the second quarter of 2019, primarily due to decreased spending in the second quarter of 2020 on SilverSneakers advertising and media campaigns compared to the second quarter of 2019.

•

For the Nutrition segment, marketing expenses as a percentage of revenues did not change materially from the second quarter of 2019 ($50.6 million, or 27.7% of revenues) to the second quarter of 2020 ($50.3 million, or 27.9% of revenues).

Marketing expenses were $138.2 million, or 23.0% of revenues, for the six months ended June 30, 2020 compared to $78.8 million, or 14.2% of revenues, for the six months ended June 30, 2019, including the following marketing expenses by segment:

•

For the Healthcare segment, marketing expenses were $8.1 million, or 3.3% of revenues, for the six months ended June 30, 2020 compared to $13.2 million, or 4.2% of revenues, for the six months ended June 30, 2019, primarily due to decreased spending during the six months ended June 30, 2020 on SilverSneakers advertising and media campaigns compared to the six months ended June 30, 2019.

•

For the Nutrition segment, marketing expenses were $130.1 million, or 36.3% of revenues, for the six months ended June 30, 2020 compared to $65.5 million, or 27.2% of revenues, for the six months ended June 30, 2019, primarily due to a disproportionate amount of annual marketing expenses being incurred in January and February of each year (the beginning of diet season), and in 2019, these expenses were incurred prior to our acquisition of Nutrisystem on March 8, 2019.

Selling, General and Administrative Expenses

Selling, general and administrative (“SG&A”) expenses were $23.5 million, or 8.9% of revenues, for the second quarter of 2020 compared to $29.7 million, or 8.7% of revenues, for the second quarter of 2019, including the following SG&A expenses by segment:

•

For the Healthcare segment, SG&A expenses were $8.9 million, or 10.9% of revenues, for the second quarter of 2020 compared to $11.1 million, or 7.1% of revenues, for the second quarter of 2019, primarily due to (i) the fixed nature of certain costs that cannot be reduced proportionately with reductions in revenue and (ii) CEO transition-related expenses associated with the termination of our former CEO in February 2020 and the hiring of a new CEO in June 2020. These increases were partially offset by a decrease in transition, acquisition, and integration costs from $3.5 million for the second quarter of 2019 to $1.0 million for the second quarter of 2020.

•

For the Nutrition segment, SG&A expenses were $14.6 million, or 8.1% of revenues, for the second quarter of 2020 compared to $18.6 million, or 10.1% of revenues, for the second quarter of 2019, primarily due to a decrease in transition, acquisition, and integration expenses from $3.4 million for the second quarter of 2019 to $0.5 million for the second quarter of 2020.

SG&A expenses were $51.5 million, or 8.6% of revenues, for the six months ended June 30, 2020 compared to $56.9 million, or 10.3% of revenues, for the six months ended June 30, 2019, including the following SG&A expenses by segment:

•

For the Healthcare segment, SG&A expenses were $21.0 million, or 8.7% of revenues, for the six months ended June 30, 2020 compared to $33.8 million, or 10.8% of revenues, for the six months ended June 30, 2019, primarily due to a decrease in transition, acquisition, and integration costs from $18.8 million for the six months ended June 30, 2019 to $2.6 million for the six months ended June 30, 2020. This decrease was partially offset by (i) CEO transition-related expenses associated with the termination of our former CEO in February 2020 and the hiring of a new CEO in June 2020 and (ii) the fixed nature of certain costs that cannot be reduced proportionately with reductions in revenue.

•

For the Nutrition segment, SG&A expenses were $30.5 million, or 8.5% of revenues, for the six months ended June 30, 2020 compared to $23.1 million, or 9.6% of revenues, for the six months ended June 30, 2019, primarily due to a decrease in transition, acquisition, and integration expenses from $4.3 million for the six months ended June 30, 2019 to $0.7 million for the six months ended June 30, 2020.

Impairment Loss

During the first quarter of 2020, we recorded an impairment loss of $199.5 million, including $80.0 million related to the Nutrisystem tradename and $119.5 million related to goodwill allocated to the Nutrition segment. These impairment losses were primarily attributable to rapidly changing market and economic conditions resulting from the COVID-19 pandemic. See Note 12 of the notes to consolidated financial statements included in this report.

Restructuring and Related Charges

2019 Restructuring Plan

During the first quarter of 2019, we began a reorganization primarily related to integrating the Healthcare and Nutrition segments and streamlining our corporate and operations support ("2019 Restructuring Plan"). The 2019 Restructuring Plan concluded during the first quarter of 2020. For the three and six months ended June 30, 2019, we incurred restructuring charges of $2.4 million and $3.9 million, respectively, related to the 2019 Restructuring Plan, of which $0.8 million and $1.8 million, respectively, related to the Healthcare segment and $1.6 million and $2.1 million, respectively, related to the Nutrition segment. For the six months ended June 30, 2020, we incurred restructuring charges of $0.7 million related to the 2019 Restructuring Plan, of which $0.5 million related to the Healthcare segment and $0.2 million related to the Nutrition segment. To date, we have incurred restructuring charges of $7.8 million related to the 2019 Restructuring Plan, of which $2.4 million related to the Healthcare segment and $5.4 million related to the Nutrition segment. These expenses consist entirely of severance and other employee-related costs. The 2019 Restructuring Plan is expected to result in total annualized savings in 2020 of approximately $19.5 million, with $6.7 million relating to the Healthcare segment and $12.8 million relating to the Nutrition segment.

2020 COVID Restructuring Plan

During the second quarter of 2020, we began a reorganization plan primarily related to eliminating certain compensation costs in response to the COVID-19 pandemic in order to preserve our liquidity and manage our cash flows (“2020 COVID Restructuring Plan”). To date, and for the three and six months ended June 30, 2020, we incurred restructuring charges of $1.0 million related to the 2020 COVID Restructuring Plan, of which $0.8 million related to the Healthcare segment and $0.2 million related to the Nutrition segment. These expenses consist entirely of severance and other employee-related costs. The 2020 COVID Restructuring Plan is expected to result in total annualized savings at target performance of approximately $7.5 million, with $6.0 million relating to the Healthcare segment and $1.5 million relating to the Nutrition segment.

Depreciation and Amortization

Depreciation and amortization expense increased by $3.8 million for the second quarter of 2020 compared to the second quarter of 2019, primarily due to increased amortization expense on intangible assets in the Nutrition segment due to an adjustment to the customer list intangible asset to finalize the preliminary purchase price allocation during the fourth quarter of 2019 based on information obtained regarding facts and circumstances that existed as of the acquisition date.

Depreciation and amortization expense increased by $15.0 million for the six months ended June 30, 2020 compared to the six months ended June 30, 2019, primarily due to the acquisition of Nutrisystem on March 8, 2019, which resulted in additional depreciation and amortization expense in 2020 attributable to the acquisition of Nutrisystem’s property and equipment as well as intangible assets recorded in connection with the acquisition.

Interest Expense

Interest expense decreased by $2.4 million for the second quarter of 2020 compared to the second quarter of 2019, primarily due to a lower level of outstanding borrowings in 2020 under the Credit Agreement (as defined below).

Interest expense increased by $11.6 million for the six months ended June 30, 2020 compared to the six months ended June 30, 2019, primarily due to our entering into a new Credit and Guaranty Agreement (the “Credit Agreement”) with a group of lenders, Credit Suisse AG, Cayman Islands Branch, as general administrative agent, term facility agent and collateral agent, and SunTrust Bank, as revolving facility agent and swingline lender, on March 8, 2019, including term loans with an initial borrowing of $1,180 million, in connection with the acquisition of Nutrisystem.

Income Tax Expense

See Note 8 of the notes to consolidated financial statements in this report for a discussion of income tax expense.

Liquidity and Capital Resources

Overview

As of June 30, 2020, outstanding debt under the Credit Agreement was $1.0 billion, and we had $60.3 million of cash and cash equivalents.

As of June 30, 2020, we had a working capital deficit of $5.7 million. While the COVID-19 pandemic has created significant uncertainty as to general economic and market conditions for the remainder of 2020 and beyond, as of the date of this report, we believe our cash on hand, expected cash flows from operations, and anticipated available credit under the Credit Agreement will be sufficient to fund our operations, principal and interest payments, and capital expenditures (which we currently plan to curtail for the remainder of 2020) for the next 12 months. We cannot assure you that we will be able to secure additional financing if needed and, if such funds are available, whether the terms or conditions will be favorable to us. With the uncertainty surrounding COVID-19, our ability to engage in financing transactions may be constrained by (i) volatile or tight economic, capital, credit and/or financial market conditions, (ii) moderated investor and/or lender interest or capacity, (iii) restrictions under our Credit Agreement, and/or (iv) our liquidity, leverage and net worth, and we can provide no assurance as to successfully completing, the costs of, or the operational limitations arising from any one or series of such transactions. As of June 30, 2020, availability under the Revolving Credit Facility totaled $124.5 million as calculated under the most restrictive covenant.

Credit Facility

In connection with the consummation of the acquisition of Nutrisystem, on March 8, 2019, we entered into the Credit Agreement. The Credit Agreement provides us with (i) a $350.0 million Term Loan A, (ii) an $830.0 million Term Loan B, (iii) a $125.0 million revolving credit facility that includes a $35.0 million sublimit for swingline loans and a $50.0 million sublimit for letters of credit, and (iv) uncommitted incremental accordion facilities in an aggregate amount at any date equal to the greater of $125.0 million or 50% of our consolidated EBITDA for the then-preceding four fiscal quarters, plus additional amounts based on, among other things, satisfaction of certain financial ratio requirements.

We are required to repay Term Loan A loans in consecutive quarterly installments, each in the amount of 2.50% of the aggregate initial amount of such loans, payable beginning on June 30, 2019 and on the last day of each succeeding quarter thereafter until maturity on March 8, 2024, at which time the entire outstanding principal balance of such loans is due and payable in full. We are required to repay Term Loan B loans in consecutive quarterly installments, each in the amount of 0.75% of the aggregate initial amount of such loans, payable beginning on June 30, 2019 and on the last day of each succeeding quarter thereafter until maturity on March 8, 2026, at which time the entire outstanding principal balance of such loans is due and payable in full. We are permitted to make voluntary prepayments of borrowings under the Term Loans at any time without penalty. From March 8, 2019 through June 30, 2020, we made payments of $125.0 million on the Term Loans, which included prepayments of all amounts due through March 31, 2021, excluding any Excess Cash Flow Payments that may be required, as described below. We are required to repay in full any outstanding swingline loans and revolving loans under the Revolving Credit Facility on March 8, 2024. In addition, the Credit Agreement contains provisions that, beginning with fiscal 2019, may require annual excess cash flow (as defined in the Credit Agreement and generally designed to equal cash generated by our business in excess of cash used in the business) to be applied towards the Term Loans. We are required to make prepayments on the Term Loans equal to our excess cash flow for a given fiscal year multiplied by the following excess cash flow percentages (such resulting payment an “Excess Cash Flow Payment”) based on our Net Leverage Ratio (as defined in the Credit Agreement) on the last day of such fiscal year: (a) 75% if the Net Leverage Ratio is greater than 3.75:1, (b) 50% if the Net Leverage Ratio is equal to or less than 3.75:1 but greater than 3.25:1 (c) 25% if the Net Leverage Ratio is equal to or less than 3.25:1 but greater than 2.75:1, and (d) 0% if the Net Leverage Ratio is equal to or less than 2.75:1. Any such potential mandatory prepayments are reduced by voluntary prepayments. We were not required to make an Excess Cash Flow Payment for fiscal 2019.

In July 2020, we repaid $24.8 million of principal on the term loans under our credit agreement, resulting in our next required quarterly installment being due in December 2021. Based on our current assumptions with respect to the COVID-19 pandemic, including, among other things, our fitness partner locations reopening and/or remaining open and the average monthly total participation levels of our members at such locations, we currently believe we will be in compliance with the Net Leverage Ratio covenant over the next 12 months; however, given the significant uncertainty relating to the potential impacts of the COVID-19 pandemic on our business going forward, there are potential scenarios under which we could fail to comply with the Net Leverage Ratio covenant. Our failure to comply with the Net Leverage Ratio covenant would result in an event of default that, if not waived, could have a material adverse effect on our financial condition, results of operations or debt service capability. We will continue to monitor our projected ability to comply with all covenants under the Credit Agreement, including the Net Leverage Ratio, which could include seeking an amendment to or waiver of the Net Leverage Ratio covenant if necessary.

Cash Flows Provided by Operating Activities

Operating activities during the six months ended June 30, 2020 provided cash of $130.9 million compared to $49.6 million during the six months ended June 30, 2019. The increase in operating cash flow is primarily due to (i) increased collections on accounts receivable, (ii) decreased payments related to acquisition and integration costs, and (iii) decreased payments related to visit costs. These changes were partially offset by higher interest payments related to borrowings under the Credit Agreement.

Cash Flows Used in Investing Activities

Investing activities during the six months ended June 30, 2020 used $10.4 million in cash, compared to $1,072 million during the six months ended June 30, 2019. This change is primarily due to the acquisition of Nutrisystem in March 2019.

Cash Flows Provided by (Used In) Financing Activities

Financing activities during the six months ended June 30, 2020 used $62.8 million in cash, compared to cash provided of $1,025 million during the six months ended June 30, 2019. This decrease is primarily due to a higher amount of net borrowings under the Credit Agreement in 2019 (compared to net payments under the Credit Agreement in 2020) and the payment of deferred loan costs in 2019, each related to the acquisition of Nutrisystem in March 2019.

Recent Relevant Accounting Standards

See Note 2 of the notes to consolidated financial statements included in this report for discussion of recent relevant accounting standards.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are subject to market risk related to interest rate changes, primarily as a result of the Credit Agreement. Borrowings under the Credit Agreement bear interest at variable rates based on a margin or spread in excess of either (1) one-month, two-month, three-month or six-month LIBOR (or, with the approval of all lenders holding the particular class of loans, 12-month LIBOR), which may not be less than zero, or (2) the greatest of (a) the prime lending rate of the agent bank for the particular facility, (b) the federal funds rate plus 0.50%, and (c) one-month LIBOR plus 1.00% (“Base Rate”), as selected by the Company. The LIBOR margin for Term Loan A loans is 4.25%, the LIBOR margin for Term Loan B loans is 5.25%, and the LIBOR margin for revolving loans varies between 3.75% and 4.25%, depending on our total Net Leverage Ratio. The Base Rate margin for Term Loan A loans is 3.25%, the Base Rate margin for Term Loan B loans is 4.25%, and the Base Rate margin for revolving

loans varies between 2.75% and 3.25%, depending on our total Net Leverage Ratio. Effective May 31, 2019, we maintain amortizing interest rate swap agreements with current notional amounts totaling $800.0 million, through which we receive a variable rate of interest based on LIBOR, and we pay a fixed rate of interest equal to approximately 2.2% plus a spread.

We estimate that a one-point interest rate change in our floating rate debt would have resulted in a change in interest expense of approximately $1.6 million for the six months ended June 30, 2020.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company's principal executive officer and principal financial officer have reviewed and evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) promulgated under the Exchange Act) as of June 30, 2020. Based on that evaluation, the principal executive officer and principal financial officer have concluded that the Company's disclosure controls and procedures are effective as of June 30, 2020. They are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and forms and to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company's management, including the principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company's internal controls over financial reporting during the three months ended June 30, 2020 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Part II Other Information

Item 1. Legal Proceedings

See Note 11 of the notes to consolidated financial statements included in this report for discussion of recent legal proceedings.

Item 1A. Risk Factors

Part I, Item 1A. “Risk Factors” in the 2019 Form 10-K, as amended and restated in its entirety in Part II, Item 1A. “Risk Factors” in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, is amended and restated in its entirety as follows:

In the execution of our business strategy, our operations and financial condition are subject to certain risks. A summary of certain material risks is provided below, and you should take such risks into account in evaluating any investment decision involving the Company. This section does not describe all risks applicable to us and is intended only as a summary of certain material factors that could impact our operations in the industry in which we operate. Other sections of this report contain additional information concerning these and other risks.

Risks Relating to Our Business Generally

The COVID-19 pandemic has had, and is expected to continue to have, a material adverse effect on our business and results of operations.

In late 2019, COVID-19 was reported to have surfaced in Wuhan, China and has spread to other countries, including the United States. In January 2020, the Secretary of HHS declared a national public health emergency due to COVID-19, and in March 2020, the World Health Organization characterized the outbreak of COVID-19 as a global pandemic. Many state and local governments, together with public health officials, have recommended and mandated precautions to mitigate the spread of COVID-19, including ordering closure of certain businesses and imposing stay-at-home orders and social distancing guidelines for individuals. As a result, by March 31, 2020, substantially all of the fitness centers in our national network were temporarily closed. A substantial number of our fitness partner locations remained closed through April 2020. Although some locations reopened in May 2020 and additional locations reopened in June 2020, the average monthly total participation levels of our members after such locations reopened were significantly below historical levels, thus adversely impacting revenues in our Healthcare segment during the second quarter of 2020. We may face reclosures and/or long-term closures and other operational restrictions with respect to some or all of our Healthcare segment’s fitness partner locations for prolonged periods of time due to, among other factors, evolving governmental restrictions including public health directives, quarantine policies, or social distancing measures. Additionally, even if fitness partner locations are open, members may avoid public gathering places because of a perceived risk of infection or risk to health, which could reduce overall demand and adversely impact their use of our services. Because a significant portion of our Healthcare segment revenues from our SilverSneakers program is based on member visits to a fitness partner location, this decrease in member participation has affected and could further adversely affect our business and results of operations.

Consumer spending generally may also be negatively impacted by adverse general macroeconomic conditions and reduced consumer confidence, including the impacts of any recession resulting from the COVID-19 pandemic. This may further negatively impact the number of paid subscribers in our Prime Fitness program. In addition, it may negatively impact sales in our Nutrition segment and may cause our Nutrition segment’s direct to consumer and retail customers to purchase fewer products from us. Any significant reduction in consumer spending caused by COVID-19 and decreased consumer confidence and spending following the pandemic would likely result in a loss of sales and profits in our Nutrition segment and other material adverse effects.

The COVID-19 pandemic also has the potential to significantly impact our Nutrition segment’s supply chain, food manufacturers, distribution centers, or logistics and other service providers. We have experienced delays and some additional costs in fulfilling orders for our Nutrition segment’s products at certain of our warehouses due to some employees of our fulfillment provider testing positive for COVID-19 and could experience similar events or delays at our other warehouses. Additionally, our service providers and their operations may be disrupted, temporarily closed or experience worker shortages, which could result in additional disruptions or delays in shipments of our Nutrition segment’s products.

As a result of the COVID-19 pandemic, including related governmental guidance or requirements, we have implemented a work-from-home policy for our employees, which may negatively impact productivity and cause other disruptions to our business. We closed our corporate offices and/or call centers in Franklin, Tennessee, Fort Washington, Pennsylvania and Chandler, Arizona from mid-March through May and began reopening our corporate offices on a limited basis in June as we continue to prioritize the safety and well-being of our employees. We have incurred, and may incur in the future, costs related to implementing our work-from-home policy as well as additional cleaning fees and supplies related to the COVID-19 pandemic.

The full extent of the impact of the COVID-19 pandemic on our business is highly uncertain and difficult to predict, as information is rapidly evolving with respect to the duration and severity of the pandemic. At this point, we cannot predict with certainty the duration and severity of the COVID-19 pandemic or its future impact on our business, and our estimates could change in the future.

The performance of our business (as it could further be affected by the COVID-19 pandemic) and the level of our indebtedness could prevent us from meeting the obligations under our Credit Agreement or have an adverse effect on our future financial condition, our ability to raise additional capital, or our ability to react to changes in the economy or our industry.

In connection with the consummation of the acquisition of Nutrisystem, on March 8, 2019, we entered the Credit Agreement. As of June 30, 2020, outstanding debt under the Credit Agreement was $1,012.3 million.

Our ability to service our indebtedness will depend on our ability to generate cash in the future. We cannot assure you that our business will generate sufficient cash flow from operations or that future borrowings will be available in an amount sufficient to enable us to service our indebtedness or to fund other liquidity needs. If there are prolonged or worsening effects of the COVID-19 pandemic, such as long-term closures of our fitness partner locations, we could be unable to generate revenues and cash flows sufficient to conduct our business, service our outstanding debt and comply with the covenants under the Credit Agreement. This could, among other things, exhaust our available liquidity (and ability to access liquidity sources) and/or result in an acceleration of the maturity of a significant portion or all of our then-outstanding debt obligations, which we may be unable to repay or refinance.

The Credit Agreement contains a Net Leverage Ratio covenant. Given the significant uncertainty relating to the potential impacts of the COVID-19 pandemic on our business going forward, there are potential scenarios under which we could fail to comply with the Net Leverage Ratio covenant contained in our Credit Agreement. Our failure to comply with such covenant would result in an event of default that, if not waived, could have a material adverse effect on our financial condition, results of operations or debt service capability. The Credit Agreement also contains various other affirmative and negative covenants customary for financings of this type that, subject to certain exceptions, impose restrictions and limitations on us and certain of our subsidiaries with respect to, among other things, indebtedness; liens; negative pledges; restricted payments (including dividends, distributions, buybacks, redemptions, repurchases with respect to equity interests, and payments, redemptions, retirements, purchases, acquisitions, defeasance, exchange, conversion, cancellation or termination with respect to junior lien, subordinated or unsecured debt); restrictions on subsidiary distributions; loans, advances, guarantees, acquisitions and other investments; mergers and other fundamental changes; sales and other dispositions of assets (including equity interests in subsidiaries); sale/leaseback transactions; transactions with affiliates; conduct of business; amendments and waivers of organizational documents and material junior debt agreements; and changes to fiscal year.

Our indebtedness could adversely affect our future financial condition or our ability to react to changes in the economy or industry by, among other things:

•

increasing our vulnerability to a downturn in general economic conditions (including any downturn or recession caused by the COVID-19 pandemic), loss of revenue and/or profit margins in our business, or to increases in interest rates, particularly with respect to the portion of our outstanding debt that is subject to variable interest rates;

•

potentially limiting our ability to obtain additional financing or to obtain such financing on favorable terms;

causing us to dedicate a portion of future cash flow from operations to service or pay down our debt, which reduces the cash available for other purposes, such as operations, capital expenditures, and future business opportunities; and

•

possibly limiting our ability to adjust to changing market conditions and placing us at a competitive disadvantage compared to our competitors who may be less leveraged.

If our customers experience financial distress, or seek to change or delay payment terms, it could negatively affect our financial position and results.

At any given time, one or more of our customers may experience financial difficulty, file for bankruptcy protection or go out of business. Unfavorable economic and financial conditions, such as the current events surrounding the COVID-19 pandemic, could result in an increase in our customers’ financial difficulties that then affect us. The direct impact on us could include reduced revenues and write-offs of accounts receivable and negatively impact our operating cash flow. While we currently cannot estimate what those effects will be, if they are severe, the indirect impact could include impairments of intangible assets and reduced liquidity, among others.

We are reviewing strategic alternatives for our Nutrition business unit, but there can be no assurance that we will be successful in identifying or consummating any strategic alternatives, that strategic alternatives will yield additional value for stockholders, or that exploration of strategic alternatives for our Nutrition business unit will not adversely impact the Company.

On May 6, 2020, we announced we are exploring strategic alternatives relating to our Nutrition business unit, including a potential transaction. If we determine to divest of the Nutrition business unit, we can give no assurance as to whether we will be able to secure a buyer for our Nutrition business unit or, if we do so, whether such divestiture will be at a price or on terms that are favorable to us, and we may incur a loss on disposal. Speculation regarding any developments related to the review of strategic alternatives for our Nutrition business unit and perceived uncertainties related to the future of the Company could cause our stock price to fluctuate significantly.

Our exploration of strategic alternatives for our Nutrition business unit could result in management distraction, incurrence of significant transaction expenses, failure to retain or attract key personnel, vendors or customers, or exposure to potential litigation. If we are unable to mitigate these or other potential risks related to the uncertainty caused by our exploration of strategic alternatives for our Nutrition business unit, it may disrupt our business and could have a material adverse effect on our business, financial condition, results of operations or cash flows.

We may not be able to realize the anticipated benefits from a divestiture of our Nutrition business unit. There can be no assurance that any potential transaction or other strategic alternative, if identified, evaluated and consummated, will provide greater value to our stockholders than that reflected in our current stock price. Further, the Board may determine to suspend or terminate the exploration of strategic alternatives for our Nutrition business unit at any time due to various factors. Any potential transaction or other outcome of this process is also dependent upon a number of factors that may be beyond our control, including among other factors, market conditions (including the impact of the COVID-19 pandemic), industry trends, regulatory limitations and the interest of third parties in our business.

Our business strategy relating to the development and introduction of new products and services exposes us to risks such as limited customer and/or market acceptance and additional expenditures that may not result in additional net revenue.

An important component of our business strategy is to focus on new products and services that enable us to provide immediate value to our customers. We cannot predict whether customers and/or the market will accept these new products and services, and if we fail to execute successfully on this strategy or to adapt this strategy as market conditions evolve, our ability to grow revenue and our results of operations may be adversely affected.

If we fail to successfully implement our business strategy, our financial performance and our growth could be materially and adversely affected.

Our future financial performance and success are dependent in large part upon our ability to implement our business strategy successfully. Implementation of our strategy will require effective management of our operational, financial and human resources and will place significant demands on those resources. See Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations – Business Strategy" in this report for more information regarding our business strategy. There are risks involved in pursuing our strategy, including the ability to hire or retain the personnel necessary to manage our strategy effectively.

In addition to the risks set forth above, implementation of our business strategy could be affected by a number of factors beyond our control, such as epidemics and pandemics (including the responses of governmental authorities to contain such epidemics and pandemics), increased competition, legal developments, government regulation, general economic conditions, increased operating costs or expenses, and changes in industry trends. We may decide to alter or discontinue certain aspects of our business strategy at any time. If we are not able to implement our business strategy successfully, our long-term growth and profitability may be adversely affected. Even if we are able to implement some or all of the initiatives of our business strategy successfully, our operating results may not improve to the extent we anticipate, or at all.

We may experience difficulties associated with the implementation and/or integration of new businesses, services (including outsourced services), technologies, solutions, or products.

We may face difficulties, costs, and delays in effectively implementing and/or integrating acquired businesses, services (including outsourced services), technologies, solutions, or products into our business. Implementing internally-developed solutions and products, and/or integrating newly acquired businesses, services (including outsourced services), and technologies could be time-consuming and may strain our resources. Consequently, we may not be successful in implementing and/or integrating these new businesses, services, technologies, solutions, or products and may not achieve anticipated revenue and cost benefits.

Our variable rate indebtedness subjects us to interest rate risk, which could cause our debt service obligations to increase significantly, and changes in LIBOR reporting practices could lead to an increase in the cost of our indebtedness and adversely affect our results of operations.

Borrowings under our Credit Agreement are at variable rates of interest and expose us to interest rate risk. Interest rates are currently at historically low levels, but if interest rates increase, our debt service obligations with respect to our variable rate indebtedness would increase even if the amount borrowed remained the same, and our net income and cash flows would correspondingly decrease.

To mitigate our exposure to future interest rate volatility with respect to our variable rate indebtedness, we have entered into interest rate swaps and may in the future enter into additional interest rate swaps, which involve the exchange of floating for fixed rate interest payments. Considering hedging gains and losses and cash settlement costs, we may not elect to maintain such interest rate swaps, and any swaps may not fully mitigate our interest rate risk.

In addition, a transition away from LIBOR as a benchmark for establishing the applicable interest rate may adversely affect our variable rate debt and interest rate swaps. The Financial Conduct Authority of the United Kingdom has announced that by the end of calendar year 2021 it will no longer require LIBOR submissions, resulting in the possible unavailability or lack of suitability of LIBOR as a benchmark rate. While our borrowing arrangements provide for alternative base rates as well as a method for selecting a benchmark replacement for LIBOR, the consequences of the possibility of LIBOR becoming unavailable or not suitable cannot be entirely predicted at this time. Use of an alternative base rate or a benchmark replacement for LIBOR as a basis for calculating interest with respect to our outstanding variable rate indebtedness or interest rate swap agreements could lead to an increase in the interest we pay and a corresponding increase in the cost of such indebtedness, and could affect our ability to refinance some or all of our existing indebtedness or otherwise have a material adverse impact on our business, financial condition and results of operations.

Changes in macroeconomic conditions and certain market risks may adversely affect our business.

Economic difficulties and other macroeconomic conditions (including any downturn or recession caused by the COVID-19 pandemic) could reduce the demand and/or the timing of purchases for certain of our services from customers and potential customers. In addition, changes in economic conditions could create liquidity and credit constraints. We cannot assure you that we would be able to secure additional financing if needed and, if such funds were available, that the terms and conditions would be acceptable to us.

We have a significant amount of goodwill and intangible assets, the value of which could become further impaired.

We have recorded significant portions of the purchase price of certain acquisitions as goodwill and/or intangible assets. We review goodwill and intangible assets not subject to amortization for impairment on an annual basis (during the fourth quarter) or more frequently whenever events or circumstances indicate that the carrying value may not be recoverable. In the fourth quarter of 2019, we recorded impairment losses of $240.0 million and $137.1 million related to the Nutrisystem tradename and goodwill, respectively. The COVID-19 pandemic has had and is having an adverse impact on the overall economy, resulting in rapidly changing market and economic conditions that have impacted the Company. In March 2020, we experienced a significant decline in the Company’s market capitalization and, as discussed above under Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations – Overview”, in the actual and forecasted operating results of our Healthcare segment, in addition to the unfavorable change in market conditions. As a result, management concluded that there were triggering events during the first quarter of 2020 necessitating an impairment evaluation of our goodwill and indefinite-lived intangible assets. During the first quarter of 2020, we recorded an impairment loss of $199.5 million, including $80.0 million related to the Nutrisystem tradename and $119.5 million related to goodwill allocated to the Nutrition segment. At June 30, 2020, we had approximately $535.1 million and $593.5 million of goodwill and intangible assets, respectively, remaining. Following the impairment loss, as of June 30, 2020, there is no excess of estimated fair value over carrying value (“headroom”) for the Nutrition reporting unit. If we determine that the carrying values of our goodwill and/or intangible assets should be further impaired, we may incur additional non-cash charges to earnings, which could have a material adverse effect on our results of operations for the period in which the additional impairment occurs.

A failure of our information technology or systems could adversely affect our business.

Our ability to deliver our products and services depends on effectively using information technology. We rely upon our information technology and systems, employees, and third parties for operating and monitoring all major aspects of our business. These technologies and systems and, therefore, our operations could be damaged or interrupted by natural disasters, power loss, network failure, improper operation by our employees, data privacy or security breaches, computer viruses, computer hacking, network penetration or other illegal intrusions, epidemics or pandemics (such as the COVID-19 pandemic), or other unexpected events. Any disruption in the operation of our information technology or systems, regardless of the cause, could adversely impact our operations, which may adversely affect our financial condition, results of operations and cash flows.

A cybersecurity incident could result in the loss of confidential data, give rise to remediation and other expenses, expose us to liability under the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), consumer protection laws, common law theories or other laws, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business.

The nature of our business involves the receipt, storage and use of personal data about the participants in our programs, including individually identifiable health information, as well as employees and customers. Additionally, we rely upon third parties that are not directly under our control to store and use portions of that personal data as well. The secure maintenance of this and other confidential information or other proprietary information is critical to our business operations. To protect our information systems from attack, damage and unauthorized use, we have implemented multiple layers of security, including technical safeguards, processes, and our people. Our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, threats from malicious persons and groups, new vulnerabilities, technology failures, and advanced attacks against information systems create risk of cybersecurity incidents. We cannot provide assurance that we or our third-party vendors or other service providers will not be subject to cybersecurity incidents, which may result in unauthorized access by third parties, loss, misappropriation, disclosure or corruption of customer, employee, or our information; member

personal health information; or other data subject to privacy laws. In addition, COVID-19 may have an adverse impact on our information technology systems and our ability to securely preserve confidential information, including as a result of telecommuting issues associated with our employees working remotely. Such cybersecurity incidents or delays in responding to or remedying damage caused by such incidents may lead to a disruption in our systems or business, costs to modify, enhance, or remediate our cybersecurity measures, liability under privacy, security and consumer protection laws or litigation under these or other laws, including common law theories, and subject us to enforcement actions, fines, regulatory proceedings or litigation against us, damage to our business reputation, a reduction in participation and sales of our products and services, and legal obligations to notify customers or other affected individuals about an incident, which could cause us to incur substantial costs and negative publicity, any of which could have a material adverse effect on our financial condition and results of operations and harm our business reputation.

As a result, cybersecurity and the continued development and enhancement of our controls, processes and practices remain a priority for us. We may be required to expend significant additional resources in our efforts to modify or enhance our protective measures against evolving threats or to investigate and remediate any cybersecurity vulnerabilities.

Our business is subject to changing privacy and security laws, rules and regulations, including HIPAA, the Payment Card Industry Data Security Standards, the Telephone Consumer Protection Act and other state privacy regulations, which impact our operating costs and for which failure to adhere could negatively impact our business.

Our business is subject to various privacy and data security laws, regulations, and codes of conduct that apply to our business units, which may include the rules and regulations of the Payment Card Industry Data Security Standards and the Telephone Consumer Protection Act (“TCPA”). In addition, we are Health Information Trust Alliance (“HITRUST”) Common Security Framework certified, which is an industry operating standard applied to our data security practices. Some of these state laws and regulations may be inconsistent across jurisdictions and subject to evolving and differing (sometimes conflicting) interpretations and applications. While we are using internal and external resources to monitor compliance with and to continue to modify our data processing practices and policies in order to comply with evolving privacy laws, relevant regulatory authorities could determine that our data handling practices fail to address all the requirements of certain new laws, which could subject us to penalties and/or litigation. Government regulators, privacy advocates and class action attorneys are increasingly scrutinizing how companies collect, process, use, store, share and transmit personal data. This increased scrutiny may result in new interpretations of existing laws as well as new laws, regulations, and industry standards concerning privacy, data protection, and information security proposed and enacted in various jurisdictions, thereby further impacting our business. For example, the California Consumer Privacy Act of 2018 (“CCPA”), went into effect on January 1, 2020, and it applies broadly to information that identifies or is associated with any California household or individual, and compliance with the new law requires that we implement several operational changes, including processes to respond to individuals’ data access and deletion requests. Failure to comply with the CCPA may result in attorney general enforcement action and damage to our reputation. The CCPA also provides for civil penalties for violations, as well as a private right of action for data breaches that may increase data breach litigation. We may also be exposed to litigation, regulatory fines, penalties or other sanctions if the personal, confidential or proprietary information of our customers is mishandled or misused by any of our suppliers, counterparties or other third parties, or if such third-parties do not have appropriate controls in place to protect such personal, confidential or proprietary information. Additionally, the Federal Trade Commission (“FTC”) and many state attorneys general are interpreting federal and state consumer protection laws to impose standards for the collection, use, dissemination and security of data. The obligations imposed by the CCPA and other similar laws that may be enacted at the federal and state level may require us to modify our business practices and policies and to incur substantial expenditures in order to comply.

In order to be successful, we must attract, engage, retain and integrate key employees and have adequate succession plans in place, and failure to do so could have an adverse effect on our ability to manage our business.

Our success depends, in large part, on our ability to attract, engage, retain and integrate qualified executives and other key employees throughout all areas of our business. Identifying, developing internally or hiring externally, training and retaining highly skilled managerial and other personnel are critical to our future, and competition for experienced employees can be intense. Failure to successfully recruit executives and key employees or the loss of any executives and key employees could have a significant impact on our operations. The loss of services of any

key personnel, the inability to retain and attract qualified personnel in the future, or delays in hiring may harm our business and results of operations. Further, changes in our management team may be disruptive to our business, and any failure to successfully integrate key newly hired employees could adversely affect our business and results of operations.

We face competition for staffing, which may increase our labor costs and reduce profitability.

We compete with other healthcare and services providers in recruiting qualified management, including executives with the required skills and experience to operate and grow our business, and staff personnel for the day-to-day operations of our business. These challenges may require us to enhance wages and benefits to recruit and retain qualified management and other professionals. Difficulties in attracting and retaining qualified management and other professionals, or in controlling labor costs, could have a material adverse effect on our profitability.

We are or may become a party to litigation that could potentially force us to pay significant damages and/or harm our reputation.

We are subject to certain legal proceedings, which potentially involve large claims and significant defense costs (see Part II, Item 1. "Legal Proceedings" in this report). These legal proceedings and any other claims that we may face in the future, whether with or without merit, could result in costly litigation, and divert the time, attention, and resources of our management. The coverage limits of our insurance policies may not be adequate to cover all such claims and some claims may not be covered by insurance. Additionally, insurance coverage with respect to some claims against us or our directors and officers may not be available on terms that would be favorable to us, or the cost of such coverage could increase in the future. Further, although we believe that we have conducted our operations in compliance with applicable statutory and contractual requirements and that we have meritorious defenses to outstanding claims, it is possible that resolution of these legal matters could have a material adverse effect on our results of operations. In addition, legal expenses associated with the defense of these matters may be material to our results of operations in a particular financial reporting period.

Third parties may infringe on our brands, trademarks and other intellectual property rights, which may have an adverse impact on our business.

We currently rely on a combination of trademark and other intellectual property laws and confidentiality procedures to establish and protect our proprietary rights, including our brands. If we fail to successfully enforce our intellectual property rights, the value of our brands, services and products could be diminished and our business may suffer. Our precautions may not prevent misappropriation of our intellectual property. Any legal action that we may bring to protect our brands and other intellectual property could be unsuccessful and expensive and could divert management’s attention from other business concerns. In addition, legal standards relating to the validity, enforceability and scope of protection of intellectual property, especially in Internet-related businesses, are uncertain and evolving. We cannot assure you that these evolving legal standards will sufficiently protect our intellectual property rights in the future.

We may be subject to intellectual property rights claims.

Third parties may make claims against us alleging infringement of their intellectual property rights. Any intellectual property claims, regardless of merit, could be time-consuming and expensive to litigate or settle and could significantly divert management’s attention from other business concerns. In addition, if we were unable to successfully defend against such claims, we may have to pay damages, stop selling the service or product or stop using the software, technology or content found to be in violation of a third party’s rights, seek a license for the infringing service, product, software, technology or content or develop alternative non-infringing services, products, software, technology or content. If we cannot license on reasonable terms, develop alternatives or stop using the service, product, software, technology or content for any infringing aspects of our business, we may be forced to limit our service and product offerings. Any of these results could reduce our revenue and our ability to compete effectively, increase our costs or harm our business.

Damage to our reputation could harm our business, including our competitive position and business prospects.

Our ability to attract and retain customers, members and employees is impacted by our reputation. Harm to our reputation can arise from various sources, including employee misconduct, cyber security breaches, unethical behavior, litigation or regulatory outcomes, which could, among other consequences, increase the size and number of litigation claims and damages asserted or subject us to enforcement actions, fines and penalties and cause us to incur related costs and expenses.

We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act (the “FCPA”) and similar anti-bribery laws of other countries in which we provided services prior to the sale of our total population health services (“TPHS”) business.

Because of the international operations that we previously conducted as part of our TPHS business that we sold to Sharecare, Inc. in July 2016, we could be adversely affected by violations of the FCPA and similar anti-bribery laws of other countries in which we provided services prior to the sale. The FCPA and similar anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to government officials or other third parties for the purpose of obtaining or retaining business or gaining any business advantage. While our policies mandated compliance with these anti-bribery laws, we cannot provide assurance that our internal control policies and procedures always protected us from reckless or criminal acts committed by our employees, contractors or agents. Failure to comply with the FCPA and similar legislation prior to the sale of our TPHS business could result in the imposition of civil or criminal fines and penalties and could disrupt our business and adversely affect our results of operations, cash flows and financial condition.

Risks Relating to Our Healthcare Segment

A significant percentage of Healthcare segment revenues is derived from health plan customers.

A significant percentage of our Healthcare segment revenues is derived from health plan customers. The health plan industry may continue to consolidate, and we cannot assure you that we will be able to retain health plan customers, or continue to provide our products and services to such health plan customers on terms at least as favorable to us as currently provided, if they are acquired by other health plans that already participate in competing programs or are not interested in our programs. Increasing vertical integration efforts involving health plans and healthcare providers or entities that provide wellness services may increase these challenges. Our health plan customers that are part of larger healthcare enterprises may have greater bargaining power, which may lead to further pressure on the prices for our products and services. In addition, a reduction in the number of covered lives enrolled with our health plan customers or in the payments we receive could adversely affect our results of operations. Our health plan customers are subject to continuing competition and reduced reimbursement rates from governmental and private sources, which could lead current or prospective customers to seek reduced fees or choose to reduce or delay the purchase of our services. Finally, health plan customers could offer (and in some cases are offering) services themselves that compete directly with our offerings, stop providing our offerings to certain or all of their members (as one of our customers, United Healthcare, has done), or offer fitness benefits in addition to SilverSneakers and Prime Fitness, which could adversely affect our business and results of operations.

We currently derive a significant percentage of our Healthcare segment revenues from three customers.

For the year ended December 31, 2019, three customers each comprised more than 10%, and together comprised approximately 45%, of our Healthcare segment’s revenues. Our primary contracts with two of these customers continue through December 31, 2022, and our primary contract with the third customer continues through December 31, 2021. The loss or restructuring of a contract with any of these three customers or any other significant customers of our Healthcare segment could have a material adverse effect on our business and results of operations. None of these three contracts allows the customer to terminate for convenience prior to the expiration of the contract.

Our inability to renew and/or maintain contracts with our Healthcare segment customers and/or fitness partner locations under existing terms or restructure these contracts under favorable terms could adversely affect our business and results of operations.

If our Healthcare segment customers and/or fitness partner locations choose not to renew their contracts with us (which occurs from time to time), our business and results of operations could be materially adversely affected. Loss of a significant fitness partner or health plan customer or a reduction in a health plan customer's enrolled lives (including as a result of increased unemployment and the resulting loss of health insurance coverage) could have a material adverse effect on our business and results of operations. In addition, a restructuring of a contract with a health plan customer and/or fitness partner on terms that aren’t favorable to us could adversely affect our business and results of operations. Moreover, the businesses of our fitness partner locations have been and will likely continue to be adversely affected by the closure of locations, any public health directives, or social distancing measures applicable upon reopening of locations and reduced overall consumer demand for fitness center use as a result of the COVID-19 pandemic. If a significant portion of our fitness partner network is unable to return to normal operations within a reasonable period of time as a result of financial or operational stresses brought on by the COVID-19 pandemic, we may be unable to make alternative arrangements with substitute fitness partners on favorable terms or at all.

Reductions in Medicare Advantage health plan reimbursement rates or changes in plan designs may negatively impact our Healthcare segment business and results of operations.

A significant portion of our Healthcare segment revenue is indirectly derived from the monthly premium payments paid by the U.S. Department of Health and Human Services to our health plan customers for services they provide to Medicare Advantage beneficiaries. As a result, our results of operations are, in part, dependent on government funding levels for Medicare Advantage programs. An executive order issued in October 2019 seeks to encourage innovative Medicare Advantage benefit structures and plan designs, including through changes to supplemental benefits. Any changes that limit or reduce Medicare Advantage reimbursement levels, such as reductions in or limitations of reimbursement amounts or rates under these programs, reductions in funding of these programs, expansion of benefits without adequate funding, elimination of coverage for certain benefits, or elimination of coverage affecting the services that we provide, could have a material adverse effect on our Healthcare segment health plan customers, and as a result, on our business and results of operations.

Our results of operations could be adversely affected by severe or unexpected weather, epidemics, pandemics or outbreaks of disease.

Adverse weather conditions or other extreme changes in the weather may cause people to refrain, or prevent people, from visiting fitness partner locations and using our Healthcare segment services. Additionally, widespread health epidemics or outbreaks of disease, such as influenza or COVID-19, may cause members to avoid public gathering places and negatively impact their use of our services. As some of the fees that we charge our customers are based on member participation, a decrease in member participation could adversely affect our business and results of operations.

Compliance with existing or newly adopted federal and state laws and regulations or new or revised interpretations of such requirements could adversely affect our results of operations or may require us to spend substantial amounts, and the failure to comply with applicable laws and regulations could subject us to penalties or negatively impact our ability to provide services.

Our Healthcare segment customers are subject to considerable state and federal government regulation, and a substantial majority of our Healthcare segment business involves providing services to Medicare Advantage beneficiaries. As a result, we are subject directly to various federal laws and regulations, including the federal False Claims Act, billing and reimbursement requirements and other provisions related to fraud and abuse. In addition, our contracts with Medicare Advantage plans require us to comply with a number of regulatory provisions and to permit these health plan customers to perform compliance audits of our processes and programs. Many of these regulations are vaguely written and subject to differing interpretations that may, in certain cases, result in unintended consequences that could impact our ability to effectively deliver services. Further, we are required to comply with most requirements of the HIPAA privacy and security laws and regulations and may be subject to criminal or civil penalties for violations of these regulations. Certain of our services, including health utilization management and certain claims payment functions, require licensure and may be regulated by government agencies. We are subject to a variety of legal requirements in order to obtain and maintain such licenses, but little guidance is available to determine the scope of some of these requirements.

We continually monitor the extent to which federal and state legislation and regulations govern our operations. New federal or state laws or regulations or new interpretations of existing requirements that affect our operations could have a material adverse effect on our results of operations. If we are found to have violated applicable laws, to have caused any of our Healthcare segment customers to submit false claims or make false statements, or to have failed to comply with our contractual compliance obligations, we could be required to restructure our Healthcare segment operations, be subject to contractual penalties, including termination of our Healthcare segment customer agreements, and be subject to significant civil and criminal penalties.

Healthcare reform efforts may result in a reduction to our revenues from government health programs and private insurance companies or otherwise directly or indirectly impact our business.

The healthcare industry is subject to various political, regulatory, scientific, and technological influences. Efforts at federal and state levels of government have resulted in laws and regulations intended to effect significant change within the healthcare system. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “ACA”), the most prominent of these efforts, affects coverage, delivery, and reimbursement of healthcare services. Among other effects, several of its provisions may increase the costs and/or reduce the revenues of our customers or prospective customers. For example, the ACA eliminates pre-existing condition exclusions by commercial health plans, bans annual benefit limits, and mandates minimum medical loss ratios for health plans. On April 27, 2020, the United States Supreme Court held that Congress owes health insurers approximately $12 billion as startup costs incurred in the first three years of the ACA. Since this decision, judgments and stipulations for judgment have been entered for individual insurers identifying the amount owed by the federal government.

However, there is substantial uncertainty regarding the net effect and future of the ACA. The presidential administration and Congress have made significant changes to the ACA, its implementation and its interpretation. Effective January 2019, Congress eliminated the penalty associated with the ACA’s individual mandate. As a result, a federal court in Texas ruled in December 2018 that the individual mandate was unconstitutional and determined that the rest of the ACA was, therefore, invalid. In December 2019, the Fifth Circuit Court of Appeals upheld this decision with respect to the individual mandate but remanded for further consideration of how this affects the rest of the law. The law remains in effect pending appeal. It is possible that the reforms imposed by the ACA or uncertainty regarding significant changes or court challenges to the law will adversely affect the profitability of our Healthcare segment customers and cause our Healthcare segment customers or prospective customers to reduce or delay the purchase of our services or to demand reduced fees. Because of this uncertainty and many other variables, including the ACA’s complexity and the difficulty of predicting the impact of changes on other healthcare industry participants and the ultimate outcome of court challenges, we are unable to predict all of the ways in which the ACA could impact us. Furthermore, we could also be impacted by other legislative and regulatory healthcare reform initiatives. For example, beginning in 2020, the Creating High-quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2018 allows Medicare Advantage plans to cover supplemental benefits that are not primarily health-related, but that have the reasonable expectation of improving or maintaining health. Additionally, some presidential candidates and members of Congress have proposed measures that would expand government-sponsored coverage, including single-payor proposals (often referred to as "Medicare for All"). Further, the outcome of the 2020 federal election and its potential impact on health reform efforts is unknown.

Risks Relating to Our Nutrition Segment

Our Nutrition segment's future growth and profitability will depend in large part upon the effectiveness and efficiency of our marketing expenditures and our ability to select effective markets and media in which to advertise.

Our Nutrition segment's future growth and profitability will depend in large part upon the effectiveness and efficiency of our marketing expenditures, including our ability to:

•

create greater awareness of our Nutrition segment brands and programs;

•

identify the most effective and efficient levels of spending in each market, media and specific media vehicle;

•

determine the appropriate creative messages and media mix for advertising, marketing and promotional expenditures;

•

effectively manage marketing costs (including creative and media) in order to maintain acceptable customer acquisition costs;

•

acquire cost-effective advertising;

•

select the most effective markets, media and specific media vehicles in which to advertise; and

•

convert Nutrition segment customer inquiries into actual orders.

Our planned marketing expenditures for our Nutrition segment may not result in increased revenue or generate sufficient levels of brand name and program awareness. We may not be able to manage our Nutrition segment's marketing expenditures on a cost-effective basis whereby our Nutrition segment customer acquisition costs may exceed the contribution profit generated from each additional customer.

Our Nutrition segment relies on third parties to provide it with adequate food supply, freight and fulfillment and Internet and networking services, the loss or disruption of any of which could cause our revenue, earnings or reputation to suffer.

Food Manufacturers and Other Suppliers. Our Nutrition segment relies solely on third-party manufacturers to supply all of the food and other products we sell as well as packaging materials. If we are unable to obtain sufficient quantity, quality and variety of food, other products and packaging materials in a timely and low-cost manner from our manufacturers, we will be unable to fulfill our Nutrition segment customers’ orders in a timely manner, which may cause us to lose revenue and market share or incur higher costs, as well as damage the value of our brands.

Freight and Fulfillment. Currently, all of our Nutrition segment customer order fulfillment is handled by one third-party provider. Also, almost all of our direct to consumer Nutrition segment customer orders are shipped by one third-party provider and almost all of our orders for Nutrition segment retail programs were shipped by another third-party provider. Should these providers be unable to service our needs for even a short duration, our revenue and business could be adversely affected. Additionally, the cost and time associated with replacing these providers on short notice would add to our costs. Any replacement fulfillment provider would also require startup time, which could cause us to lose sales and market share.

Internet and Networking. Our Nutrition segment business also depends on a number of third parties for Internet access and networking, and we have limited control over these third parties. Should our Nutrition segment's network connections go down, our ability to fulfill orders would be delayed. Further, if our Nutrition segment's websites or call center become unavailable for a noticeable period of time due to Internet or communication failures, our business could be adversely affected, including harm to our brands and loss of sales.

Therefore, we are dependent on these third parties. The services we require from these parties may be disrupted by a number of factors, including the following:

•

labor disruptions;

•

delivery problems;

•

financial condition or results of operations;

•

internal inefficiencies;

•

equipment failure;

•

severe weather;

•

fire;

•

natural or man-made disasters; and

•

with respect to our food suppliers, shortages of ingredients or United States Department of Agriculture ("USDA") or United States Food and Drug Administration (“FDA”) compliance issues.

Further, the COVID-19 pandemic (or another regional or global epidemic or pandemic, depending upon its location, duration and severity), could severely affect our Nutrition segment’s business, including as a result of impacts associated with preventive and precautionary measures that we and other businesses and governments may take. A regional or global epidemic or pandemic could also adversely affect our business by disrupting the operations of our call center, creating negative popular sentiment among consumers of delivered food, or by disrupting or delaying our third-party providers' ability to, among other things (i) supply the products that we sell as well as packaging materials, (ii) fulfill and deliver Nutrition segment customer orders and (iii) provide Internet and networking services. In addition, any significant change in the pricing or payment terms that we have with our third-party providers could adversely affect our liquidity. The COVID-19 pandemic has caused, and may cause in the future, delays in fulfilling orders for our Nutrition segment’s products at our warehouses due to employees of our fulfillment provider testing positive for COVID-19. Due to the COVID-19 pandemic, we have incurred, and may incur in the future, charges related to increased labor rates and overtime for employees of our fulfillment provider, as well as additional shipping and related charges if it is necessary to transfer the fulfillment of certain orders to other warehouses that are farther from the customer’s delivery destination.

We may be subject to claims that our Nutrition segment personnel are unqualified to provide proper weight loss advice.

We offer counseling options from weight loss counselors, registered dietitians and certified diabetes educators with varying levels of training. We may be subject to claims from our Nutrition segment customers alleging that our personnel lack the qualifications necessary to provide proper advice regarding weight loss and related topics. We may also be subject to claims that our Nutrition segment personnel have provided inappropriate advice or have inappropriately referred or failed to refer customers to health care providers for matters other than weight loss. Such claims could result in lawsuits, damage to our reputation and divert management’s attention from our business, which would adversely affect our business.

We may be subject to health-related claims from our customers.

Our Nutrition segment's weight loss programs do not include medical treatment or medical advice, and we do not engage physicians or nurses to monitor the progress of our Nutrition segment customers. Many people who are overweight suffer from other physical conditions, and our target customers could be considered a high-risk population. A Nutrition segment customer who experiences health problems could allege or bring a lawsuit against us on the basis that those problems were caused or worsened by participating in our weight management programs or by consuming one or more of our individual products. For example, our Nutrition segment's predecessor businesses suffered substantial losses due to health-related claims and related publicity. If we become subject to any such claims, while we would defend ourselves against such claims, we may ultimately be unsuccessful in our defense. Also, defending ourselves against such claims, regardless of their merit and ultimate outcome, would likely be lengthy and costly, and adversely affect our results of operations. Further, our general liability insurance may not cover claims of these types.

The weight management industry is highly competitive. If any of our competitors or a new entrant into the market with significant resources pursues a weight management program similar to ours, our Nutrition segment business could be significantly affected.

Competition is intense in the weight management industry and we must remain competitive in the areas of program efficacy, price, taste, customer service and brand recognition. The competitors of our Nutrition segment include companies selling pharmaceutical products and weight loss programs, digital tools and wearable trackers, as well as a wide variety of diet foods and meal replacement bars and shakes, appetite suppressants and nutritional supplements. Some of our Nutrition segment's competitors are significantly larger than we are and have substantially greater resources. Our Nutrition segment business could be adversely affected if someone with significant resources decided to imitate our weight management programs. For example, if a major supplier of pre-packaged foods decided to enter this market and made a substantial investment of resources in advertising and training diet counselors, our Nutrition segment business could be significantly affected. Any increased competition from new entrants into our Nutrition segment's industry or any increased success by existing competition could result in reductions in our Nutrition segment sales or prices, or both, which could have an adverse effect on our business and results of operations.

We are dependent on certain third-party agreements for a percentage of revenue.

Our Nutrition segment has agreements with certain third-party retailers. Under these agreements, these third parties control when and how often our Nutrition segment products are offered, and we are not guaranteed any minimum level of sales. Our Nutrition segment's largest third-party retailer has indicated to us that they will be reducing orders for, and the promotion of, our Nutrition segment products in 2020. If any third party elects not to renew their agreement with us or further reduces orders for our Nutrition segment products or the promotion of our Nutrition segment products, our revenue will suffer.

In addition, our third-party retailers may decide to stop selling our Nutrition segment products upon written notice, which may result in an increased level of reclamation claims. In the event any retailer terminates its relationship with us and the level of reclamation claims exceeds the estimated amount reserved on our balance sheet at the time of sale to the retailer, we will have to record an expense for the excess claims, which could adversely impact our results of operations and financial condition. Additionally, in certain instances, we could be prohibited from selling our Nutrition segment products through competitors of these third parties for a specified time after the termination of the agreements.

Furthermore, some retailers are experiencing fewer than usual customer visits at their locations as a result of the COVID-19 pandemic, which has adversely affected and could continue to adversely affect the sales of our products at those retailers.

New weight loss products or services may put us at a competitive disadvantage.

On an ongoing basis, many existing and potential providers of weight loss solutions, including many pharmaceutical firms with significantly greater financial and operating resources than we have, are developing new products and services. The creation of a weight loss solution, such as a drug therapy, that is perceived to be safe, effective and “easier” than a portion-controlled meal plan would put our Nutrition segment at a disadvantage in the marketplace and our results of operations could be negatively affected.

If our Nutrition segment’s efforts to attract and retain customer subscriptions are not successful, our business will be adversely affected.

Our Nutrition segment’s ability to continue to attract customer subscriptions will depend in part on our ability to consistently provide customers with compelling food choices that are desirable in taste and quality, effectively market our products, and offer convenience and value to our customers. The relative offerings, pricing, and other factors of our Nutrition segment’s competitors may adversely impact our ability to attract and retain customer subscriptions. If our Nutrition segment’s customers do not perceive our products to be of value, we may not be able to attract and retain customers. We must continually add new customer subscriptions both to replace canceled subscriptions and to grow our business beyond our current customer base. Further, if excessive numbers of our Nutrition segment’s customers cancel their subscriptions, we may be required to incur significantly higher marketing expenditures than we currently anticipate to replace these customers with new customers, and our results of operations may be adversely affected.

We may be subject to litigation from our competitors.

Our Nutrition segment's competitors may pursue litigation against us based on our advertising or other marketing practices regardless of its merit and chances of success, especially if we engage in comparative advertising, which includes advertising that directly or indirectly mentions a competitor or a competitor’s weight loss program in comparison to our Nutrition segment programs. While we would defend ourselves against any such claims, our defense may ultimately be unsuccessful. Also, defending against such claims, regardless of their merit and ultimate outcome, may be lengthy and costly, strain our resources and divert management’s attention from their core responsibilities, which would have a negative impact on our business.

We have launched and expect to continue to launch new weight loss and nutrition programs and brands which may not be successful due to the failure of such programs or brands to achieve anticipated levels of market acceptance, which could adversely affect our Nutrition segment business, financial condition and results of operations.

There are a number of risks inherent in any new program or brand introduction, which could prevent us from achieving revenue growth and increasing our Nutrition segment's overall market share in the commercial weight loss and nutrition markets. Any new program or brand may fail to achieve the anticipated level of market acceptance or appeal to customer tastes and preferences. In addition, introduction costs, including product testing and marketing, may be greater than anticipated. If the new program or brand is not successful or falls short of anticipated market acceptance, we may be adversely affected by continued expenses and the diversion of management time to this initiative. Any or all of such events could have adverse effects on our business, financial condition and results of operations.

If we do not continue to receive referrals from existing Nutrition segment customers, our Nutrition segment's customer acquisition cost may increase.

We rely on word-of-mouth advertising for a portion of our new Nutrition segment customers. If our brands suffer or the number of customers acquired through referrals drops due to other circumstances, our costs associated with acquiring new Nutrition segment customers and generating revenue will increase, which will, in turn, have an adverse effect on our profitability.

We use third-party marketing vendors to promote our Nutrition segment products. If the spokespersons affiliated with the third-party marketing vendors suffer adverse publicity or elect to not renew, our revenue could be adversely affected.

Our Nutrition segment's marketing strategy depends in part on celebrity spokespersons, as well as customer spokespersons, to promote our weight loss programs. Any of these spokespersons may become the subject of adverse news reports, negative publicity or otherwise be alienated from a segment of our Nutrition segment customer base, whether weight loss related or not. If so, such events may reduce the effectiveness of his or her endorsement and, in turn, adversely affect our revenue and results of operations. Additionally, if a spokesperson elects not to renew their agreement with us, our revenue may suffer.

Changes in customer preferences could negatively impact our operating results.

Our Nutrition segment programs feature frozen and ready-to-go food selections, which we believe offer convenience and value to our customers. Our continued success depends, to a large degree, upon the continued popularity of our Nutrition segment programs versus various other weight loss, weight management and fitness regimens, such as low carbohydrate diets, appetite suppressants and diets featured in the published media. Changes in customer tastes and preferences away from our frozen or ready-to-go food and support and counseling services, and any failure to provide innovative responses to these changes, may have a materially adverse impact on our business, financial condition, operating results and cash flows.

Our success is also dependent on our food innovation including maintaining a robust array of food items and improving the quality of existing items. If we do not continually expand our food items or provide customers with items that are desirable in taste and quality, our business could be adversely impacted.

The seasonal nature of the business of our Nutrition segment could cause our operating results to fluctuate.

The business of our Nutrition segment is seasonal, with revenue generally greatest (and advertising expenses generally highest) in the first calendar quarter, also known as diet season. Weak performance during diet season could negatively impact our Nutrition segment’s performance for the remainder of the year. This seasonality could cause the market price of our Common Stock to fluctuate as the results of an interim financial period may not be indicative of our full year results. Seasonality also impacts relative revenue and profitability of each quarter of the year, both on a quarter-to-quarter and year-over-year basis.

The weight loss industry is subject to adverse publicity, which could harm our Nutrition segment business.

The weight loss industry receives adverse publicity from time to time, and the occurrence of such publicity could harm us, even if the adverse publicity is not directly related to us. In the early 1990s, our Nutrition segment's predecessor businesses were subject to extremely damaging adverse publicity relating to a large number of lawsuits alleging that the Nutrisystem weight loss program in use at that time led to gall bladder disease. This publicity was a factor that contributed to the bankruptcy of our Nutrition segment's predecessor businesses in 1993. In addition, our Nutrition segment's predecessor businesses were severely impacted by significant litigation and damaging publicity related to their customers’ use of fen-phen as an appetite suppressant, which the FDA ordered withdrawn from the market in September 1997. The significant decline in business resulting from the fen-phen problems caused our Nutrition segment's predecessor businesses to close all of their company-owned weight loss centers.

Congressional hearings about practices in the weight loss industry have also resulted in adverse publicity and a consequent decline in the revenue of weight loss businesses. Future research reports or publicity that is perceived as unfavorable or that question certain weight loss programs, products or methods could result in a decline in our revenue. Because of our dependence on customer perceptions, adverse publicity associated with illness or other undesirable effects resulting from the consumption of our Nutrition segment products or similar products by competitors, whether or not accurate, could also damage customer confidence in our Nutrition segment weight loss programs and result in a decline in revenue. Adverse publicity could arise even if the unfavorable effects associated with weight loss products or services resulted from the user’s failure to use such products or services appropriately.

The industry in which our Nutrition segment operates is subject to governmental regulation that could increase in severity and hurt results of operations.

The industry in which our Nutrition segment operates is subject to federal, state and other governmental regulation. Certain federal and state agencies, such as the FTC, regulate and enforce such laws relating to advertising, disclosures to customers, privacy, customer pricing and billing arrangements and other customer protection matters. A determination by a federal or state agency, or a court, that any of our practices do not meet existing or new laws or regulations could result in liability, adverse publicity and restrictions on our business operations. Some advertising practices in the weight loss industry, in particular, have led to investigations from time to time by the FTC and other governmental agencies and many companies in the weight loss industry, including our Nutrition segment's predecessor businesses, have entered into consent decrees with the FTC relating to weight loss claims and other advertising practices. In addition, the FTC’s Guides Concerning the Use of Endorsements and Testimonials in Advertising require us and other weight loss companies to use a statement as to what the typical weight loss a customer can expect to achieve on our Nutrition segment programs when using a customer’s weight loss testimonial in advertising. Federal and state regulation of advertising practices generally, and in the weight loss industry in particular, may increase in scope or severity in the future, which could have a material adverse impact on our business.

Other aspects of the industry in which our Nutrition segment operates are also subject to government regulation. For example, the manufacturing, labeling and distribution of food products, including dietary supplements, are subject to strict USDA and FDA requirements and food manufacturers are subject to rigorous inspection and other requirements of the USDA and FDA, and companies operating in foreign markets must comply with those countries’ requirements for proper labeling, controls on hygiene, food preparation and other matters. If federal, state, local or foreign regulation of the weight loss industry increases for any reason, then we may be required to incur significant expenses, as well as modify our operations to comply with new regulatory requirements, which could harm our operating results. Additionally, remedies available in any potential administrative or regulatory actions may include product recalls and requiring us to refund amounts paid by all affected customers or pay other damages, which could be substantial.

Laws and regulations directly applicable to communications, operations or commerce over the Internet such as those governing intellectual property, privacy, libel and taxation, are becoming more prevalent and some remain unsettled. If we are required to comply with new laws or regulations or new interpretations of existing laws or regulations, or if we are unable to comply with these laws, regulations or interpretations, our business could be adversely affected.

Future laws or regulations, including laws or regulations affecting our marketing and advertising practices, relations with customers, employees, service providers, or our services and products, may have an adverse impact on us.

The sale of ingested products involves product liability and other risks.

Like other distributors of products that are ingested, we face an inherent risk of exposure to product liability claims if the use of our Nutrition segment products results in illness or injury. The foods that we resell in the U.S. are subject to laws and regulations, including those administered by the USDA and FDA that establish manufacturing practices and quality standards for food products. Product liability claims could have a material adverse effect on our business as existing insurance coverage may not be adequate. Distributors of weight loss food products, including dietary supplements, as well as our Nutrition segment's predecessor businesses, have been named as defendants in product liability lawsuits from time to time. The successful assertion or settlement of an uninsured claim, a significant number of insured claims or a claim exceeding the limits of our insurance coverage would harm us by adding costs to the business and by diverting the attention of senior management from the operation of our business. We may also be subject to claims that our Nutrition segment products contain contaminants, are improperly labeled, include inadequate instructions as to use or inadequate warnings covering interactions with other substances. Product liability litigation, even if not meritorious, is very expensive and could also entail adverse publicity for us and adversely affect our results of operations. In addition, the products we distribute, or certain components of those products, may be subject to product recalls or other deficiencies. Any negative publicity associated with these actions would adversely affect our brands and may result in decreased product sales and, as a result, lower revenue and profits.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The stock repurchase activity for the second quarter of 2020 was as follows:

ISSUER PURCHASES OF EQUITY SECURITIES
Period	Total Number of Shares Purchased ⁽¹⁾		Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs ⁽²⁾		Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs ⁽²⁾
4/1/2020 - 4/30/2020		66	$	5.27		—	$	—
5/1/2020 - 5/31/2020		589		5.35		—		—
6/1/2020 - 6/30/2020		—		—		—		—
Total		655	$	5.34

(1)

Total shares purchased include shares attributable to the withholding of shares by Tivity Health to satisfy the payment of tax obligations related to the vesting of restricted shares.

(2)

We had no publicly announced plans or open market repurchase programs for shares of our Common Stock during the three months ended June 30, 2020.

Item 6. Exhibits

(a)

Exhibits

10.1		Employment Agreement by and between the Company and Richard M. Ashworth, dated May 20, 2020 [incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K dated May 22, 2020, File No. 000-19364]

10.2		Form of Restricted Stock Unit Award Agreement for Richard M. Ashworth (Inducement Award), dated June 1, 2020 [incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K dated May 22, 2020, File No. 000-19364]

10.3		Form of Restricted Stock Unit Award Agreement for Richard M. Ashworth, dated June 1, 2020 [incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K dated May 22, 2020, File No. 000-19364]

10.4		Form of Market Stock Unit Award Agreement for Richard M. Ashworth, dated June 1, 2020 [incorporated by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K dated May 22, 2020, File No. 000-19364]

31.1		Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002 made by Richard M. Ashworth, Chief Executive Officer.*

31.2		Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002 made by Adam Holland, Chief Financial Officer.*

32		Certification Pursuant to 18 U.S.C section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 made by Richard M. Ashworth, Chief Executive Officer, and Adam Holland, Chief Financial Officer.*

101		The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, formatted in Inline XBRL: (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations (iii) Consolidated Statements of Comprehensive Income, (iv) Consolidated Statement of Changes in Stockholders' Equity; (v) Consolidated Statements of Cash Flows; and (vi) Notes to Consolidated Financial Statements.

104		The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, formatted in Inline XBRL (included in Exhibit 101 hereto).

*		Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Tivity Health, Inc.
			(Registrant)

Date:	August 7, 2020	By	/s/ Adam Holland

			Chief Financial Officer
			(Principal Financial Officer)

EX-31.1 2 tvty-ex311_8.htm EX-31.1 tvty-ex311_8.htm

Exhibit 31.1

CERTIFICATION

I, Richard M. Ashworth, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Tivity Health, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 7, 2020

	/s/ Richard M. Ashworth
	Richard M. Ashworth
	Chief Executive Officer

EX-31.2 3 tvty-ex312_6.htm EX-31.2 tvty-ex312_6.htm

Exhibit 31.2

CERTIFICATION

I, Adam Holland, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Tivity Health, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 7, 2020

	/s/ Adam Holland
	Adam Holland
	Chief Financial Officer

EX-32 4 tvty-ex32_7.htm EX-32 tvty-ex32_7.htm

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Tivity Health, Inc. (the "Company") on Form 10-Q for the quarter ended June 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), we, Richard M. Ashworth, Chief Executive Officer of the Company, and Adam Holland, Chief Financial Officer of the Company, each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Richard M. Ashworth

Richard M. Ashworth

Chief Executive Officer

August 7, 2020

/s/ Adam Holland

Adam Holland

Chief Financial Officer

August 7, 2020

GRAPHIC 5 gs5ggmptrgcs000001.jpg GRAPHIC begin 644 gs5ggmptrgcs000001.jpg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tvty-20200630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100070 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100080 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Basis of Presentation and Recent Developments link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Recent Relevant Accounting Standards link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Revenue Recognition link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Intangible Assets and Goodwill link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Marketing Expenses link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Share-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Leases link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Debt link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Derivative Instruments and Hedging Activities link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Earnings (Loss) Per Share link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Accumulated OCI link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Segment Disclosures and Concentrations of Risk link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Basis of Presentation and Recent Developments (Policies) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Revenue Recognition (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Intangible Assets and Goodwill (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Leases (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Derivative Instruments and Hedging Activities (Tables) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Earnings (Loss) Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Accumulated OCI (Tables) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Segment Disclosures and Concentrations of Risk (Tables) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Basis of Presentation and Recent Developments - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Revenue Recognition - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Revenue Recognition - Summary of Revenue Disaggregated by Program (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Revenue Recognition - Summary of Revenue Disaggregated by Program (Parenthetical) (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Revenue Recognition - Summary of Revenue Disaggregated by Source (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Revenue Recognition - Summary of Information about Receivables, Contract Assets and Contract Liabilities from Contracts with Customers (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Revenue Recognition - Summary of Significant Changes in Contract Liabilities (Deferred Revenue) Balance (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Revenue Recognition - Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Revenue Recognition - Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Revenue Recognition - Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied (Details 1) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Revenue Recognition - Additional Information (Details 1) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Inventories - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Intangible Assets and Goodwill - Reconciliation of Goodwill Balance (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Marketing Expenses - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Share-Based Compensation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Income Taxes- Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Leases - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Leases - Schedule of Components of Lease Expense (Details) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Debt - Summary of Debt, Net of Unamortized Deferred Loan Costs And Original Issue Discount (Details) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Debt - Summary of Debt, Net of Unamortized Deferred Loan Costs And Original Issue Discount (Details)2 link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Debt - Credit Facility - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Commitments and Contingencies - Additional Information - (Details) link:calculationLink link:presentationLink link:definitionLink 100580 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100590 - Disclosure - Fair Value Measurements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100600 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100610 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Estimated Gross Fair Values of Derivative Instruments and Their Classification on Consolidated Balance Sheet (Details) link:calculationLink link:presentationLink link:definitionLink 100620 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Effect of Cash Flow Hedge Accounting on Accumulated OCI (Details) link:calculationLink link:presentationLink link:definitionLink 100630 - Disclosure - Earnings (Loss) Per Share - Reconciliation of the Numerator and Denominator of Basic and Diluted Earnings (Loss) Per Share (Details) link:calculationLink link:presentationLink link:definitionLink 100640 - Disclosure - Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Details) link:calculationLink link:presentationLink link:definitionLink 100650 - Disclosure - Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Parenthetical) (Details) link:calculationLink link:presentationLink link:definitionLink 100660 - Disclosure - Accumulated OCI - Schedule of Reclassifications Out of Accumulated OCI (Details) link:calculationLink link:presentationLink link:definitionLink 100670 - Disclosure - Segment Disclosures and Concentrations of Risk - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100680 - Disclosure - Segment Disclosures and Concentrations of Risk - Schedule of Reported Segment Revenues and Profit or Loss, Net of Intersegment Eliminations, and Reconciliation (Details) link:calculationLink link:presentationLink link:definitionLink 100690 - Disclosure - Segment Disclosures and Concentrations of Risk - Schedule of Total Assets by Segment (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 tvty-20200630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 tvty-20200630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 tvty-20200630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Amount, after unamortized (discount) premium and before debt issuance costs, of debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Deferred loan costs and original issue discount. Transition costs. Covid nineteen costs. Adjusted earning before interest tax depreciation and amortization. Cover [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Current Reporting Status Entity Current Reporting Status Entity Shell Company Entity Shell Company Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Interactive Data Current Entity Interactive Data Current Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Entity Incorporation, State or Country Code Entity Incorporation State Country Code Amount of other long-term liabilities, classified as current. Statement Of Financial Position [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Accounts receivable, net Accounts Receivable Net Current Inventories Inventory Net Prepaid expenses Prepaid Expense Current Other current assets Other Assets Current Total current assets Assets Current Property and equipment, net of accumulated depreciation of $53,525 and $42,510 respectively Property Plant And Equipment Net Right-of-use assets, operating leases Operating Lease Right Of Use Asset Right-of-use assets, finance leases Finance Lease Right Of Use Asset Intangible assets, net Intangible Assets Net Excluding Goodwill Goodwill, net Goodwill Other assets Other Assets Noncurrent Total assets Assets Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued salaries and benefits Employee Related Liabilities Current Accrued liabilities Accrued Liabilities Current Deferred revenue Contract With Customer Liability Current Income taxes payable Taxes Payable Current Current portion of operating lease liabilities Operating Lease Liability Current Current portion of finance lease liabilities Finance Lease Liability Current Current portion of long-term debt Long Term Debt Current Current portion of other long-term liabilities Other Long Term Liabilities Current Maturities Total current liabilities Liabilities Current Long-term debt Long Term Debt Noncurrent Long-term operating lease liabilities Operating Lease Liability Noncurrent Long-term finance lease liabilities Finance Lease Liability Noncurrent Long-term deferred tax liability Deferred Income Tax Liabilities Net Other long-term liabilities Other Liabilities Noncurrent Commitments and contingent liabilities Commitments And Contingencies Stockholders' equity: Stockholders Equity [Abstract] Preferred stock $.001 par value, 5,000,000 shares authorized, none outstanding Preferred Stock Value Common Stock $.001 par value, 120,000,000 shares authorized, 48,548,741 and 48,156,786 shares outstanding, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated deficit Retained Earnings Accumulated Deficit Treasury stock, at cost, 2,254,953 shares in treasury Treasury Stock Value Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Total stockholders' equity Stockholders Equity Total liabilities and stockholders' equity Liabilities And Stockholders Equity Accumulated depreciation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Preferred stock, par value (in dollars per share) Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock Shares Authorized Preferred stock, shares outstanding (in shares) Preferred Stock Shares Outstanding Common stock, par value (in dollars per share) Common Stock Par Or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock Shares Authorized Common stock, shares outstanding (in shares) Common Stock Shares Outstanding Treasury stock (in shares) Treasury Stock Shares Income Statement [Abstract] Statement [Table] Statement [Table] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Services Service [Member] Products Product [Member] Statement [Line Items] Statement [Line Items] Revenues: Revenues [Abstract] Total revenues Revenue From Contract With Customer Excluding Assessed Tax Cost of revenue: Cost Of Revenue [Abstract] Total cost of revenue Cost Of Goods And Services Sold Marketing expenses Marketing Expense Selling, general and administrative expenses Selling General And Administrative Expense Depreciation and amortization Depreciation Depletion And Amortization Impairment loss Asset Impairment Charges Restructuring and related charges Restructuring Charges Operating income (loss) Operating Income Loss Interest expense Interest Expense Income (loss) before income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax expense (benefit) Income Tax Expense Benefit Net income (loss) Net Income Loss Earnings (loss) per share: Earnings Per Share [Abstract] Basic Earnings Per Share Basic Diluted Earnings Per Share Diluted Comprehensive income (loss) Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest Weighted average common shares and equivalents: Weighted Average Number Of Shares Outstanding [Abstract] Basic Weighted Average Number Of Shares Outstanding Basic Diluted Weighted Average Number Of Diluted Shares Outstanding Depreciation Cost Of Goods And Services Sold Depreciation Depreciation and amortization Cost Of Goods And Services Sold Depreciation And Amortization Statement Of Income And Comprehensive Income [Abstract] Net income (loss) Net change in fair value of interest rate swaps, net of income tax benefit of $393, $4,068, $7,195, and $4,068, respectively Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax Comprehensive income (loss) Net change in fair value of interest rate swaps, income tax benefit Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax Adjustments to additional paid in capital share-based compensation replacement awards related to merger and attributable to pre-combination services. Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Preferred Stock Preferred Stock [Member] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid In Capital [Member] Retained Earnings (Accumulated Deficit) Retained Earnings [Member] Treasury Stock Treasury Stock [Member] Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Income [Member] Balance Comprehensive income (loss) Comprehensive Income Net Of Tax Issuance of Common Stock in connection with Merger Stock Issued During Period Value Acquisitions Share-based compensation replacement awards related to Merger and attributable to pre-combination services Adjustments To Additional Paid In Capital Share Based Compensation Replacement Awards Related To Merger And Attributable To Pre Combination Services Exercise of stock options Stock Issued During Period Value Stock Options Exercised Tax withholding for share-based compensation Adjustments Related To Tax Withholding For Share Based Compensation Share-based employee compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Other Adjustments To Additional Paid In Capital Other Balance Amortization and write-off of deferred loan costs. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Net income (loss) Profit Loss Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Amortization and write-off of deferred loan costs Amortization And Write Off Of Deferred Loan Costs Amortization of debt discount Amortization Of Debt Discount Premium Share-based employee compensation expense Share Based Compensation Impairment of goodwill and intangible assets Deferred income taxes Deferred Income Tax Expense Benefit Decrease (increase) in accounts receivable, net Increase Decrease In Accounts Receivable Decrease in inventory Increase Decrease In Inventories Decrease in other current assets Increase Decrease In Other Current Assets Increase (decrease) in accounts payable Increase Decrease In Accounts Payable (Decrease) increase in accrued salaries and benefits Increase Decrease In Employee Related Liabilities Decrease in other current liabilities Increase Decrease In Other Current Liabilities Increase (decrease) in deferred revenue Increase Decrease In Contract With Customer Liability Other Other Operating Activities Cash Flow Statement Net cash flows provided by operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Acquisition of property and equipment Payments To Acquire Property Plant And Equipment Business acquisitions, net of cash acquired Payments To Acquire Businesses Net Of Cash Acquired Net cash flows used in investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of long-term debt Proceeds From Issuance Of Long Term Debt Payments of long-term debt Repayments Of Long Term Debt Payments related to tax withholding for share-based compensation Payments Related To Tax Withholding For Share Based Compensation Exercise of stock options Proceeds From Stock Options Exercised Deferred loan costs Payments Of Loan Costs Principal payments related to financing leases Finance Lease Principal Payments Change in cash overdraft and other Proceeds From Payments For Other Financing Activities Net cash flows (used in) provided by financing activities Net Cash Provided By Used In Financing Activities Effect of exchange rate changes on cash Effect Of Exchange Rate On Cash And Cash Equivalents Net increase in cash and cash equivalents Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Organization Consolidation And Presentation Of Financial Statements [Abstract] Basis of Presentation and Recent Developments Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] New Accounting Pronouncements And Changes In Accounting Principles [Abstract] Recent Relevant Accounting Standards New Accounting Pronouncements And Changes In Accounting Principles [Text Block] Revenue From Contract With Customer [Abstract] Revenue Recognition Revenue From Contract With Customer [Text Block] Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] Goodwill And Intangible Assets Disclosure [Abstract] Intangible Assets and Goodwill Goodwill And Intangible Assets Disclosure [Text Block] Marketing expense disclosure. Marketing And Advertising Expense [Abstract] Marketing Expenses Marketing Expense Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Share-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Leases disclosure. Leases [Abstract] Leases Leases Disclosure [Text Block] Debt Disclosure [Abstract] Debt Debt Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Derivative Instruments And Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities EX-101.PRE 10 tvty-20200630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 tvty-10q_20200630_htm.xml IDEA: XBRL DOCUMENT 0000704415 2020-01-01 2020-06-30 0000704415 2020-08-04 0000704415 2020-06-30 0000704415 2019-12-31 0000704415 us-gaap:ServiceMember 2020-04-01 2020-06-30 0000704415 us-gaap:ServiceMember 2019-04-01 2019-06-30 0000704415 us-gaap:ServiceMember 2020-01-01 2020-06-30 0000704415 us-gaap:ServiceMember 2019-01-01 2019-06-30 0000704415 us-gaap:ProductMember 2020-04-01 2020-06-30 0000704415 us-gaap:ProductMember 2019-04-01 2019-06-30 0000704415 us-gaap:ProductMember 2020-01-01 2020-06-30 0000704415 us-gaap:ProductMember 2019-01-01 2019-06-30 0000704415 2020-04-01 2020-06-30 0000704415 2019-04-01 2019-06-30 0000704415 2019-01-01 2019-06-30 0000704415 us-gaap:CommonStockMember 2019-03-31 0000704415 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000704415 us-gaap:RetainedEarningsMember 2019-03-31 0000704415 us-gaap:TreasuryStockMember 2019-03-31 0000704415 2019-03-31 0000704415 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000704415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000704415 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000704415 us-gaap:CommonStockMember 2019-06-30 0000704415 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000704415 us-gaap:RetainedEarningsMember 2019-06-30 0000704415 us-gaap:TreasuryStockMember 2019-06-30 0000704415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000704415 2019-06-30 0000704415 us-gaap:CommonStockMember 2018-12-31 0000704415 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000704415 us-gaap:RetainedEarningsMember 2018-12-31 0000704415 us-gaap:TreasuryStockMember 2018-12-31 0000704415 2018-12-31 0000704415 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0000704415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-06-30 0000704415 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0000704415 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0000704415 us-gaap:CommonStockMember 2020-03-31 0000704415 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000704415 us-gaap:RetainedEarningsMember 2020-03-31 0000704415 us-gaap:TreasuryStockMember 2020-03-31 0000704415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000704415 2020-03-31 0000704415 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000704415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000704415 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000704415 us-gaap:CommonStockMember 2020-06-30 0000704415 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000704415 us-gaap:RetainedEarningsMember 2020-06-30 0000704415 us-gaap:TreasuryStockMember 2020-06-30 0000704415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000704415 us-gaap:CommonStockMember 2019-12-31 0000704415 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000704415 us-gaap:RetainedEarningsMember 2019-12-31 0000704415 us-gaap:TreasuryStockMember 2019-12-31 0000704415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000704415 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0000704415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-06-30 0000704415 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0000704415 us-gaap:HealthCareMember 2020-01-01 2020-06-30 0000704415 tvty:NutritionMember 2020-01-01 2020-06-30 0000704415 tvty:SilverSneakersMember 2020-06-01 2020-06-30 0000704415 tvty:CovidNineteenMember 2020-04-01 2020-06-30 0000704415 us-gaap:RevolvingCreditFacilityMember tvty:CreditAgreementMember tvty:CovidNineteenMember 2020-03-31 0000704415 us-gaap:RevolvingCreditFacilityMember tvty:CreditAgreementMember tvty:CovidNineteenMember 2020-01-01 2020-06-30 0000704415 tvty:CreditAgreementMember 2020-06-30 0000704415 tvty:CreditAgreementMember us-gaap:SubsequentEventMember 2020-07-01 2020-07-31 0000704415 2020-04-01 2020-04-30 0000704415 2020-04-30 0000704415 tvty:ExecutiveOfficersAndOtherEmployeesMember 2020-04-01 2020-04-30 0000704415 tvty:NonManagementMembersOfBoardMember 2020-01-01 2020-06-30 0000704415 us-gaap:TradeNamesMember tvty:NutrisystemMember 2020-01-01 2020-06-30 0000704415 tvty:NutrisystemMember 2020-01-01 2020-06-30 0000704415 us-gaap:HealthCareMember 2020-04-01 2020-06-30 0000704415 us-gaap:HealthCareMember 2020-06-30 0000704415 us-gaap:HealthCareMember 2019-12-31 0000704415 tvty:SilverSneakersMember us-gaap:HealthCareMember 2020-04-01 2020-06-30 0000704415 tvty:SilverSneakersMember us-gaap:HealthCareMember 2019-04-01 2019-06-30 0000704415 tvty:SilverSneakersMember us-gaap:HealthCareMember 2020-01-01 2020-06-30 0000704415 tvty:SilverSneakersMember us-gaap:HealthCareMember 2019-01-01 2019-06-30 0000704415 tvty:PrimeFitnessMember us-gaap:HealthCareMember 2020-04-01 2020-06-30 0000704415 tvty:PrimeFitnessMember us-gaap:HealthCareMember 2019-04-01 2019-06-30 0000704415 tvty:PrimeFitnessMember us-gaap:HealthCareMember 2020-01-01 2020-06-30 0000704415 tvty:PrimeFitnessMember us-gaap:HealthCareMember 2019-01-01 2019-06-30 0000704415 tvty:WholeHealthLivingMember us-gaap:HealthCareMember 2020-04-01 2020-06-30 0000704415 tvty:WholeHealthLivingMember us-gaap:HealthCareMember 2019-04-01 2019-06-30 0000704415 tvty:WholeHealthLivingMember us-gaap:HealthCareMember 2020-01-01 2020-06-30 0000704415 tvty:WholeHealthLivingMember us-gaap:HealthCareMember 2019-01-01 2019-06-30 0000704415 us-gaap:ProductAndServiceOtherMember us-gaap:HealthCareMember 2020-04-01 2020-06-30 0000704415 us-gaap:ProductAndServiceOtherMember us-gaap:HealthCareMember 2019-04-01 2019-06-30 0000704415 us-gaap:ProductAndServiceOtherMember us-gaap:HealthCareMember 2020-01-01 2020-06-30 0000704415 us-gaap:ProductAndServiceOtherMember us-gaap:HealthCareMember 2019-01-01 2019-06-30 0000704415 us-gaap:HealthCareMember 2019-04-01 2019-06-30 0000704415 us-gaap:HealthCareMember 2019-01-01 2019-06-30 0000704415 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-06-30 0000704415 us-gaap:ProductAndServiceOtherMember 2020-04-01 2020-06-30 0000704415 tvty:WellBeingProgramMember 2020-01-01 2020-06-30 0000704415 tvty:WellBeingProgramMember 2020-04-01 2020-06-30 0000704415 us-gaap:ShippingAndHandlingMember tvty:NutritionMember 2020-04-01 2020-06-30 0000704415 us-gaap:ShippingAndHandlingMember tvty:NutritionMember 2020-01-01 2020-06-30 0000704415 us-gaap:ShippingAndHandlingMember tvty:NutritionMember 2019-04-01 2019-06-30 0000704415 us-gaap:ShippingAndHandlingMember tvty:NutritionMember 2019-03-09 2019-06-30 0000704415 tvty:NutrisystemDirectToConsumerMember tvty:NutritionMember 2020-04-01 2020-06-30 0000704415 tvty:NutrisystemDirectToConsumerMember tvty:NutritionMember 2019-04-01 2019-06-30 0000704415 tvty:NutrisystemDirectToConsumerMember tvty:NutritionMember 2020-01-01 2020-06-30 0000704415 tvty:NutrisystemDirectToConsumerMember tvty:NutritionMember 2019-01-01 2019-06-30 0000704415 tvty:SouthBeachDietDirectToConsumerMember tvty:NutritionMember 2020-04-01 2020-06-30 0000704415 tvty:SouthBeachDietDirectToConsumerMember tvty:NutritionMember 2019-04-01 2019-06-30 0000704415 tvty:SouthBeachDietDirectToConsumerMember tvty:NutritionMember 2020-01-01 2020-06-30 0000704415 tvty:SouthBeachDietDirectToConsumerMember tvty:NutritionMember 2019-01-01 2019-06-30 0000704415 us-gaap:RetailMember tvty:NutritionMember 2020-04-01 2020-06-30 0000704415 us-gaap:RetailMember tvty:NutritionMember 2019-04-01 2019-06-30 0000704415 us-gaap:RetailMember tvty:NutritionMember 2020-01-01 2020-06-30 0000704415 us-gaap:RetailMember tvty:NutritionMember 2019-01-01 2019-06-30 0000704415 tvty:QVCMember tvty:NutritionMember 2020-04-01 2020-06-30 0000704415 tvty:QVCMember tvty:NutritionMember 2019-04-01 2019-06-30 0000704415 tvty:QVCMember tvty:NutritionMember 2020-01-01 2020-06-30 0000704415 tvty:QVCMember tvty:NutritionMember 2019-01-01 2019-06-30 0000704415 us-gaap:ProductAndServiceOtherMember tvty:NutritionMember 2020-04-01 2020-06-30 0000704415 us-gaap:ProductAndServiceOtherMember tvty:NutritionMember 2019-04-01 2019-06-30 0000704415 us-gaap:ProductAndServiceOtherMember tvty:NutritionMember 2020-01-01 2020-06-30 0000704415 us-gaap:ProductAndServiceOtherMember tvty:NutritionMember 2019-01-01 2019-06-30 0000704415 tvty:NutritionMember 2020-04-01 2020-06-30 0000704415 tvty:NutritionMember 2019-04-01 2019-06-30 0000704415 tvty:NutritionMember 2019-01-01 2019-06-30 0000704415

2020-07-01

2020-06-30 0000704415

2021-01-01

2020-06-30 0000704415

2022-01-01

2020-06-30 0000704415

2023-01-01

2020-06-30 0000704415

2024-01-01

2020-06-30 0000704415

2025-01-01

2020-06-30 0000704415 tvty:NutritionMember 2019-03-09 2019-06-30 0000704415 us-gaap:AccruedLiabilitiesMember tvty:NutritionMember 2020-06-30 0000704415 us-gaap:AccruedLiabilitiesMember tvty:NutritionMember 2019-12-31 0000704415 tvty:NutrisystemIncorporationMember us-gaap:TradeNamesMember 2020-01-01 2020-03-31 0000704415 tvty:NutrisystemIncorporationMember 2020-01-01 2020-03-31 0000704415 tvty:NutritionMember 2019-12-31 0000704415 tvty:NutritionMember 2020-06-30 0000704415 us-gaap:TradeNamesMember 2020-06-30 0000704415 us-gaap:TradeNamesMember 2019-12-31 0000704415 2020-03-09 2020-06-30 0000704415 srt:MinimumMember 2020-01-01 2020-06-30 0000704415 srt:MaximumMember 2020-01-01 2020-06-30 0000704415 us-gaap:RestructuringChargesMember 2019-04-01 2019-06-30 0000704415 us-gaap:RestructuringChargesMember 2019-01-01 2019-06-30 0000704415 us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-06-30 0000704415 2020-01-01 2020-03-31 0000704415 us-gaap:EarliestTaxYearMember 2020-01-01 2020-06-30 0000704415 tvty:TermLoanFacilityAMember 2020-06-30 0000704415 tvty:TermLoanFacilityAMember 2019-12-31 0000704415 tvty:TermLoanFacilityBMember 2020-06-30 0000704415 tvty:TermLoanFacilityBMember 2019-12-31 0000704415 us-gaap:RevolvingCreditFacilityMember 2019-12-31 0000704415 tvty:CreditAgreementMember 2020-01-01 2020-06-30 0000704415 us-gaap:RevolvingCreditFacilityMember tvty:CreditAgreementMember 2019-03-08 0000704415 tvty:SwinglineSubFacilityMember tvty:CreditAgreementMember 2019-03-08 0000704415 us-gaap:LetterOfCreditMember tvty:CreditAgreementMember 2019-03-08 0000704415 tvty:TermLoanFacilityAMember tvty:CreditAgreementMember 2019-03-08 0000704415 tvty:TermLoanFacilityBMember tvty:CreditAgreementMember 2019-03-08 0000704415 srt:MinimumMember tvty:UncommittedIncrementalAccordionFacilityMember tvty:CreditAgreementMember 2019-03-08 0000704415 srt:MinimumMember tvty:UncommittedIncrementalAccordionFacilityMember tvty:CreditAgreementMember 2019-03-06 2019-03-08 0000704415 us-gaap:RevolvingCreditFacilityMember 2020-06-30 0000704415 srt:MinimumMember tvty:CreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-03-06 2019-03-08 0000704415 tvty:CreditAgreementMember tvty:FederalFundsRateMember 2019-03-06 2019-03-08 0000704415 tvty:CreditAgreementMember tvty:OneMonthLondonInterbankOfferedRateLIBORMember 2019-03-06 2019-03-08 0000704415 tvty:TermLoanFacilityAMember tvty:CreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-03-06 2019-03-08 0000704415 tvty:TermLoanFacilityBMember tvty:CreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-03-06 2019-03-08 0000704415 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember tvty:CreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-03-06 2019-03-08 0000704415 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember tvty:CreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-03-06 2019-03-08 0000704415 tvty:TermLoanFacilityAMember tvty:CreditAgreementMember us-gaap:BaseRateMember 2019-03-06 2019-03-08 0000704415 tvty:TermLoanFacilityBMember tvty:CreditAgreementMember us-gaap:BaseRateMember 2019-03-06 2019-03-08 0000704415 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember tvty:CreditAgreementMember us-gaap:BaseRateMember 2019-03-06 2019-03-08 0000704415 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember tvty:CreditAgreementMember us-gaap:BaseRateMember 2019-03-06 2019-03-08 0000704415 tvty:TermLoanFacilityAMember tvty:CreditAgreementMember 2019-03-06 2019-03-08 0000704415 tvty:TermLoanFacilityBMember tvty:CreditAgreementMember 2019-03-06 2019-03-08 0000704415 tvty:TermLoansMember tvty:CreditAgreementMember 2019-03-09 2020-06-30 0000704415 tvty:TermLoanFacilityAMember tvty:CreditAgreementMember 2020-01-01 2020-06-30 0000704415 tvty:TermLoanFacilityBMember tvty:CreditAgreementMember 2020-01-01 2020-06-30 0000704415 tvty:SwinglineSubFacilityMember tvty:CreditAgreementMember 2020-01-01 2020-06-30 0000704415 us-gaap:RevolvingCreditFacilityMember tvty:CreditAgreementMember 2020-01-01 2020-06-30 0000704415 tvty:InterestRateSwapAgreementMember 2019-05-31 0000704415 tvty:InterestRateSwapAgreementMember 2019-05-01 2019-05-31 0000704415 tvty:InterestRateSwapAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-05-31 0000704415 tvty:InterestRateSwapAgreementMember 2020-06-30 0000704415 tvty:CreditAgreementMember tvty:PrepaymentsConditionOneMember 2020-01-01 2020-06-30 0000704415 tvty:CreditAgreementMember tvty:PrepaymentsConditionTwoMember 2020-01-01 2020-06-30 0000704415 tvty:CreditAgreementMember tvty:PrepaymentsConditionThreeMember 2020-01-01 2020-06-30 0000704415 tvty:CreditAgreementMember tvty:PrepaymentsConditionFourMember 2020-01-01 2020-06-30 0000704415 srt:MinimumMember tvty:CreditAgreementMember 2019-03-06 2019-03-08 0000704415 srt:MaximumMember tvty:CreditAgreementMember 2019-03-06 2019-03-08 0000704415 2017-11-06 0000704415 2017-11-06 2017-11-06 0000704415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateSwapMember 2020-06-30 0000704415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateSwapMember 2019-12-31 0000704415 tvty:NutritionMember 2020-01-01 2020-03-31 0000704415 us-gaap:TradeNamesMember tvty:NutrisystemMember 2020-01-01 2020-03-31 0000704415 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000704415 tvty:TermLoansMember 2020-06-30 0000704415 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-05-31 0000704415 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-05-01 2019-05-31 0000704415 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-06-30 0000704415 tvty:LongTermLiabilitiesCurrentMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-06-30 0000704415 tvty:LongTermLiabilitiesCurrentMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000704415 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-06-30 0000704415 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000704415 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000704415 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-04-01 2020-06-30 0000704415 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-04-01 2019-06-30 0000704415 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-06-30 0000704415 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-06-30 0000704415 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-04-01 2020-06-30 0000704415 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-04-01 2019-06-30 0000704415 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-06-30 0000704415 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-06-30 0000704415 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0000704415 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0000704415 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0000704415 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0000704415 us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0000704415 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0000704415 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0000704415 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0000704415 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0000704415 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0000704415 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0000704415 us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0000704415 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0000704415 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0000704415 us-gaap:RestrictedStockMember 2020-04-01 2020-06-30 0000704415 us-gaap:RestrictedStockMember 2019-04-01 2019-06-30 0000704415 us-gaap:RestrictedStockMember 2020-01-01 2020-06-30 0000704415 us-gaap:RestrictedStockMember 2019-01-01 2019-06-30 0000704415 us-gaap:PerformanceSharesMember 2020-04-01 2020-06-30 0000704415 us-gaap:PerformanceSharesMember 2020-01-01 2020-06-30 0000704415 tvty:MarketStockUnitsMember 2020-04-01 2020-06-30 0000704415 tvty:MarketStockUnitsMember 2020-01-01 2020-06-30 0000704415 us-gaap:InterestRateSwapMember 2019-12-31 0000704415 us-gaap:InterestRateSwapMember 2020-01-01 2020-06-30 0000704415 us-gaap:InterestRateSwapMember 2020-06-30 0000704415 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-06-30 0000704415 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-06-30 0000704415 2019-03-07 2019-03-07 0000704415 tvty:WiselyWellMember 2020-04-01 2020-06-30 0000704415 tvty:WiselyWellMember 2020-01-01 2020-06-30 0000704415 srt:ChiefExecutiveOfficerMember 2020-04-01 2020-06-30 0000704415 srt:ChiefExecutiveOfficerMember 2020-01-01 2020-06-30 0000704415 tvty:SilverSneakersSeniorFitnessMember 2020-04-01 2020-06-30 0000704415 tvty:SilverSneakersSeniorFitnessMember 2020-01-01 2020-06-30 shares iso4217:USD iso4217:USD shares tvty:Segment pure tvty:Employee tvty:Program tvty:Obligation tvty:Source tvty:Type tvty:Agreement tvty:Lawsuit tvty:Tradename 0000704415 --12-31 Large Accelerated Filer Q2 false

true

P6M

P1Y

10-Q true 2020-06-30 2020 false 000-19364 TIVITY HEALTH, INC. DE 62-1117144 701 Cool Springs Boulevard Franklin TN 37067 800 869-5311 Common Stock - $.001 par value TVTY NASDAQ Yes Yes false false false 48560369

60274000

2486000

36339000

97596000

22088000

36407000

15058000

18255000

8110000

6993000

141869000

161737000

53525000

42510000

52436000

52909000

35300000

41518000

1356000

1680000

593520000

689686000

535135000

654635000

21554000

23740000

1381170000

1625905000

35492000

46480000

10539000

13071000

42020000

55663000

12440000

12037000

7835000

405000

13157000

13131000

644000

624000

9775000

15664000 4947000

147566000

146358000

1002547000

1048127000

23515000

30321000

753000

1080000

137205000

160846000

31863000

12263000

0.001

5000000

0.001

120000000

48548741

48156786

48000

505760000

504419000

-406840000

-237284000

2254953

28182000

-33065000

-12091000

37721000

226910000

1381170000

1625905000

79856000

157481000

239548000

314008000

182742000

182896000

360705000

240463000

262598000

340377000

600253000

554471000

2240000

1503000

4071000

2859000

31886000

111073000

147034000

224916000

8587000

5861000

19280000

7488000

86355000

83685000

170363000

110181000

118241000

194758000

317397000

335097000

51105000

54603000

138177000

78751000

23471000

29667000

51480000

56852000

12919000

9084000

27682000

12666000

199500000

1009000

2352000

1752000

3943000

55853000

49913000

-135735000

67162000

21235000

23661000

42898000

31328000

34618000

26252000

-178633000

35834000

6107000

8115000

-9038000

13483000

28511000

18137000

-169595000

22351000

0.59

0.38

-3.49

0.49

0.58

0.37

-3.49

0.49

27366000

5901000

-190569000

10115000

48711000

47790000

48662000

45165000

48794000

48461000

48662000

45719000

28511000

18137000

-169595000

22351000

-393000

-4068000

-7195000

-4068000

-1145000

-12236000

-20974000

-12236000

27366000

5901000

-190569000

10115000

47000

491548000

53751000

-28182000

517164000

18137000

-12236000

5901000

137000

794000

6898000

47000

497789000

71888000

-28182000

-12236000

529306000

41000

347487000

49655000

-28182000

369001000

22351000

-12236000

10115000

6000

132832000

132838000

9107000 9107000

370000

1135000

9257000

-129000

-118000

-247000

47000

497789000

71888000

-28182000

-12236000

529306000

48000

503049000

-435371000

-28182000

-31920000

7624000

28511000

-1145000

27366000

154000

2865000

20000

48000

505760000

-406840000

-28182000

-33065000

37721000

48000

504419000

-237284000

-28182000

-12091000

226910000

-169595000

-20974000

-190569000

601000

2949000

3689000

39000

48000

505760000

-406840000

-28182000

-33065000

37721000

-169595000

22351000

27682000

12666000

2315000 3073000

2049000

389000

3689000

9257000

199500000

-16447000

10789000

-61257000

3754000

-14319000

-8719000

-1363000

-1057000

9411000

-5872000

-2532000

570000

-5925000

-8266000

403000

-2725000

3454000

1345000

130943000

49599000

10362000

8918000

1062818000

-10362000

-1071736000

196525000

1399945000

236375000

347879000

2949000

1135000

601000

370000

30189000

306000

22000

-20289000

3530000

-62793000

1024620000

-12000

57788000

2471000

2486000

1933000

60274000

4404000

<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In our opinion, the accompanying consolidated financial statements of Tivity Health®, Inc. and its wholly-owned subsidiaries, including the results of Nutrisystem®, Inc. (“Nutrisystem”) acquired on March 8, 2019 (collectively, “Tivity Health,” the “Company,” or such terms as “we,” “us,” or “our”) reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement. In preparing our consolidated financial statements in conformity with U.S. GAAP, management must make estimates and assumptions that affect: (1) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements; and (2) the reported amounts of revenues and expenses during the reporting period. By their nature, estimates are subject to an inherent degree of uncertainty. Due to the significant uncertainty relating to the potential future impacts of the coronavirus pandemic on our business and the overall market, actual results could differ from those estimates, including, but not limited to, estimates of fair value of goodwill and indefinite-lived intangible assets, allowances for doubtful accounts, and valuation allowances on deferred tax assets. Our consolidated statements of operations include results of Nutrisystem from March 8, 2019 forward. We have reclassified certain items in prior periods to conform to current classifications. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the acquisition of Nutrisystem (the “Merger”), we organize and manage our operations within two reportable segments, based on the types of products and services they offer: Healthcare and Nutrition. The Healthcare segment is comprised of our legacy business and includes SilverSneakers® senior fitness, Prime® Fitness, WholeHealth Living® and Wisely WellTM. The Nutrition segment is comprised of Nutrisystem’s legacy business and includes the Nutrisystem® and the South Beach Diet® programs. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have omitted certain financial information that is normally included in financial statements prepared in accordance with U.S. GAAP but that is not required for interim reporting purposes. You should read the accompanying consolidated financial statements in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Recent Developments <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the Secretary of the U.S. Department of Health and Human Services (“HHS”) declared a national public health emergency due to a novel strain of coronavirus, which causes the disease known as “COVID-19”. In March 2020, the World Health Organization characterized the outbreak of COVID-19 as a global pandemic, and COVID-19 continues to spread throughout the United States and other countries. Many state and local governments, together with public health officials, have recommended and mandated precautions to mitigate the spread of COVID-19, including ordering closure of certain businesses and imposing stay-at-home orders and social distancing guidelines for individuals. Such measures have resulted in significantly reduced demand for many businesses that have continued in operation. By March 31, 2020, substantially all of the fitness centers in our national network were temporarily closed, which had an adverse impact on the results of operations in our Healthcare segment for the first quarter of 2020 because a significant portion of our Healthcare segment revenues from our SilverSneakers program is based on member visits to a fitness partner location. A substantial number of our fitness partner locations remained closed through April, with some locations reopening in May and additional locations reopening in June. For the month of June 2020, approximately 66% of our fitness partner locations reported at least one visit from our SilverSneakers program. For the second quarter of 2020, the average monthly total participation levels of our SilverSneakers members were significantly below historical levels, and we also experienced a decline in paid subscribers for Prime Fitness, each of which adversely impacted revenues in our Healthcare segment. <p style="Background-color:#FFFFFF;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not believe that COVID-19-related developments had a material impact on the results of operations or cash flows of our Nutrition segment for the first or second quarters of 2020. While overall we did not experience any significant disruptions, interruptions, or increased costs related to our supply chain, inventory, or distribution channels as a result of COVID-19, we experienced delays in fulfilling orders for our Nutrition segment’s products at certain of our warehouses due to some employees of our fulfillment provider testing positive for COVID-19. As a result, we incurred incremental expense of $1.3 million in the second quarter related to increased labor rates and overtime for employees of our fulfillment provider as well as additional shipping and related charges as we transferred the fulfillment of certain orders to other warehouses that were farther from the customer’s delivery destination. We have taken a number of actions in response to the pandemic, including the following: <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.04%;white-space:nowrap" valign="top"> </td> <td style="width:3.52%;white-space:nowrap" valign="top"> •</td> <td valign="top"> Given the continued uncertainty surrounding COVID-19, in March 2020, we borrowed $75 million under our Revolving Credit Facility as a precautionary measure to increase our cash position and maintain financial flexibility. We repaid such $75 million in full in June 2020. As of June 30, 2020, outstanding debt under our credit agreement was $1,012.3 million, and we had $60.3 million of cash and cash equivalents. In July 2020, we repaid $24.8 million of principal on the term loans under our credit agreement, resulting in our next required quarterly installment being due in December 2021. As of June 30, 2020, we had a working capital deficit of $5.7 million. While the COVID-19 pandemic has created significant uncertainty as to general economic and market conditions for the remainder of 2020 and beyond, as of the date of this report, we believe our cash on hand, expected cash flows from operations, and anticipated available credit under the Credit Agreement (as defined below) will be sufficient to fund our operations, principal and interest payments, and capital expenditures for the next 12 months.</td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.04%;white-space:nowrap" valign="top"> </td> <td style="width:3.52%;white-space:nowrap" valign="top"> •</td> <td valign="top"> We are taking a variety of measures to ensure the availability and functioning of our critical infrastructure, to promote the safety and security of our employees and to support the communities in which we operate. These measures include implementing remote working arrangements for employees where practicable. We are following public and private sector policies and initiatives to reduce the transmission of COVID-19, such as the imposition of travel restrictions, the promotion of social distancing, and the adoption of work-from-home arrangements.</td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.04%;white-space:nowrap" valign="top"> </td> <td style="width:3.52%;white-space:nowrap" valign="top"> •</td> <td valign="top"> We are focused on preserving our liquidity and managing our cash flow, including, but not limited to, managing our working capital, optimizing tax savings under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) and other COVID-19-related legislation, curtailing capital expenditures, reducing discretionary spending, and reducing compensation costs. </td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:14.08%;white-space:nowrap" valign="top"> </td> <td style="width:3.52%;white-space:nowrap" valign="top"> o</td> <td valign="top"> In April 2020, we furloughed 13% of our approximately 1,000 employees. In June 2020, some of these furloughed employees’ positions were eliminated (in addition to other position eliminations, resulting in approximately 8% of our employees being terminated), and we extended the furlough for substantially all of the remaining furloughed employees through the end of 2020. Also in June 2020, we placed an additional 2% of our total employees on furlough through the end of 2020. </td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:14.08%;white-space:nowrap" valign="top"> </td> <td style="width:3.52%;white-space:nowrap" valign="top"> o</td> <td valign="top"> Also in April 2020, the Compensation Committee of the Company’s Board of Directors (the “Board”) approved a 25% reduction in base salary for the Company’s executive officers and certain other employees for the period from April 20, 2020 through August 23, 2020. In June 2020, the Compensation Committee determined to extend such reductions in base salary through December 31, 2020. Additionally, the Board approved a 100% reduction in the annual cash retainer and annual committee retainers payable to non-management members of the Board who stood for reelection at the 2020 Annual Meeting of Stockholders (except for Daniel G. Tully who does not receive compensation for his service on the Board) for a period of four months, beginning May 1, 2020 or as soon thereafter as reasonably practicable. In June 2020, the Board determined to extend such reduction in cash compensation to the Board through December 31, 2020. </td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:14.08%;white-space:nowrap" valign="top"> </td> <td style="width:3.52%;white-space:nowrap" valign="top"> o</td> <td valign="top"> Effective at the end of July 2020, the Compensation Committee suspended the Company matching contribution to the Company’s 401(k) plan.</td></tr></table></div> As a result of the COVID-19 pandemic, in March 2020, we experienced a significant decline in the Company’s market capitalization and in the actual and forecasted operating results of our Healthcare segment, in addition to the unfavorable change in market conditions. As a result, management concluded that there were triggering events during the first quarter of 2020 necessitating an impairment evaluation of our goodwill (for each of our reporting units) and indefinite-lived intangible assets (which consist of the Nutrisystem tradename and the SilverSneakers tradename). Through this evaluation, management concluded that the fair value of goodwill allocated to the Nutrition business unit as well as the fair value of the Nutrisystem tradename were below their carrying amounts, and we recorded an impairment loss of $199.5 million, including $80.0 million related to the Nutrisystem tradename and $119.5 million related to goodwill allocated to the Nutrition segment. There were no impairment triggers during the second quarter of 2020 related to our goodwill or indefinite-lived intangible assets.

0.66 1300000

75000000

1012300000

60300000

24800000

5700000 0.13 1000 0.08 0.02 0.25 1 P4M

199500000

80000000.0

119500000

In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-04, “Reference Rate Reform (“ASC 848”): Facilitation of the Effects of Reference Rate Reform on Financial Reporting”. ASC 848 contains temporary optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform, such as a transition away from the use of LIBOR. ASC 848 was effective for the Company as of January 1, 2020. The provisions of ASC 848 are available through December 31, 2022, at which time the reference rate replacement activity is expected to have been completed. The provisions of ASC 848 must be applied at a Topic, Subtopic or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. The accounting relief provided by ASC 848 is applicable only to legacy contracts if the amendments made to the agreements are solely for reference rate reform activities. Modifications that are unrelated to reference rate reform will scope out a given contract. ASC 848 allows for different elections to be made at different points in time, and the timing of those elections will be documented as applicable. For the avoidance of doubt, we intend to reassess the elections of optional expedients and exceptions included within ASC 848 related to our hedging activities and will document the election of these items on a quarterly basis. In March 2020, we elected the expedient that allows us to assume that our hedged interest payments are probable of occurring regardless of any expected modification in their terms related to reference rate reform. In addition, we have the option to change the method of assessing effectiveness upon a change in the critical terms of the derivative or the hedged transactions and upon the end of relief under ASC 848. In June 2020, we elected to (i) continue the method of assessing effectiveness as documented in the original hedge documentation and (ii) apply the expedient wherein the reference rate on the hypothetical derivative matches the reference rate on the hedging instrument. We will also apply the aforementioned elections to any future designated cash flow hedging relationship. In October 2018, the FASB issued ASU 2018-16, "Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (“SOFR”) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes" (“ASU 2018-16”), which adds the OIS rate based on SOFR as a U.S. benchmark interest rate to facilitate the LIBOR to SOFR transition and provide lead time for entities to prepare for changes to interest rate risk hedging strategies. ASU 2018-16 is effective for fiscal years beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. As of March 31, 2020, the benchmark interest rate in our existing interest rate swap agreements is LIBOR. The adoption of this standard did not have an impact on our financial position, results of operations, or cash flows. In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other” (“ASU 2017-04”), which simplifies the subsequent measurement of goodwill by eliminating step two from the goodwill impairment test. ASU 2017-04 is effective for annual and interim impairment tests in fiscal years beginning after December 15, 2019 and is required to be applied prospectively. Early adoption is allowed for annual goodwill impairment tests performed on testing dates after January 1, 2017. We adopted ASU 2017-04 on October 1, 2019. As further discussed in Note 12, we recorded impairment losses related to goodwill during the fourth quarter of 2019 and the first quarter of 2020. In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”), which changes the fair value measurement disclosure requirements of ASC 820. ASU 2018-13 is effective for fiscal years beginning on or after December 15, 2019, including interim periods therein, and is generally required to be applied retrospectively, except for certain components that are to be applied prospectively. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU No. 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract,” which requires implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the arrangement, if those costs would be capitalized by the customer in a software licensing arrangement. This standard is effective for annual periods beginning after December 15, 2019, and interim periods within those fiscal years. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), which requires companies to measure credit losses for financial assets held at the reporting date utilizing a methodology that reflects current expected credit losses over the lifetime of such assets. ASU 2016-13 was effective for the Company on January 1, 2020 and is generally required to be applied using the modified retrospective approach, with limited exceptions for specific instruments. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.52%;white-space:nowrap" valign="top"> 3.</td> <td valign="top"> Revenue Recognition</td></tr></table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for revenue from contracts with customers in accordance with Accounting Standards Codification (“ASC”) Topic 606. The unit of account in ASC Topic 606 is a performance obligation, which is a promise in a contract to transfer to a customer either a distinct good or service (or bundle of goods or services) or a series of distinct goods or services provided over a period of time. ASC Topic 606 requires that a contract's transaction price, which is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, is to be allocated to each performance obligation in the contract based on relative standalone selling prices and recognized as revenue when or as the performance obligation is satisfied. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Healthcare Segment Our Healthcare segment earns revenue from three programs, SilverSneakers senior fitness, Prime Fitness and WholeHealth Living. We provide the SilverSneakers senior fitness program to members of Medicare Advantage and Medicare Supplement plans through our contracts with such plans. We offer Prime Fitness, a fitness facility access program, through contracts with commercial health plans, employers, and other sponsoring organizations that allow their members to individually purchase the program. We sell our WholeHealth Living program primarily to health plans. Except for Prime Fitness, our Healthcare segment’s customer contracts generally have initial terms of approximately three years. Some contracts allow the customer to terminate early and/or determine on an annual basis to which of their members they will offer our programs. For Prime Fitness, our contracts with commercial health plans, employers, and other sponsoring organizations generally have initial terms of approximately three years, while individuals who purchase the Prime Fitness program through these organizations may cancel at any time (on a monthly basis) after an initial period of one to three months. The significant majority of our Healthcare segment’s customer contracts contain one performance obligation - to stand ready to provide access to our network of fitness locations and fitness programming - which is satisfied over time as services are rendered each month over the contract term. There are generally no performance obligations that are unsatisfied at the end of a particular month. There was no material revenue recognized during the three and six months ended June 30, 2020 from performance obligations satisfied in a prior period. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our fees within the Healthcare segment are variable month to month and are generally billed per member per month (“PMPM”) or billed based on a combination of PMPM and member visits to a network location. We bill PMPM fees by multiplying the contractually negotiated PMPM rate by the number of members eligible for or receiving our services during the month. We bill for member visits approximately one month in arrears once actual member visits are known. Payments from customers are typically due within 30 days of invoice date. When material, we capitalize costs to obtain contracts with customers and amortize them over the expected recovery period. At June 30, 2020 and December 31, 2019, $0.7 million and $0.5 million, respectively, of such costs were capitalized. During the three and six months ended June 30, 2020 and 2019, the amortization of such capitalized costs was immaterial. Our Healthcare segment’s customer contracts include variable consideration, which is allocated to each distinct month over the contract term based on eligible members and/or member visits each month. The allocated consideration corresponds directly with the value to our customers of our services completed for the month. Under the majority of our Healthcare segment’s contracts, we recognize revenue each month using the practical expedient available under ASC 606-10-55-18, which provides that revenue is recognized in the amount for which we have the right to invoice. ASC 606-10-50-14(b) provides an optional exemption, which we have elected to apply, from disclosing remaining performance obligations when revenue is recognized from the satisfaction of the performance obligation in accordance with the “right to invoice” practical expedient. <p style="Background-color:#FFFFFF;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we evaluate our financial performance and make resource allocation decisions based upon the results of our two reportable segments, we believe the following information depicts how our Healthcare segment revenues and cash flows are affected by economic factors. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth Healthcare revenue disaggregated by program. Revenue from our SilverSneakers program is predominantly contracted with Medicare Advantage and Medicare Supplement plans. <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;" valign="top"> SilverSneakers</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,157</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122,899</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170,764</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,922</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;" valign="top"> Prime Fitness</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,047</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,751</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,858</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,494</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;" valign="top"> WholeHealth Living</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,747</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,467</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,796</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,041</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.12%; border-bottom:solid 0.75pt transparent;" valign="top"> Other (1)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,972</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,197</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">551</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.12%; border-bottom:double 2.5pt transparent;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,923</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,481</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241,615</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314,008</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.52%;white-space:nowrap" valign="top"> <p style="Background-color:#FFFFFF;line-height:12pt;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"> </td> <td style="width:3.52%;white-space:nowrap" valign="top"> <p style="Background-color:#FFFFFF;line-height:12pt;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</td> <td valign="top"> <p style="Background-color:#FFFFFF;line-height:12pt;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">For the three and six months ended June 30, 2020, other revenue in the table above includes $6.8 million from a well-being program with a large employer as well as $2.1 million of Wisely Well revenue.</td></tr></table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:3.52%;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and usage-based taxes are excluded from revenues. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Nutrition Segment <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Nutrition segment earns revenue from four sources: direct to consumer, retail, QVC and other. Revenue is measured based on the consideration specified in a contract with a customer and excludes any sales incentives and amounts collected on behalf of third parties. As explained in more detail below, revenue is recognized upon satisfaction of the performance obligation by transferring control over a product to a Nutrition segment customer. Direct-mail advertising costs are expensed as incurred. We recognize an asset for the carrying amount of product to be returned and for costs to obtain a contract if the amortization is more than one year in duration. We expense costs to obtain a contract as incurred if the amortization period is less than one year. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We sell pre-packaged foods directly to weight loss program participants primarily through the Internet and telephone (referred to as the direct to consumer channel), through QVC (a television shopping network), and select retailers. Pre-packaged foods include both frozen and non-frozen (ready-to-go), shelf-stable products. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products sold through the direct to consumer channel, both frozen and non-frozen, may be sold separately (a la carte) or as part of a packaged monthly meal plan for which Nutrition segment customers pay at the point of sale. Products sold through QVC are payable by QVC upon our shipment of the product to the end consumer. For both the direct to consumer channel and QVC, we recognize revenue at a point in time, i.e., at the shipping point. Direct to consumer customers may return unopened ready-to-go Nutrisystem products within 30 days after purchase in order to receive a refund or credit. Frozen Nutrisystem products are refundable only if the order is canceled within 14 days after delivery. South Beach Diet products are not refundable. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products sold to retailers include both frozen and non-frozen products and are payable by the retailer upon receipt. We recognize revenue at a point in time, i.e., when the retailers take possession of the product. Certain retailers have the right to return unsold products. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for the shipment of frozen and non-frozen, ready-to-go products as separate performance obligations. The consideration, including variable consideration for product returns, is allocated between frozen and non-frozen products based on their standalone selling prices. The amount of revenue recognized is adjusted for expected returns, which are estimated based on historical data. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our pre-packaged foods, we sell prepaid gift cards through a wholesaler that are redeemable through the Internet or telephone. Prepaid gift cards represent grants of rights to goods to be provided in the future to gift card buyers. The wholesaler has the right to return all unsold prepaid gift cards. The wholesaler’s retail selling price of the gift cards is deferred in the balance sheet and recognized as revenue when we have satisfied our performance obligation, i.e., when a gift card holder redeems the gift card with us. We recognize breakage amounts (the estimated amount of unused gift cards) as revenue, in proportion to the actual gift card redemptions exercised by gift card holders in relation to the total expected redemptions of gift cards. We utilize historical experience in estimating the total expected breakage and period over which the gift cards will be redeemed. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and other taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a Nutrition segment customer are excluded from revenue and presented on a net basis. After control over a product has transferred to a Nutrition segment customer, shipping and handling costs associated with outbound freight are accounted for as a fulfillment cost and are included in revenue and cost of revenue in the accompanying consolidated statements of operations. Revenue from shipping and handling charges was $6.5 million and $13.0 million for the three and six months ended June 30, 2020, respectively, and $6.3 million and $8.1 million for the three and six months ended June 30, 2019 (from March 8, 2019 forward), respectively. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth Nutrition segment revenue, from March 8, 2019 forward, disaggregated by the source of revenue: <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.88%;" valign="top"> Nutrisystem direct to consumer</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165,118</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,976</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">320,509</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,977</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.88%;" valign="top"> South Beach Diet direct to consumer</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,650</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,464</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,414</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,118</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.88%;" valign="top"> Retail</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,902</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,728</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,350</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,032</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.88%;" valign="top"> QVC</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,901</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,522</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,088</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,044</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.88%; border-bottom:solid 0.75pt transparent;" valign="top"> Other</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">277</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">292</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.88%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,675</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182,896</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358,638</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,463</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides information about receivables, contract assets and contract liabilities from contracts with customers: <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%;" valign="top"> Contract assets</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%;" valign="top"> Contract liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,937</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,911</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contract assets primarily relate to unbilled accounts receivable and are included as other current assets in the accompanying consolidated balance sheet. The contract liabilities (deferred revenue) primarily relate to sale of prepaid gift cards and unshipped foods, which are deferred until such time as the Company has satisfied its performance obligations. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant changes in the contract liabilities (deferred revenue) balance during the period are as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%;" valign="top"> Revenue recognized that was included in the contract liability (deferred revenue) balance on January 1, 2020</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,395</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,112</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%;" valign="top"> Increases due to cash received for prepaid gift cards sold or unshipped food, excluding amounts recognized as revenue, and (decreases) due to returns</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,138</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes estimated revenue from the prepaid gift cards expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) at the end of the reporting period: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> Remaining 2020</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,789</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,901</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> 2022</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,192</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> 2023</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">468</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> 2024</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> 2025</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,867</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We apply the practical expedient in subtopic ASC 606-10-50-14 and do not disclose information about remaining performance obligations that have original expected durations of one year or less. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We review the reserves for our Nutrition segment customer returns at each reporting period and adjust them to reflect data available at that time. To estimate reserves for returns, we consider actual return rates in preceding periods and changes in product offerings or marketing methods that might impact returns going forward. To the extent the estimate of returns changes, we will adjust the reserve, which will impact the amount of revenue recognized in the period of the adjustment. The provision for estimated returns for the three and six months ended June 30, 2020 was $4.1 million and $9.3 million, respectively, and $5.6 million and $7.0 million for the three and six months ended June 30, 2019 (from March 8, 2019 forward), respectively. At June 30, 2020 and December 31, 2019, the reserve for estimated returns incurred but not received and processed was $1.4 million and $0.8 million, respectively, and has been included in accrued liabilities in the accompanying consolidated balance sheet.

3 1 0

P1M P30D

700000

500000

<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth Healthcare revenue disaggregated by program. Revenue from our SilverSneakers program is predominantly contracted with Medicare Advantage and Medicare Supplement plans. <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;" valign="top"> SilverSneakers</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,157</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122,899</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170,764</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,922</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;" valign="top"> Prime Fitness</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,047</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,751</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,858</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,494</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;" valign="top"> WholeHealth Living</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,747</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,467</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,796</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,041</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.12%; border-bottom:solid 0.75pt transparent;" valign="top"> Other (1)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,972</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,197</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">551</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.12%; border-bottom:double 2.5pt transparent;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,923</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,481</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241,615</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314,008</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.52%;white-space:nowrap" valign="top"> <p style="Background-color:#FFFFFF;line-height:12pt;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"> </td> <td style="width:3.52%;white-space:nowrap" valign="top"> <p style="Background-color:#FFFFFF;line-height:12pt;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</td> <td valign="top"> <p style="Background-color:#FFFFFF;line-height:12pt;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">For the three and six months ended June 30, 2020, other revenue in the table above includes $6.8 million from a well-being program with a large employer as well as $2.1 million of Wisely Well revenue.</td></tr></table></div>

49157000

122899000

170764000

245922000

19047000

29751000

51858000

58494000

4747000

4467000

9796000

9041000

8972000

364000

9197000

551000

81923000

157481000

241615000

314008000

6800000

2100000

Direct to consumer customers may return unopened ready-to-go Nutrisystem products within 30 days after purchase in order to receive a refund or credit.

P30D P14D

6500000

13000000.0

6300000

8100000

<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth Nutrition segment revenue, from March 8, 2019 forward, disaggregated by the source of revenue: <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.88%;" valign="top"> Nutrisystem direct to consumer</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165,118</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,976</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">320,509</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,977</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.88%;" valign="top"> South Beach Diet direct to consumer</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,650</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,464</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,414</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,118</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.88%;" valign="top"> Retail</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,902</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,728</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,350</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,032</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.88%;" valign="top"> QVC</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,901</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,522</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,088</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,044</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.88%; border-bottom:solid 0.75pt transparent;" valign="top"> Other</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">277</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">292</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.88%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,675</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182,896</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358,638</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,463</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div>

165118000

155976000

320509000

203977000

8650000

14464000

21414000

19118000

3902000

8728000

9350000

13032000

2901000

3522000

7088000

4044000

104000

206000

277000

292000

180675000

182896000

358638000

240463000

243000

95000

10937000

10911000

-2395000

-8112000

-71000 8138000

1789000

1901000

1192000

468000

297000

220000

5867000

4100000 9300000 5600000 7000000.0 1400000 800000

2000000.0

1800000

80000000.0

119500000

A reconciliation of our goodwill balance is as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Healthcare</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Nutrition</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Consolidated</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%;" valign="top"> Balance, January 1, 2020</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334,680</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">319,955</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">654,635</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.9%; border-bottom:solid 0.75pt transparent;" valign="top"> Impairment loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(119,500</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(119,500</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr style="height:10.25pt;"> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.9%; border-bottom:double 2.5pt transparent;" valign="top"> Balance, June 30, 2020</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334,680</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,455</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">535,135</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> At June 30, 2020 and December 31, 2019, intangible assets not subject to amortization consist of tradenames of $509.0 million and $589.0 million, respectively.

334680000

319955000

654635000

119500000

334680000

200455000

535135000

509000000.0

589000000.0

45100000

122400000

47300000

67500000

300000

5000000.0

P1Y

P4Y

2900000

3700000

6900000

9300000

500000

600000

0.176

0.309

0.051

0.376

119500000

2700000

1800000

-900000

2016

<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.52%;white-space:nowrap" valign="top"> 9. </td> <td valign="top"> Leases </td></tr></table></div> We maintain lease agreements principally for our office spaces and certain equipment. In addition, certain of our contracts, such as those with our fulfillment vendor related to our warehouse space or contracts with certain equipment vendors, contain embedded leases. We maintain three sublease agreements with respect to two of our office locations, each of which continues through the initial term of our master lease agreement. Such sublease income and payments, while they reduce our rent expense, are not considered in the value of the right-of-use asset or lease liability. With the exception of two finance leases related to a network server and office equipment, all of our leases are classified as operating leases. In the aggregate, our leases generally have remaining lease terms of one to five years, some of which include options to extend the lease for additional periods. The following table shows the components of lease expense for the three and six months ended June 30, 2020 and 2019: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> Finance lease cost:</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of leased <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest of lease liabilities</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> Operating lease cost</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,675</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,804</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,350</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,520</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.38%; border-bottom:solid 0.75pt transparent;" valign="top"> Short-term lease cost</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost before subleases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,996</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,934</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,987</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,697</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.38%; border-bottom:solid 0.75pt transparent;" valign="top"> Sublease income</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,363</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,356</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,764</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,700</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost, net</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,633</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,578</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,223</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,997</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> Supplemental cash flow information related to leases is as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> Cash paid for amounts included in the measurement of lease liabilities</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flow attributable to operating leases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,545</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,561</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,611</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,108</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flow attributable to <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> finance leases</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flow attributable to <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> finance leases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(155</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(306</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> Supplemental noncash information:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> operating lease liabilities (1)</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,972</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> finance lease liabilities (1)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.52%;white-space:nowrap" valign="top"> </td> <td style="width:3.52%;white-space:nowrap" valign="top"> (1)</td> <td valign="top"> No new leases were entered into during the six months ended June 30, 2019. Amounts shown are due to the adoption of ASC 842 and reflect balances as of January 1, 2019 for the Healthcare segment and as of March 8, 2019 for the Nutrition segment (i.e., the date of our acquisition of Nutrisystem).</td></tr></table></div> 3 P1Y P5Y

The following table shows the components of lease expense for the three and six months ended June 30, 2020 and 2019: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> Finance lease cost:</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of leased <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest of lease liabilities</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> Operating lease cost</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,675</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,804</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,350</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,520</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.38%; border-bottom:solid 0.75pt transparent;" valign="top"> Short-term lease cost</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost before subleases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,996</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,934</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,987</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,697</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.38%; border-bottom:solid 0.75pt transparent;" valign="top"> Sublease income</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,363</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,356</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,764</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,700</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost, net</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,633</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,578</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,223</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,997</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div>

162000

12000

324000

24000

22000

2000

47000

4000

3675000

3804000

7350000

6520000

137000

116000

266000

149000

3996000 3934000 7987000 6697000

1363000

1356000

2764000

2700000

2633000

2578000

5223000

3997000

Supplemental cash flow information related to leases is as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> Cash paid for amounts included in the measurement of lease liabilities</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flow attributable to operating leases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,545</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,561</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,611</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,108</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flow attributable to <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> finance leases</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flow attributable to <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> finance leases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(155</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(306</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> Supplemental noncash information:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> operating lease liabilities (1)</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,972</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> finance lease liabilities (1)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.52%;white-space:nowrap" valign="top"> </td> <td style="width:3.52%;white-space:nowrap" valign="top"> (1)</td> <td valign="top"> No new leases were entered into during the six months ended June 30, 2019. Amounts shown are due to the adoption of ASC 842 and reflect balances as of January 1, 2019 for the Healthcare segment and as of March 8, 2019 for the Nutrition segment (i.e., the date of our acquisition of Nutrisystem).</td></tr></table></div>

2545000

3561000

5611000

5108000

22000

2000

47000

4000

155000

11000

306000

22000

48972000

181000

The Company's debt, net of unamortized deferred loan costs and original issue discount, consisted of the following at June 30, 2020 and December 31, 2019: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.98%;" valign="top"> Term Loan A</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280,000</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288,750</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.98%;" valign="top"> Term Loan B</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">775,000</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786,250</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.98%; border-bottom:solid 0.75pt transparent;" valign="top"> Revolving Credit Facility</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,850</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.98%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,055,000</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,094,850</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.98%; border-bottom:solid 0.75pt transparent;" valign="top"> Less: deferred loan costs and original issue discount</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,678</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,723</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.98%;" valign="top"> Total debt</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,012,322</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,048,127</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.98%; border-bottom:solid 0.75pt transparent;" valign="top"> Less: current portion</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,775</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.98%; border-bottom:double 2.5pt transparent;" valign="top"> Total non-current portion of debt</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,002,547</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,048,127</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div>

280000000 288750000 775000000 786250000 19850000 1055000000 1094850000 42678000 46723000

1012322000

1048127000

9775000

1002547000

1048127000

2019-03-08

350000000.0

830000000.0

125000000.0

35000000.0

50000000.0

125000000.0

0.50

1012000000

124500000

0.0250

2024-03-08

0.0075

2026-03-08

125000000.0

2021-03-31

2024-03-08

We are required to make prepayments on the Term Loans equal to our excess cash flow for a given fiscal year multiplied by the following excess cash flow percentages (such resulting payment an “Excess Cash Flow Payment”) based on our Net Leverage Ratio (as defined below) on the last day of such fiscal year: (a) 75% if the Net Leverage Ratio is greater than 3.75:1, (b) 50% if the Net Leverage Ratio is equal to or less than 3.75:1 but greater than 3.25:1 (c) 25% if the Net Leverage Ratio is equal to or less than 3.25:1 but greater than 2.75:1, and (d) 0% if the Net Leverage Ratio is equal to or less than 2.75:1 0.75 0.50 3.75 3.25 0.25 2.75 0 5.75 5.25 4.75 4.08 0

0.0050

0.0100

0.0425 0.0525 0.0375 0.0425 0.0325 0.0425 0.0275 0.0325

2024-05

0.022

800000000.0

0.00250

0.00500

0.001

The following table presents our assets and liabilities measured at fair value on a recurring basis at June 30, 2020 and December 31, 2019. <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;" valign="top"> Liabilities:</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest rate swap agreements</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,407</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,238</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div>

44407000

16238000

119500000

80000000.0

60300000

921200000

1012300000

2024-05

0.022

800000000.0

15800000

The estimated gross fair values of derivative instruments and their classification on the consolidated balance sheet at June 30, 2020 and December 31, 2019 were as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;" valign="top"> Liabilities:</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;" valign="top"> Derivatives designated as hedging instruments:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of long-term liabilities</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,664</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,947</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,743</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,291</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.2%; border-bottom:double 2.5pt transparent;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,407</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,238</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div>

15664000

4947000

28743000

11291000

44407000

16238000

The following table presents the effect of cash flow hedge accounting on accumulated OCI as of June 30, 2020 and 2019: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Ended</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">For the Six Months <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Ended</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> Derivatives in Cash Flow Hedging Relationships</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.54%;" valign="top"> Loss related to effective portion of derivatives recognized in accumulated OCI, gross of tax effect</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,020</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,144</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,772</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,144</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.54%;" valign="top"> Gain (loss) related to effective portion of derivatives reclassified from accumulated OCI to interest expense, gross of tax effect</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,482</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,603</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div>

-5020000

-16144000

-32772000

-16144000

-3482000

160000

-4603000

160000

14. Earnings (Loss) Per Share We use the two-class method to calculate earnings per share as the unvested restricted stock awards outstanding under our equity incentive plan are participating shares with nonforfeitable rights to dividends. Under the two-class method, we compute earnings per share of Common Stock by dividing the sum of distributed earnings to common stockholders (currently not applicable as we do not pay dividends) and undistributed earnings allocated to common stockholders by the weighted average number of outstanding shares of Common Stock for the period. In applying the two-class method, we allocate undistributed earnings to both shares of Common Stock and participating securities based on the number of weighted average shares outstanding during the period. Any undistributed losses are not allocated to unvested restricted stock as the restricted stockholders are not obligated to share in the losses. Following is a reconciliation of the numerator and denominator of basic and diluted earnings (loss) per share for the three and six months ended June 30, 2020 and 2019: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands except per share data)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Numerator:</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Net income (loss)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,511</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,137</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(169,595</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,351</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:solid 0.75pt transparent;" valign="top"> Net income allocated to unvested restricted stock</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(77</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:double 2.5pt transparent;" valign="top"> Net income (loss) allocated to shares of Common Stock</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,491</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,044</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(169,595</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,274</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Denominator:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Shares used for basic income (loss) per share</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,711</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,790</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,662</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,165</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Effect of dilutive stock options and restricted stock units outstanding:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Non-qualified stock options</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:solid 0.75pt transparent;" valign="top"> Restricted stock units</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">578</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">444</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:double 2.5pt transparent;" valign="top"> Shares used for diluted income (loss) per share (1)</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,794</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,461</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,662</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,719</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Earnings (loss) per share:</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Basic</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.59</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.38</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.49</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.49</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Diluted (1)</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.58</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.37</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.49</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.49</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Dilutive securities outstanding not included in the computation of earnings per share because their effect is anti-dilutive:</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Non-qualified stock options</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Restricted stock units</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Restricted stock awards</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Performance-based stock units</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Market-based stock units</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.52%;white-space:nowrap" valign="top"> </td> <td style="width:3.52%;white-space:nowrap" valign="top"> (1)</td> <td valign="top"> The impact of potentially dilutive securities for the six months ended June 30, 2020 was not considered because the impact would be anti-dilutive.</td></tr></table></div> Market stock units and performance stock units outstanding are considered contingently issuable shares, and certain of these stock units were excluded from the calculations of diluted earnings per share for all periods presented as the performance criteria had not been met as of the end of the reporting periods.

Following is a reconciliation of the numerator and denominator of basic and diluted earnings (loss) per share for the three and six months ended June 30, 2020 and 2019: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands except per share data)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Numerator:</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Net income (loss)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,511</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,137</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(169,595</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,351</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:solid 0.75pt transparent;" valign="top"> Net income allocated to unvested restricted stock</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(77</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:double 2.5pt transparent;" valign="top"> Net income (loss) allocated to shares of Common Stock</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,491</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,044</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(169,595</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,274</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Denominator:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Shares used for basic income (loss) per share</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,711</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,790</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,662</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,165</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Effect of dilutive stock options and restricted stock units outstanding:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Non-qualified stock options</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:solid 0.75pt transparent;" valign="top"> Restricted stock units</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">578</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">444</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:double 2.5pt transparent;" valign="top"> Shares used for diluted income (loss) per share (1)</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,794</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,461</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,662</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,719</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Earnings (loss) per share:</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Basic</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.59</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.38</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.49</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.49</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Diluted (1)</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.58</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.37</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.49</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.49</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Dilutive securities outstanding not included in the computation of earnings per share because their effect is anti-dilutive:</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Non-qualified stock options</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Restricted stock units</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Restricted stock awards</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Performance-based stock units</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;" valign="top"> Market-based stock units</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.52%;white-space:nowrap" valign="top"> </td> <td style="width:3.52%;white-space:nowrap" valign="top"> (1)</td> <td valign="top"> The impact of potentially dilutive securities for the six months ended June 30, 2020 was not considered because the impact would be anti-dilutive.</td></tr></table></div>

28511000

18137000

-169595000

22351000

20000 93000 77000

28491000

18044000

-169595000

22274000

48711000

47790000

48662000

45165000

8000

93000

110000

75000

578000

444000

48794000

48461000

48662000

45719000

0.59

0.38

-3.49

0.49

0.58

0.37

-3.49

0.49

235000

71000

202000

76000

750000

288000

544000

172000

32000

128000

35000

64000

95000

64000

49000

25000

15. Accumulated OCI The following tables summarize the changes in accumulated OCI, net of tax, for the six months ended June 30, 2020: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Net Change in Fair Value of Interest Rate Swaps</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr style="height:14.3pt;"> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.62%;" valign="top"> Accumulated OCI, net of tax, as of January 1, 2020</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,091</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.62%;" valign="top"> Other comprehensive income (loss) before reclassifications, net of tax of $8,370</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,402</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.62%; border-bottom:solid 0.75pt transparent;" valign="top"> Amounts reclassified from accumulated OCI, net of tax of $1,175</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,428</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.62%; border-bottom:double 2.5pt transparent;" valign="top"> Accumulated OCI, net of tax, as of June 30, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,065</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> )</td> </tr> </table></div> The following table presents details about reclassifications out of accumulated OCI for the six months ended June 30, 2020: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:23.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Statement of Operations Classification</td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%;" valign="top"> Interest rate swaps</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,603</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:23.64%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,175</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:23.64%; border-bottom:double 2.5pt transparent;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,428</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net of tax</td> </tr> </table></div> See Note 13 for a further discussion of our interest rate swaps.

The following tables summarize the changes in accumulated OCI, net of tax, for the six months ended June 30, 2020: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Net Change in Fair Value of Interest Rate Swaps</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr style="height:14.3pt;"> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.62%;" valign="top"> Accumulated OCI, net of tax, as of January 1, 2020</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,091</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.62%;" valign="top"> Other comprehensive income (loss) before reclassifications, net of tax of $8,370</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,402</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.62%; border-bottom:solid 0.75pt transparent;" valign="top"> Amounts reclassified from accumulated OCI, net of tax of $1,175</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,428</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.62%; border-bottom:double 2.5pt transparent;" valign="top"> Accumulated OCI, net of tax, as of June 30, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,065</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> )</td> </tr> </table></div>

-12091000

8370000

-24402000

1175000

3428000

-33065000

The following table presents details about reclassifications out of accumulated OCI for the six months ended June 30, 2020: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:23.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Statement of Operations Classification</td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%;" valign="top"> Interest rate swaps</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,603</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:23.64%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,175</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:23.64%; border-bottom:double 2.5pt transparent;" valign="top"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,428</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net of tax</td> </tr> </table></div>

4603000

1175000

3428000

16. Segment Disclosures and Concentrations of Risk Background and Basis of Organization Following the acquisition of Nutrisystem in March 2019, we organize and manage our operations within two reportable segments, based on the types of products and services they offer: Healthcare and Nutrition. The Healthcare segment derives its revenues from SilverSneakers senior fitness, Prime Fitness and WholeHealth Living. The Nutrition segment provides weight management products and services and derives its revenues from Nutrisystem and South Beach Diet products. Prior to the acquisition of Nutrisystem, we had one reportable segment. Segment Revenues, Profit or Loss, and Assets Our chief operating decision maker evaluates performance and allocates resources based on each segment’s EBITDA excluding acquisition and integration costs, impairment loss, restructuring and related charges, CEO transition costs, and direct, incremental costs related to COVID-19. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. Transactions between the segments primarily consist of payments made by one segment on behalf of the other segment, which are recorded as current assets and eliminated in consolidation. Intersegment revenues and costs related to Wisely Well totaled $1.9 million for the three and six months ended June 30, 2020. The following tables present information about reported segment revenues and profit or loss, net of intersegment eliminations, as well as reconciliations of each such amount to consolidated totals: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="22" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Healthcare</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Nutrition</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Segments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Healthcare</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Nutrition</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Segments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.2%; border-bottom:solid 0.75pt transparent;" valign="top"> Revenues</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,923</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,675</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,598</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,481</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182,896</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340,377</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (1)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> Consolidated income before income taxes</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,618</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,252</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition and integration costs</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,049</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,999</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CEO transition costs</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,745</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 costs</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,260</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restructuring and related charges</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,009</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,352</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,235</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,661</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,919</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,084</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjusted EBITDA</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,472</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,363</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,835</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,681</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,667</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,348</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> </tr> </table></div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="22" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Healthcare</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Nutrition</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Segments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Healthcare</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Nutrition</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Segments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.24%; border-bottom:solid 0.75pt transparent;" valign="top"> Revenues</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241,615</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358,638</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600,253</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314,008</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,463</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">554,471</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (1)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> Consolidated income (loss) before income taxes</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(178,633</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,834</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition and integration costs</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,844</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,049</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199,500</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CEO transition costs</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,332</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 costs</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,260</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restructuring and related charges</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,752</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,943</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,898</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,328</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.24%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,682</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,666</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.24%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjusted EBITDA</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,719</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,916</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,635</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,810</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,010</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,820</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> </tr> </table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.52%;white-space:nowrap" valign="top"> </td> <td style="width:3.52%;white-space:nowrap" valign="top"> (1)</td> <td valign="top"> The figure for total segments equals the consolidated figure for such item.</td></tr></table></div> Our total assets by segment were as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;" valign="top"> Healthcare</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">527,353</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">526,013</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.4%; border-bottom:solid 0.75pt transparent;" valign="top"> Nutrition</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">853,817</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,099,892</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.4%; border-bottom:double 2.5pt transparent;" valign="top"> Total assets</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,381,170</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,625,905</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> Concentrations of Risk As of June 30, 2020, we were subject to concentration of revenue risk related to the services that we provide. For the three and six months ended June 30, 2020, a significant portion (19% and 28%, respectively) of our consolidated revenues was derived from our SilverSneakers senior fitness offering, in which a meaningful amount of our fees is earned based on member visits to fitness partner locations. Due to widespread closures of our partner locations beginning in March 2020 related to the COVID-19 pandemic, there was a significant decrease in member participation and the related revenues during March 2020, with visits decreasing sharply by the end of March. A substantial number of our fitness partner locations remained closed for at least a portion of the second quarter. During the second quarter of 2020, the average monthly total participation levels of our SilverSneakers members were significantly below historical levels, and we also experienced a decline in paid subscribers for Prime Fitness, each of which adversely impacted revenues in our Healthcare segment. These adverse impacts to revenue were somewhat mitigated by a reduction in cost of services as our visit costs decreased in a corresponding manner.

1900000 1900000

The following tables present information about reported segment revenues and profit or loss, net of intersegment eliminations, as well as reconciliations of each such amount to consolidated totals: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="22" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Healthcare</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Nutrition</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Segments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Healthcare</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Nutrition</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Segments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.2%; border-bottom:solid 0.75pt transparent;" valign="top"> Revenues</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,923</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,675</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,598</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,481</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182,896</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340,377</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (1)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> Consolidated income before income taxes</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,618</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,252</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition and integration costs</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,049</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,999</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CEO transition costs</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,745</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 costs</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,260</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restructuring and related charges</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,009</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,352</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,235</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,661</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,919</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,084</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjusted EBITDA</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,472</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,363</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,835</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,681</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,667</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,348</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> </tr> </table></div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="22" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Healthcare</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Nutrition</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Segments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Healthcare</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Nutrition</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Segments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.24%; border-bottom:solid 0.75pt transparent;" valign="top"> Revenues</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241,615</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358,638</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600,253</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314,008</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,463</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">554,471</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (1)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> Consolidated income (loss) before income taxes</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(178,633</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,834</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition and integration costs</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,844</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,049</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199,500</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CEO transition costs</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,332</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 costs</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,260</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restructuring and related charges</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,752</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,943</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.24%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,898</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,328</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.24%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,682</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,666</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.24%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjusted EBITDA</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,719</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,916</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,635</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,810</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,010</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,820</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> </tr> </table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.52%;white-space:nowrap" valign="top"> </td> <td style="width:3.52%;white-space:nowrap" valign="top"> (1)</td> <td valign="top"> The figure for total segments equals the consolidated figure for such item.</td></tr></table></div>

81923000

180675000

262598000

157481000

182896000

340377000

34618000

26252000

2049000

8999000

1745000 1260000

1009000

2352000

21235000

23661000

12919000

9084000

41472000 33363000 74835000 35681000 34667000 70348000

241615000

358638000

600253000

314008000

240463000

554471000

-178633000

35834000

4844000

26049000

199500000

4332000 1260000

1752000

3943000

42898000

31328000

27682000

12666000

71719000 31916000 103635000 61810000 48010000 109820000

Our total assets by segment were as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> (In thousands)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;" valign="top"> Healthcare</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">527,353</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">526,013</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.4%; border-bottom:solid 0.75pt transparent;" valign="top"> Nutrition</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">853,817</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,099,892</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.4%; border-bottom:double 2.5pt transparent;" valign="top"> Total assets</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,381,170</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,625,905</td> <td style="background-color:#EAF9E8;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div>

527353000

526013000

853817000

1099892000

1381170000

1625905000

0.19

0.28

0.75 0.50 3.75 3.25 0.25 2.75 0 The impact of potentially dilutive securities for the six months ended June 30, 2020 was not considered because the impact would be anti-dilutive. No new leases were entered into during the six months ended June 30, 2019. Amounts shown are due to the adoption of ASC 842 and reflect balances as of January 1, 2019 for the Healthcare segment and as of March 8, 2019 for the Nutrition segment (i.e., the date of our acquisition of Nutrisystem). The figure for total segments equals the consolidated figure for such item. For the three and six months ended June 30, 2020, other revenue in the table above includes $6.8 million from a well-being program with a large employer as well as $2.1 million of Wisely Well revenue.

XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Aug. 04, 2020
Cover [Abstract]
Entity Registrant Name	TIVITY HEALTH, INC.
Entity Central Index Key	0000704415
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Trading Symbol	TVTY
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Entity Common Stock, Shares Outstanding		48,560,369
Entity File Number	000-19364
Entity Tax Identification Number	62-1117144
Entity Address, Address Line One	701 Cool Springs Boulevard
Entity Address, City or Town	Franklin
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37067
City Area Code	800
Local Phone Number	869-5311
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock - $.001 par value
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 60,274	$ 2,486
Accounts receivable, net	36,339	97,596
Inventories	22,088	36,407
Prepaid expenses	15,058	18,255
Other current assets	8,110	6,993
Total current assets	141,869	161,737
Property and equipment, net of accumulated depreciation of $53,525 and $42,510 respectively	52,436	52,909
Right-of-use assets, operating leases	35,300	41,518
Right-of-use assets, finance leases	1,356	1,680
Intangible assets, net	593,520	689,686
Goodwill, net	535,135	654,635
Other assets	21,554	23,740
Total assets	1,381,170	1,625,905
Current liabilities:
Accounts payable	35,492	46,480
Accrued salaries and benefits	10,539	13,071
Accrued liabilities	42,020	55,663
Deferred revenue	12,440	12,037
Income taxes payable	7,835	405
Current portion of operating lease liabilities	13,157	13,131
Current portion of finance lease liabilities	644	624
Current portion of long-term debt	9,775
Current portion of other long-term liabilities	15,664	4,947
Total current liabilities	147,566	146,358
Long-term debt	1,002,547	1,048,127
Long-term operating lease liabilities	23,515	30,321
Long-term finance lease liabilities	753	1,080
Long-term deferred tax liability	137,205	160,846
Other long-term liabilities	31,863	12,263
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock $.001 par value, 5,000,000 shares authorized, none outstanding
Common Stock $.001 par value, 120,000,000 shares authorized, 48,548,741 and 48,156,786 shares outstanding, respectively	48	48
Additional paid-in capital	505,760	504,419
Accumulated deficit	(406,840)	(237,284)
Treasury stock, at cost, 2,254,953 shares in treasury	(28,182)	(28,182)
Accumulated other comprehensive loss	(33,065)	(12,091)
Total stockholders' equity	37,721	226,910
Total liabilities and stockholders' equity	$ 1,381,170	$ 1,625,905

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Accumulated depreciation	$ 53,525	$ 42,510
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares outstanding (in shares)	48,548,741	48,156,786
Treasury stock (in shares)	2,254,953	2,254,953

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
shares in Thousands, $ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2020

Jun. 30, 2019

Revenues:

Total revenues

^[1]

$ 262,598

$ 340,377

$ 600,253

$ 554,471

Cost of revenue:

Total cost of revenue

118,241

194,758

317,397

335,097

Marketing expenses

51,105

54,603

138,177

78,751

Selling, general and administrative expenses

23,471

29,667

51,480

56,852

Depreciation and amortization

12,919

9,084

27,682

12,666

Impairment loss

199,500

Restructuring and related charges

1,009

2,352

1,752

3,943

Operating income (loss)

55,853

49,913

(135,735)

67,162

Interest expense

21,235

23,661

42,898

31,328

Income (loss) before income taxes

34,618

26,252

(178,633)

35,834

Income tax expense (benefit)

6,107

8,115

(9,038)

13,483

Net income (loss)

$ 28,511

$ 18,137

$ (169,595)

$ 22,351

Earnings (loss) per share:

Basic

$ 0.59

$ 0.38

$ (3.49)

$ 0.49

Diluted

^[2]

$ 0.58

$ 0.37

$ (3.49)

$ 0.49

Comprehensive income (loss)

$ 27,366

$ 5,901

$ (190,569)

$ 10,115

Weighted average common shares and equivalents:

Basic

48,711

47,790

48,662

45,165

Diluted

^[2]

48,794

48,461

48,662

45,719

Services

Revenues:

Total revenues

$ 79,856

$ 157,481

$ 239,548

$ 314,008

Cost of revenue:

Total cost of revenue

31,886

111,073

147,034

224,916

Products

Revenues:

Total revenues

182,742

182,896

360,705

240,463

Cost of revenue:

Total cost of revenue

$ 86,355

$ 83,685

$ 170,363

$ 110,181

[1]	The figure for total segments equals the consolidated figure for such item.
[2]	The impact of potentially dilutive securities for the six months ended June 30, 2020 was not considered because the impact would be anti-dilutive.

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Services
Depreciation	$ 2,240	$ 1,503	$ 4,071	$ 2,859
Products
Depreciation and amortization	$ 8,587	$ 5,861	$ 19,280	$ 7,488

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 28,511	$ 18,137	$ (169,595)	$ 22,351
Net change in fair value of interest rate swaps, net of income tax benefit of $393, $4,068, $7,195, and $4,068, respectively	(1,145)	(12,236)	(20,974)	(12,236)
Comprehensive income (loss)	$ 27,366	$ 5,901	$ (190,569)	$ 10,115

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 18 R7.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net change in fair value of interest rate swaps, income tax benefit	$ 393	$ 4,068	$ 7,195	$ 4,068

XML 19 R8.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Treasury Stock	Accumulated Other Comprehensive Loss
Balance at Dec. 31, 2018	$ 369,001	$ 41	$ 347,487	$ 49,655	$ (28,182)
Comprehensive income (loss)	10,115			22,351		$ (12,236)
Issuance of Common Stock in connection with Merger	132,838	6	132,832
Share-based compensation replacement awards related to Merger and attributable to pre-combination services	9,107		9,107
Exercise of stock options	370		370
Tax withholding for share-based compensation	(1,135)		(1,135)
Share-based employee compensation expense	9,257		9,257
Other	(247)		(129)	(118)
Balance at Jun. 30, 2019	529,306	47	497,789	71,888	(28,182)	(12,236)
Balance at Mar. 31, 2019	517,164	47	491,548	53,751	(28,182)
Comprehensive income (loss)	5,901			18,137		(12,236)
Exercise of stock options	137		137
Tax withholding for share-based compensation	(794)		(794)
Share-based employee compensation expense	6,898		6,898
Balance at Jun. 30, 2019	529,306	47	497,789	71,888	(28,182)	(12,236)
Balance at Dec. 31, 2019	226,910	48	504,419	(237,284)	(28,182)	(12,091)
Comprehensive income (loss)	(190,569)			(169,595)		(20,974)
Exercise of stock options	601		601
Tax withholding for share-based compensation	(2,949)		(2,949)
Share-based employee compensation expense	3,689		3,689
Other	39			39
Balance at Jun. 30, 2020	37,721	48	505,760	(406,840)	(28,182)	(33,065)
Balance at Mar. 31, 2020	7,624	48	503,049	(435,371)	(28,182)	(31,920)
Comprehensive income (loss)	27,366			28,511		(1,145)
Tax withholding for share-based compensation	(154)		(154)
Share-based employee compensation expense	2,865		2,865
Other	20			20
Balance at Jun. 30, 2020	$ 37,721	$ 48	$ 505,760	$ (406,840)	$ (28,182)	$ (33,065)

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

XML 20 R9.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net income (loss)	$ (169,595)	$ 22,351
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	27,682	12,666
Amortization and write-off of deferred loan costs	2,315	3,073
Amortization of debt discount	2,049	389
Share-based employee compensation expense	3,689	9,257
Impairment of goodwill and intangible assets	199,500
Deferred income taxes	(16,447)	10,789
Decrease (increase) in accounts receivable, net	61,257	(3,754)
Decrease in inventory	14,319	8,719
Decrease in other current assets	1,363	1,057
Increase (decrease) in accounts payable	9,411	(5,872)
(Decrease) increase in accrued salaries and benefits	(2,532)	570
Decrease in other current liabilities	(5,925)	(8,266)
Increase (decrease) in deferred revenue	403	(2,725)
Other	3,454	1,345
Net cash flows provided by operating activities	130,943	49,599
Cash flows from investing activities:
Acquisition of property and equipment	(10,362)	(8,918)
Business acquisitions, net of cash acquired		(1,062,818)
Net cash flows used in investing activities	(10,362)	(1,071,736)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	196,525	1,399,945
Payments of long-term debt	(236,375)	(347,879)
Payments related to tax withholding for share-based compensation	(2,949)	(1,135)
Exercise of stock options	601	370
Deferred loan costs		(30,189)
Principal payments related to financing leases	(306)	(22)
Change in cash overdraft and other	(20,289)	3,530
Net cash flows (used in) provided by financing activities	(62,793)	1,024,620
Effect of exchange rate changes on cash		(12)
Net increase in cash and cash equivalents	57,788	2,471
Cash and cash equivalents, beginning of period	2,486	1,933
Cash and cash equivalents, end of period	$ 60,274	$ 4,404

XML 21 R10.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Recent Developments

6 Months Ended

Jun. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Basis of Presentation and Recent Developments

1.	Basis of Presentation and Recent Developments

Recent Developments

We have taken a number of actions in response to the pandemic, including the following:

•

Effective at the end of July 2020, the Compensation Committee suspended the Company matching contribution to the Company’s 401(k) plan.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Recent Relevant Accounting Standards

6 Months Ended

Jun. 30, 2020

New Accounting Pronouncements And Changes In Accounting Principles [Abstract]

Recent Relevant Accounting Standards

2.	Recent Relevant Accounting Standards

years. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)(2)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)

+ Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Revenue Recognition

6 Months Ended

Jun. 30, 2020

Revenue From Contract With Customer [Abstract]

Revenue Recognition

3.	Revenue Recognition

Healthcare Segment

The following table sets forth Healthcare revenue disaggregated by program. Revenue from our SilverSneakers program is predominantly contracted with Medicare Advantage and Medicare Supplement plans.

(In thousands)	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
SilverSneakers	$	49,157	$	122,899	$	170,764	$	245,922
Prime Fitness		19,047		29,751		51,858		58,494
WholeHealth Living		4,747		4,467		9,796		9,041
Other ⁽¹⁾		8,972		364		9,197		551
	$	81,923	$	157,481	$	241,615	$	314,008

(1)

Sales and usage-based taxes are excluded from revenues.

Nutrition Segment

The following table sets forth Nutrition segment revenue, from March 8, 2019 forward, disaggregated by the source of revenue:

(In thousands)	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Nutrisystem direct to consumer	$	165,118	$	155,976	$	320,509	$	203,977
South Beach Diet direct to consumer		8,650		14,464	$	21,414		19,118
Retail		3,902		8,728		9,350		13,032
QVC		2,901		3,522		7,088		4,044
Other		104		206		277		292
	$	180,675	$	182,896	$	358,638	$	240,463

The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:

(In thousands)	June 30, 2020		December 31, 2019
Contract assets	$	243	$	95
Contract liabilities	$	10,937	$	10,911

Significant changes in the contract liabilities (deferred revenue) balance during the period are as follows:

	Three Months Ended June 30,			Six Months Ended June 30,
(In thousands)	2020			2020
Revenue recognized that was included in the contract liability (deferred revenue) balance on January 1, 2020	$	(2,395	)	$	(8,112	)
Increases due to cash received for prepaid gift cards sold or unshipped food, excluding amounts recognized as revenue, and (decreases) due to returns	$	(71	)	$	8,138

(In thousands)
Remaining 2020	$	1,789
2021		1,901
2022		1,192
2023		468
2024		297
2025		220
	$	5,867

We apply the practical expedient in subtopic ASC 606-10-50-14 and do not disclose information about remaining performance obligations that have original expected durations of one year or less.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Inventories

6 Months Ended

Jun. 30, 2020

Inventory Disclosure [Abstract]

Inventories

4.	Inventories

XML 25 R14.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill

6 Months Ended

Jun. 30, 2020

Goodwill And Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill

5.	Intangible Assets and Goodwill

(In thousands)	Healthcare		Nutrition			Consolidated
Balance, January 1, 2020	$	334,680	$	319,955		$	654,635
Impairment loss		—		(119,500	)	$	(119,500	)
Balance, June 30, 2020	$	334,680	$	200,455		$	535,135

At June 30, 2020 and December 31, 2019, intangible assets not subject to amortization consist of tradenames of $509.0 million and $589.0 million, respectively.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Marketing Expenses

6 Months Ended

Jun. 30, 2020

Marketing And Advertising Expense [Abstract]

Marketing Expenses

6.	Marketing Expenses

XML 27 R16.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

6 Months Ended

Jun. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Share-Based Compensation

7.	Share-Based Compensation

XML 28 R17.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Jun. 30, 2020

Income Tax Disclosure [Abstract]

Income Taxes

8.	Income Taxes

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 29 R18.htm IDEA: XBRL DOCUMENT

Leases

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Leases

The following table shows the components of lease expense for the three and six months ended June 30, 2020 and 2019:

	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)	2020			2019			2020			2019
Finance lease cost:
Amortization of leased assets	$	162		$	12		$	324		$	24
Interest of lease liabilities		22			2			47			4
Operating lease cost		3,675			3,804			7,350			6,520
Short-term lease cost		137			116			266			149
Total lease cost before subleases	$	3,996		$	3,934		$	7,987		$	6,697
Sublease income		(1,363	)		(1,356	)		(2,764	)		(2,700	)
Total lease cost, net	$	2,633		$	2,578		$	5,223		$	3,997

Supplemental cash flow information related to leases is as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)	2020			2019			2020			2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flow attributable to operating leases	$	(2,545	)	$	(3,561	)	$	(5,611	)	$	(5,108	)
Operating cash flow attributable to finance leases		(22	)		(2	)		(47	)		(4	)
Financing cash flow attributable to finance leases		(155	)		(11	)		(306	)		(22	)

Supplemental noncash information:
Right-of-use assets obtained in exchange for operating lease liabilities ⁽¹⁾		—			—			—			48,972
Right-of-use assets obtained in exchange for finance lease liabilities ⁽¹⁾		—			—			—			181

(1)

XML 30 R19.htm IDEA: XBRL DOCUMENT

Debt

6 Months Ended

Jun. 30, 2020

Debt Disclosure [Abstract]

Debt

10.

Debt

The Company's debt, net of unamortized deferred loan costs and original issue discount, consisted of the following at June 30, 2020 and December 31, 2019:

(In thousands)	June 30, 2020			December 31, 2019
Term Loan A	$	280,000		$	288,750
Term Loan B		775,000			786,250
Revolving Credit Facility		—			19,850
		1,055,000			1,094,850
Less: deferred loan costs and original issue discount		(42,678	)		(46,723	)
Total debt		1,012,322			1,048,127
Less: current portion		(9,775	)		—
Total non-current portion of debt	$	1,002,547		$	1,048,127

Credit Facility

XML 31 R20.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

11.	Commitments and Contingencies

Shareholder Lawsuits: Weiner Lawsuit, Consolidated Derivative Lawsuit, and Witmer Lawsuit

Shareholder Lawsuits: Strougo, Cobb, and Delaware Lawsuits

Trademark Lawsuit: Pacific Packaging Lawsuit

Other

XML 32 R21.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

12.	Fair Value Measurements

Fair Value Hierarchy

Level 1:

Quoted prices in active markets for identical assets or liabilities;

Level 2:

Level 3:

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table presents our assets and liabilities measured at fair value on a recurring basis at June 30, 2020 and December 31, 2019.

	Level 2
(In thousands)	June 30, 2020		December 31, 2019
Liabilities:
Interest rate swap agreements	$	44,407	$	16,238

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

We measure certain assets at fair value on a nonrecurring basis in the fourth quarter of each year, including the following:

•

reporting units measured at fair value as part of a goodwill impairment test; and

•

indefinite-lived intangible assets measured at fair value for impairment assessment.

There were no impairment triggers during the second quarter of 2020 related to our goodwill or indefinite-lived intangible assets.

Fair Value of Other Financial Instruments

The estimated fair value of each class of financial instruments at June 30, 2020 was as follows:

Cash and cash equivalents – The carrying amount of $60.3 million approximates fair value due to the short maturity of those instruments (less than three months).

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

Derivative Instruments and Hedging Activities

6 Months Ended

Jun. 30, 2020

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities

13.	Derivative Instruments and Hedging Activities

Cash Flow Hedges of Interest Rate Risk

The estimated gross fair values of derivative instruments and their classification on the consolidated balance sheet at June 30, 2020 and December 31, 2019 were as follows:

(In thousands)	June 30, 2020		December 31, 2019
Liabilities:
Derivatives designated as hedging instruments:
Current portion of long-term liabilities	$	15,664	$	4,947
Other long-term liabilities		28,743		11,291
	$	44,407	$	16,238

The following table presents the effect of cash flow hedge accounting on accumulated OCI as of June 30, 2020 and 2019:

(In thousands)	For the Three Months Ended					For the Six Months Ended
Derivatives in Cash Flow Hedging Relationships	June 30, 2020			June 30, 2019		June 30, 2020			June 30, 2019
Loss related to effective portion of derivatives recognized in accumulated OCI, gross of tax effect	$	5,020		$	16,144	$	32,772		$	16,144
Gain (loss) related to effective portion of derivatives reclassified from accumulated OCI to interest expense, gross of tax effect	$	(3,482	)	$	160	$	(4,603	)	$	160

XML 34 R23.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per Share

6 Months Ended

Jun. 30, 2020

Earnings Per Share [Abstract]

Earnings (Loss) Per Share

14. Earnings (Loss) Per Share

(In thousands except per share data)	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Numerator:
Net income (loss)	$	28,511		$	18,137		$	(169,595	)	$	22,351
Net income allocated to unvested restricted stock		(20	)		(93	)		—			(77	)
Net income (loss) allocated to shares of Common Stock	$	28,491		$	18,044		$	(169,595	)	$	22,274

Denominator:
Shares used for basic income (loss) per share		48,711			47,790			48,662			45,165
Effect of dilutive stock options and restricted stock units outstanding:
Non-qualified stock options		8			93			—			110
Restricted stock units		75			578			—			444
Shares used for diluted income (loss) per share ⁽¹⁾		48,794			48,461			48,662			45,719

Earnings (loss) per share:
Basic	$	0.59		$	0.38		$	(3.49	)	$	0.49
Diluted ⁽¹⁾	$	0.58		$	0.37		$	(3.49	)	$	0.49

Dilutive securities outstanding not included in the computation of earnings per share because their effect is anti-dilutive:
Non-qualified stock options		235			71			202			76
Restricted stock units		750			288			544			172
Restricted stock awards		32			128			35			64
Performance-based stock units		95			—			64			—
Market-based stock units		49			—			25			—

(1)

The impact of potentially dilutive securities for the six months ended June 30, 2020 was not considered because the impact would be anti-dilutive.

XML 35 R24.htm IDEA: XBRL DOCUMENT

Accumulated OCI

6 Months Ended

Jun. 30, 2020

Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]

Accumulated OCI

15. Accumulated OCI

The following tables summarize the changes in accumulated OCI, net of tax, for the six months ended June 30, 2020:

(In thousands)	Net Change in Fair Value of Interest Rate Swaps
Accumulated OCI, net of tax, as of January 1, 2020	$	(12,091	)
Other comprehensive income (loss) before reclassifications, net of tax of $8,370		(24,402	)
Amounts reclassified from accumulated OCI, net of tax of $1,175		3,428
Accumulated OCI, net of tax, as of June 30, 2020	$	(33,065	)

The following table presents details about reclassifications out of accumulated OCI for the six months ended June 30, 2020:

(In thousands)	Six Months Ended June, 2020			Statement of Operations Classification
Interest rate swaps	$	4,603		Interest expense
		(1,175	)	Income tax expense
	$	3,428		Net of tax

See Note 13 for a further discussion of our interest rate swaps.

XML 36 R25.htm IDEA: XBRL DOCUMENT

Segment Disclosures and Concentrations of Risk

6 Months Ended

Jun. 30, 2020

Segment Reporting [Abstract]

Segment Disclosures and Concentrations of Risk

16. Segment Disclosures and Concentrations of Risk

Background and Basis of Organization

Segment Revenues, Profit or Loss, and Assets

(In thousands)
	Three Months Ended June 30,
	2020						2019
	Healthcare		Nutrition		Total Segments		Healthcare		Nutrition		Total Segments
Revenues	$	81,923	$	180,675	$	262,598	$	157,481	$	182,896	$	340,377	(1)

Consolidated income before income taxes					$	34,618					$	26,252

Acquisition and integration costs						2,049						8,999
Impairment loss						—						—
CEO transition costs						1,745						—
COVID-19 costs						1,260						—
Restructuring and related charges						1,009						2,352
Interest expense						21,235						23,661
Depreciation and amortization						12,919						9,084
Adjusted EBITDA	$	41,472	$	33,363	$	74,835	$	35,681	$	34,667	$	70,348

(In thousands)
	Six Months Ended June 30,
	2020							2019
	Healthcare		Nutrition		Total Segments			Healthcare		Nutrition		Total Segments
Revenues	$	241,615	$	358,638	$	600,253		$	314,008	$	240,463	$	554,471	(1)

Consolidated income (loss) before income taxes					$	(178,633	)					$	35,834

Acquisition and integration costs						4,844							26,049
Impairment loss						199,500							—
CEO transition costs						4,332							—
COVID-19 costs						1,260							—
Restructuring and related charges						1,752							3,943
Interest expense						42,898							31,328
Depreciation and amortization						27,682							12,666
Adjusted EBITDA	$	71,719	$	31,916	$	103,635		$	61,810	$	48,010	$	109,820

(1)

The figure for total segments equals the consolidated figure for such item.

Our total assets by segment were as follows:

(In thousands)	June 30, 2020		December 31, 2019
Healthcare	$	527,353	$	526,013
Nutrition		853,817		1,099,892
Total assets	$	1,381,170	$	1,625,905

Concentrations of Risk

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

XML 37 R26.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Recent Developments (Policies)

6 Months Ended

Jun. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Basis of Presentation and Recent Developments

Recent Developments

We have taken a number of actions in response to the pandemic, including the following:

•

Effective at the end of July 2020, the Compensation Committee suspended the Company matching contribution to the Company’s 401(k) plan.

Recent Relevant Accounting Standards

years. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

XML 38 R27.htm IDEA: XBRL DOCUMENT

Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2020

Summary of Information about Contract Assets and Contract Liabilities from Contracts with Customers

The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:

(In thousands)	June 30, 2020		December 31, 2019
Contract assets	$	243	$	95
Contract liabilities	$	10,937	$	10,911

Significant changes in the contract liabilities (deferred revenue) balance during the period are as follows:

	Three Months Ended June 30,			Six Months Ended June 30,
(In thousands)	2020			2020
Revenue recognized that was included in the contract liability (deferred revenue) balance on January 1, 2020	$	(2,395	)	$	(8,112	)
Increases due to cash received for prepaid gift cards sold or unshipped food, excluding amounts recognized as revenue, and (decreases) due to returns	$	(71	)	$	8,138

Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied

(In thousands)
Remaining 2020	$	1,789
2021		1,901
2022		1,192
2023		468
2024		297
2025		220
	$	5,867

Healthcare

Summary of Revenue Disaggregated

The following table sets forth Healthcare revenue disaggregated by program. Revenue from our SilverSneakers program is predominantly contracted with Medicare Advantage and Medicare Supplement plans.

(In thousands)	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
SilverSneakers	$	49,157	$	122,899	$	170,764	$	245,922
Prime Fitness		19,047		29,751		51,858		58,494
WholeHealth Living		4,747		4,467		9,796		9,041
Other ⁽¹⁾		8,972		364		9,197		551
	$	81,923	$	157,481	$	241,615	$	314,008

(1)

Nutrition

Summary of Revenue Disaggregated

The following table sets forth Nutrition segment revenue, from March 8, 2019 forward, disaggregated by the source of revenue:

(In thousands)	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Nutrisystem direct to consumer	$	165,118	$	155,976	$	320,509	$	203,977
South Beach Diet direct to consumer		8,650		14,464	$	21,414		19,118
Retail		3,902		8,728		9,350		13,032
QVC		2,901		3,522		7,088		4,044
Other		104		206		277		292
	$	180,675	$	182,896	$	358,638	$	240,463

XML 39 R28.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill (Tables)

6 Months Ended

Jun. 30, 2020

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Reconciliation of Our Goodwill

A reconciliation of our goodwill balance is as follows:

(In thousands)	Healthcare		Nutrition			Consolidated
Balance, January 1, 2020	$	334,680	$	319,955		$	654,635
Impairment loss		—		(119,500	)	$	(119,500	)
Balance, June 30, 2020	$	334,680	$	200,455		$	535,135

At June 30, 2020 and December 31, 2019, intangible assets not subject to amortization consist of tradenames of $509.0 million and $589.0 million, respectively.

XML 40 R29.htm IDEA: XBRL DOCUMENT

Leases (Tables)

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Schedule of Components of Lease Expense

The following table shows the components of lease expense for the three and six months ended June 30, 2020 and 2019:

	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)	2020			2019			2020			2019
Finance lease cost:
Amortization of leased assets	$	162		$	12		$	324		$	24
Interest of lease liabilities		22			2			47			4
Operating lease cost		3,675			3,804			7,350			6,520
Short-term lease cost		137			116			266			149
Total lease cost before subleases	$	3,996		$	3,934		$	7,987		$	6,697
Sublease income		(1,363	)		(1,356	)		(2,764	)		(2,700	)
Total lease cost, net	$	2,633		$	2,578		$	5,223		$	3,997

Schedule of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases is as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)	2020			2019			2020			2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flow attributable to operating leases	$	(2,545	)	$	(3,561	)	$	(5,611	)	$	(5,108	)
Operating cash flow attributable to finance leases		(22	)		(2	)		(47	)		(4	)
Financing cash flow attributable to finance leases		(155	)		(11	)		(306	)		(22	)

Supplemental noncash information:
Right-of-use assets obtained in exchange for operating lease liabilities ⁽¹⁾		—			—			—			48,972
Right-of-use assets obtained in exchange for finance lease liabilities ⁽¹⁾		—			—			—			181

(1)

XML 41 R30.htm IDEA: XBRL DOCUMENT

Debt (Tables)

6 Months Ended

Jun. 30, 2020

Debt Disclosure [Abstract]

Summary of Debt, Net of Unamortized Deferred Loan Costs And Original Issue Discount

The Company's debt, net of unamortized deferred loan costs and original issue discount, consisted of the following at June 30, 2020 and December 31, 2019:

(In thousands)	June 30, 2020			December 31, 2019
Term Loan A	$	280,000		$	288,750
Term Loan B		775,000			786,250
Revolving Credit Facility		—			19,850
		1,055,000			1,094,850
Less: deferred loan costs and original issue discount		(42,678	)		(46,723	)
Total debt		1,012,322			1,048,127
Less: current portion		(9,775	)		—
Total non-current portion of debt	$	1,002,547		$	1,048,127

XML 42 R31.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table presents our assets and liabilities measured at fair value on a recurring basis at June 30, 2020 and December 31, 2019.

	Level 2
(In thousands)	June 30, 2020		December 31, 2019
Liabilities:
Interest rate swap agreements	$	44,407	$	16,238

XML 43 R32.htm IDEA: XBRL DOCUMENT

Derivative Instruments and Hedging Activities (Tables)

6 Months Ended

Jun. 30, 2020

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Schedule of Estimated Gross Fair Values of Derivative Instruments and Their Classification on Consolidated Balance Sheet

The estimated gross fair values of derivative instruments and their classification on the consolidated balance sheet at June 30, 2020 and December 31, 2019 were as follows:

(In thousands)	June 30, 2020		December 31, 2019
Liabilities:
Derivatives designated as hedging instruments:
Current portion of long-term liabilities	$	15,664	$	4,947
Other long-term liabilities		28,743		11,291
	$	44,407	$	16,238

Schedule of Effect of Cash Flow Hedge Accounting on Accumulated OCI

The following table presents the effect of cash flow hedge accounting on accumulated OCI as of June 30, 2020 and 2019:

(In thousands)	For the Three Months Ended					For the Six Months Ended
Derivatives in Cash Flow Hedging Relationships	June 30, 2020			June 30, 2019		June 30, 2020			June 30, 2019
Loss related to effective portion of derivatives recognized in accumulated OCI, gross of tax effect	$	5,020		$	16,144	$	32,772		$	16,144
Gain (loss) related to effective portion of derivatives reclassified from accumulated OCI to interest expense, gross of tax effect	$	(3,482	)	$	160	$	(4,603	)	$	160

XML 44 R33.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per Share (Tables)

6 Months Ended

Jun. 30, 2020

Earnings Per Share [Abstract]

Reconciliation of the Numerator and Denominator of Basic and Diluted Earnings (Loss) Per Share

Following is a reconciliation of the numerator and denominator of basic and diluted earnings (loss) per share for the three and six months ended June 30, 2020 and 2019:

(In thousands except per share data)	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Numerator:
Net income (loss)	$	28,511		$	18,137		$	(169,595	)	$	22,351
Net income allocated to unvested restricted stock		(20	)		(93	)		—			(77	)
Net income (loss) allocated to shares of Common Stock	$	28,491		$	18,044		$	(169,595	)	$	22,274

Denominator:
Shares used for basic income (loss) per share		48,711			47,790			48,662			45,165
Effect of dilutive stock options and restricted stock units outstanding:
Non-qualified stock options		8			93			—			110
Restricted stock units		75			578			—			444
Shares used for diluted income (loss) per share ⁽¹⁾		48,794			48,461			48,662			45,719

Earnings (loss) per share:
Basic	$	0.59		$	0.38		$	(3.49	)	$	0.49
Diluted ⁽¹⁾	$	0.58		$	0.37		$	(3.49	)	$	0.49

Dilutive securities outstanding not included in the computation of earnings per share because their effect is anti-dilutive:
Non-qualified stock options		235			71			202			76
Restricted stock units		750			288			544			172
Restricted stock awards		32			128			35			64
Performance-based stock units		95			—			64			—
Market-based stock units		49			—			25			—

(1)

The impact of potentially dilutive securities for the six months ended June 30, 2020 was not considered because the impact would be anti-dilutive.

XML 45 R34.htm IDEA: XBRL DOCUMENT

Accumulated OCI (Tables)

6 Months Ended

Jun. 30, 2020

Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]

Changes in Accumulated OCI

The following tables summarize the changes in accumulated OCI, net of tax, for the six months ended June 30, 2020:

(In thousands)	Net Change in Fair Value of Interest Rate Swaps
Accumulated OCI, net of tax, as of January 1, 2020	$	(12,091	)
Other comprehensive income (loss) before reclassifications, net of tax of $8,370		(24,402	)
Amounts reclassified from accumulated OCI, net of tax of $1,175		3,428
Accumulated OCI, net of tax, as of June 30, 2020	$	(33,065	)

Schedule of Reclassifications Out of Accumulated OCI

The following table presents details about reclassifications out of accumulated OCI for the six months ended June 30, 2020:

(In thousands)	Six Months Ended June, 2020			Statement of Operations Classification
Interest rate swaps	$	4,603		Interest expense
		(1,175	)	Income tax expense
	$	3,428		Net of tax

XML 46 R35.htm IDEA: XBRL DOCUMENT

Segment Disclosures and Concentrations of Risk (Tables)

6 Months Ended

Jun. 30, 2020

Segment Reporting [Abstract]

Schedule of Reported Segment Revenues and Profit or Loss, Net of Intersegment Eliminations, and Reconciliation

The following tables present information about reported segment revenues and profit or loss, net of intersegment eliminations, as well as reconciliations of each such amount to consolidated totals:

(In thousands)
	Three Months Ended June 30,
	2020						2019
	Healthcare		Nutrition		Total Segments		Healthcare		Nutrition		Total Segments
Revenues	$	81,923	$	180,675	$	262,598	$	157,481	$	182,896	$	340,377	(1)

Consolidated income before income taxes					$	34,618					$	26,252

Acquisition and integration costs						2,049						8,999
Impairment loss						—						—
CEO transition costs						1,745						—
COVID-19 costs						1,260						—
Restructuring and related charges						1,009						2,352
Interest expense						21,235						23,661
Depreciation and amortization						12,919						9,084
Adjusted EBITDA	$	41,472	$	33,363	$	74,835	$	35,681	$	34,667	$	70,348

(In thousands)
	Six Months Ended June 30,
	2020							2019
	Healthcare		Nutrition		Total Segments			Healthcare		Nutrition		Total Segments
Revenues	$	241,615	$	358,638	$	600,253		$	314,008	$	240,463	$	554,471	(1)

Consolidated income (loss) before income taxes					$	(178,633	)					$	35,834

Acquisition and integration costs						4,844							26,049
Impairment loss						199,500							—
CEO transition costs						4,332							—
COVID-19 costs						1,260							—
Restructuring and related charges						1,752							3,943
Interest expense						42,898							31,328
Depreciation and amortization						27,682							12,666
Adjusted EBITDA	$	71,719	$	31,916	$	103,635		$	61,810	$	48,010	$	109,820

(1)

The figure for total segments equals the consolidated figure for such item.

Schedule of Total Assets by Segment

Our total assets by segment were as follows:

(In thousands)	June 30, 2020		December 31, 2019
Healthcare	$	527,353	$	526,013
Nutrition		853,817		1,099,892
Total assets	$	1,381,170	$	1,625,905

XML 47 R36.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Recent Developments - Additional Information (Details)		1 Months Ended			3 Months Ended		6 Months Ended
	Mar. 07, 2019 Segment	Jul. 31, 2020 USD ($)	Jun. 30, 2020 USD ($)	Apr. 30, 2020 Employee	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Jun. 30, 2020 USD ($) Segment	Dec. 31, 2019 USD ($)	Jun. 30, 2019 USD ($)	Dec. 31, 2018 USD ($)
Basis Of Presentation And Recent Developments [Line Items]
Number of reportable segments \| Segment	1						2
Outstanding debt			$ 1,012,322,000		$ 1,012,322,000		$ 1,012,322,000	$ 1,048,127,000
Cash and cash equivalents			60,274,000		60,274,000		60,274,000	$ 2,486,000	$ 4,404,000	$ 1,933,000
Working capital deficit			5,700,000		5,700,000		$ 5,700,000
Percentage of employees furloughed				13.00%
Number of employees \| Employee				1,000
Percentage of employees terminated							8.00%
Percentage of additional employees furloughed							2.00%
Impairment of goodwill and intangible assets							$ 199,500,000
Impairment loss of intangibles					0
Impairment loss of goodwill					0	$ 119,500,000	119,500,000
Nutrisystem
Basis Of Presentation And Recent Developments [Line Items]
Impairment loss of goodwill							119,500,000
Nutrisystem \| Tradename
Basis Of Presentation And Recent Developments [Line Items]
Impairment loss of intangibles						80,000,000.0	$ 80,000,000.0
Executive Officers and Other Employees
Basis Of Presentation And Recent Developments [Line Items]
Percentage of reduction in base salary				25.00%
Non-management Members of Board
Basis Of Presentation And Recent Developments [Line Items]
Percentage of reduction in annual cash retainer and annual committee retainers payable							100.00%
Reduction period of annual cash retainer and annual committee retainers payable							4 months
Revolving Credit Facility
Basis Of Presentation And Recent Developments [Line Items]
Borrowed under revolving credit facility used to increase cash position			0		0		$ 0
Credit Agreement
Basis Of Presentation And Recent Developments [Line Items]
Outstanding debt			$ 1,012,300,000		1,012,300,000		1,012,300,000
Credit Agreement \| Subsequent Event
Basis Of Presentation And Recent Developments [Line Items]
Repayment of principal on the term loan		$ 24,800,000
COVID-19
Basis Of Presentation And Recent Developments [Line Items]
Incremental expense incurred due to shortage of workers					$ 1,300,000
COVID-19 \| Credit Agreement \| Revolving Credit Facility
Basis Of Presentation And Recent Developments [Line Items]
Borrowed under revolving credit facility used to increase cash position						$ 75,000,000
Repayment of revolving credit facility							$ 75,000,000
SilverSneakers
Basis Of Presentation And Recent Developments [Line Items]
Percentage of fitness partner locations having at least one visit			66.00%

XML 48 R37.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Additional Information (Details)

3 Months Ended

4 Months Ended

6 Months Ended

Mar. 07, 2019

Segment

Jun. 30, 2020

USD ($)

Jun. 30, 2019

USD ($)

Jun. 30, 2019

USD ($)

Jun. 30, 2020

USD ($)

Segment

Program

Obligation

Source

Jun. 30, 2019

USD ($)

Dec. 31, 2019

USD ($)

Disaggregation Of Revenue [Line Items]

Number of reportable segments | Segment

Revenue, Practical Expedient, Initial Application and Transition, Qualitative Assessment

true

Revenue

^[1]

$ 262,598,000

$ 340,377,000

$ 600,253,000

$ 554,471,000

Healthcare

Disaggregation Of Revenue [Line Items]

Number of programs | Program

Number of performance obligations | Obligation

Number of performance obligation unsatisfied | Obligation

Revenue recognized from performance obligations satisfied in prior period

$ 0

Period of billing in arrears once timing of services to customers is known

1 month

Number of days for customer to make payment after being invoiced

30 days

Capitalized costs

700,000

$ 700,000

$ 500,000

Number of reportable segments | Segment

Revenue

81,923,000

157,481,000

$ 241,615,000

314,008,000

Nutrition

Disaggregation Of Revenue [Line Items]

Number of sources for revenue recognition | Source

Description of return of obligation

Direct to consumer customers may return unopened ready-to-go Nutrisystem products within 30 days after purchase in order to receive a refund or credit.

Return of purchase order to refund or credit, period

30 days

Purchase order canceled of delivery, period

14 days

Revenue

180,675,000

182,896,000

$ 358,638,000

$ 240,463,000

Provision for estimated returns

4,100,000

5,600,000

$ 7,000,000.0

9,300,000

Nutrition | Accrued Liabilities

Disaggregation Of Revenue [Line Items]

Reserve for estimated returns

1,400,000

$ 800,000

Nutrition | Shipping and Handling Charges

Disaggregation Of Revenue [Line Items]

Revenue

$ 6,500,000

$ 6,300,000

$ 8,100,000

$ 13,000,000.0

[1]	The figure for total segments equals the consolidated figure for such item.

XML 49 R38.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Summary of Revenue Disaggregated by Program (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2020

Jun. 30, 2019

Disaggregation Of Revenue [Line Items]

Revenue

^[1]

$ 262,598

$ 340,377

$ 600,253

$ 554,471

Other

Disaggregation Of Revenue [Line Items]

Revenue

6,800

Healthcare

Disaggregation Of Revenue [Line Items]

Revenue

81,923

157,481

241,615

314,008

Healthcare | SilverSneakers

Disaggregation Of Revenue [Line Items]

Revenue

49,157

122,899

170,764

245,922

Healthcare | Prime Fitness

Disaggregation Of Revenue [Line Items]

Revenue

19,047

29,751

51,858

58,494

Healthcare | WholeHealth Living

Disaggregation Of Revenue [Line Items]

Revenue

4,747

4,467

9,796

9,041

Healthcare | Other

Disaggregation Of Revenue [Line Items]

Revenue

^[2]

$ 8,972

$ 364

$ 9,197

$ 551

[1]	The figure for total segments equals the consolidated figure for such item.
[2]	For the three and six months ended June 30, 2020, other revenue in the table above includes $6.8 million from a well-being program with a large employer as well as $2.1 million of Wisely Well revenue.

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 50 R39.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Summary of Revenue Disaggregated by Program (Parenthetical) (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2020

Jun. 30, 2019

Disaggregation Of Revenue [Line Items]

Revenue

^[1]

$ 262,598

$ 340,377

$ 600,253

$ 554,471

Other

Disaggregation Of Revenue [Line Items]

Revenue

6,800

Well-Being Program

Disaggregation Of Revenue [Line Items]

Revenue

$ 2,100

[1]	The figure for total segments equals the consolidated figure for such item.

- Definition

+ References

+ Details

XML 51 R40.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Summary of Revenue Disaggregated by Source (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2020

Jun. 30, 2019

Disaggregation Of Revenue [Line Items]

Revenue

^[1]

$ 262,598

$ 340,377

$ 600,253

$ 554,471

Other

Disaggregation Of Revenue [Line Items]

Revenue

6,800

Nutrition

Disaggregation Of Revenue [Line Items]

Revenue

180,675

182,896

358,638

240,463

Nutrition | Nutrisystem Direct to Consumer

Disaggregation Of Revenue [Line Items]

Revenue

165,118

155,976

320,509

203,977

Nutrition | South Beach Diet Direct to Consumer

Disaggregation Of Revenue [Line Items]

Revenue

8,650

14,464

21,414

19,118

Nutrition | Retail

Disaggregation Of Revenue [Line Items]

Revenue

3,902

8,728

9,350

13,032

Nutrition | QVC

Disaggregation Of Revenue [Line Items]

Revenue

2,901

3,522

7,088

4,044

Nutrition | Other

Disaggregation Of Revenue [Line Items]

Revenue

$ 104

$ 206

$ 277

$ 292

[1]	The figure for total segments equals the consolidated figure for such item.

- Definition

+ References

+ Details

XML 52 R41.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Summary of Information about Receivables, Contract Assets and Contract Liabilities from Contracts with Customers (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Revenue From Contract With Customer [Abstract]
Contract assets	$ 243	$ 95
Contract liabilities	$ 10,937	$ 10,911

XML 53 R42.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Summary of Significant Changes in Contract Liabilities (Deferred Revenue) Balance (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Revenue recognized that was included in the contract liability (deferred revenue) balance on January 1, 2020	$ (2,395)	$ (8,112)
Increases due to cash received for prepaid gift cards sold or unshipped food, excluding amounts recognized as revenue, and (decreases) due to returns	$ (71)	$ 8,138

XML 54 R43.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied (Details) $ in Thousands	Jun. 30, 2020 USD ($)
Disaggregation Of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 5,867
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-07-01
Disaggregation Of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 1,789
Revenue, remaining performance obligation, expected timing of satisfaction, period	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-01-01
Disaggregation Of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 1,901
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01
Disaggregation Of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 1,192
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-01-01
Disaggregation Of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 468
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-01-01
Disaggregation Of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 297
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2025-01-01
Disaggregation Of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 220
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year

XML 55 R44.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied (Details 1) $ in Thousands	Jun. 30, 2020 USD ($)
Revenue From Contract With Customer [Abstract]
Revenue, remaining performance obligation, amount	$ 5,867

XML 56 R45.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Additional Information (Details 1)	6 Months Ended
	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Revenue, practical expedient, financing component [true false]	true

XML 57 R46.htm IDEA: XBRL DOCUMENT

Inventories - Additional Information (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Reserve for excess and obsolete inventory	$ 2.0	$ 1.8

XML 58 R47.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Impairment loss of intangibles	$ 0
Impairment loss of goodwill	0	$ 119,500,000	$ 119,500,000
Tradename
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Intangible assets not subject to amortization	$ 509,000,000.0		$ 509,000,000.0	$ 589,000,000.0
Nutrisystem
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Impairment loss of goodwill		119,500,000
Nutrisystem \| Tradename
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Impairment loss of intangibles		$ 80,000,000.0

XML 59 R48.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill - Reconciliation of Goodwill Balance (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2020
Goodwill [Line Items]
Beginning balance		$ 654,635,000	$ 654,635,000
Impairment loss	$ 0	(119,500,000)	(119,500,000)
Ending balance	535,135,000		535,135,000
Healthcare
Goodwill [Line Items]
Beginning balance		334,680,000	334,680,000
Ending balance	334,680,000		334,680,000
Nutrition
Goodwill [Line Items]
Beginning balance		319,955,000	319,955,000
Impairment loss		$ (119,500,000)	(119,500,000)
Ending balance	$ 200,455,000		$ 200,455,000

XML 60 R49.htm IDEA: XBRL DOCUMENT

Marketing Expenses - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		4 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Marketing And Advertising Expense [Abstract]
Media expense	$ 45.1	$ 47.3	$ 67.5	$ 122.4
Prepaid for future advertisements and promotions	$ 0.3		$ 0.3	$ 0.3	$ 5.0

XML 61 R50.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Additional Information (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2020 USD ($) Type	Jun. 30, 2019 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Types of share based awards \| Type			5
Share based awards, description			We currently have five types of share-based awards outstanding to our employees and directors: stock options, restricted stock awards, restricted stock units, performance-based stock units, and market stock units.
Share-based compensation costs	$ 2.9	$ 6.9	$ 3.7	$ 9.3
Restructuring and Related Charges
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation costs		$ 0.5		$ 0.6
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Each of share based awards, vesting period			1 year
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Each of share based awards, vesting period			4 years

XML 62 R51.htm IDEA: XBRL DOCUMENT

Income Taxes- Additional Information (Details) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Operating Loss Carryforwards [Line Items]
Effective tax rate	17.60%		30.90%	5.10%	37.60%
Increase in income tax expense				$ 2,700,000
Impairment loss of goodwill	$ 0	$ 119,500,000		$ 119,500,000
Earliest Tax Year
Operating Loss Carryforwards [Line Items]
Open tax year				2016
State
Operating Loss Carryforwards [Line Items]
Increase in valuation allowance on deferred tax assets related to net operating loss carryforwards				$ 1,800,000
Reduction in deferred tax asset related to income tax credits				$ (900,000)

XML 63 R52.htm IDEA: XBRL DOCUMENT

Leases - Additional Information (Details)	6 Months Ended
Leases - Additional Information (Details)	Jun. 30, 2020 Agreement
Lessee Lease Description [Line Items]
Number of sublease agreements	3
Minimum
Lessee Lease Description [Line Items]
Remaining lease terms	1 year
Maximum
Lessee Lease Description [Line Items]
Remaining lease terms	5 years

XML 64 R53.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Amortization of leased assets	$ 162	$ 12	$ 324	$ 24
Interest of lease liabilities	22	2	47	4
Operating lease cost	3,675	3,804	7,350	6,520
Short-term lease cost	137	116	266	149
Total lease cost before subleases	3,996	3,934	7,987	6,697
Sublease income	(1,363)	(1,356)	(2,764)	(2,700)
Total lease cost, net	$ 2,633	$ 2,578	$ 5,223	$ 3,997

XML 65 R54.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2020

Jun. 30, 2019

Cash paid for amounts included in the measurement of lease liabilities

Operating cash flow attributable to operating leases

$ (2,545)

$ (3,561)

$ (5,611)

$ (5,108)

Operating cash flow attributable to finance leases

(22)

(2)

(47)

(4)

Financing cash flow attributable to finance leases

$ (155)

$ (11)

$ (306)

(22)

Supplemental noncash information:

Right-of-use assets obtained in exchange for operating lease liabilities

^[1]

48,972

Right-of-use assets obtained in exchange for finance lease liabilities

^[1]

$ 181

[1]	No new leases were entered into during the six months ended June 30, 2019. Amounts shown are due to the adoption of ASC 842 and reflect balances as of January 1, 2019 for the Healthcare segment and as of March 8, 2019 for the Nutrition segment (i.e., the date of our acquisition of Nutrisystem).

XML 66 R55.htm IDEA: XBRL DOCUMENT

Debt - Summary of Debt, Net of Unamortized Deferred Loan Costs And Original Issue Discount (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount	$ 1,055,000	$ 1,094,850
Less: deferred loan costs and original issue discount	(42,678)	(46,723)
Total debt	1,012,322	1,048,127
Less: current portion	(9,775)
Total non-current portion of debt	1,002,547	1,048,127
Term Loan A
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount	280,000	288,750
Term Loan B
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount	$ 775,000	786,250
Revolving Credit Facility
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount		$ 19,850

XML 67 R56.htm IDEA: XBRL DOCUMENT

Debt - Credit Facility - Additional Information (Details)		1 Months Ended	6 Months Ended	16 Months Ended
	Mar. 08, 2019 USD ($)	May 31, 2019 Agreement	Jun. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)
Line Of Credit Facility [Line Items]
Outstanding debt			$ 1,012,322,000	$ 1,012,322,000	$ 1,048,127,000
Interest Rate Swap Agreements
Line Of Credit Facility [Line Items]
Number of agreements held for maturity \| Agreement		8
Derivative maturity month and year		2024-05
Derivative, notional amount			800,000,000.0	800,000,000.0
Interest Rate Swap Agreements \| LIBOR
Line Of Credit Facility [Line Items]
Derivative, fixed interest rate		2.20%
Revolving Credit Facility
Line Of Credit Facility [Line Items]
Available borrowing capacity			$ 124,500,000	124,500,000
Credit Agreement
Line Of Credit Facility [Line Items]
Initiation date			Mar. 08, 2019
Outstanding debt			$ 1,012,300,000	1,012,300,000
Debt instrument, prepayments description			We are required to make prepayments on the Term Loans equal to our excess cash flow for a given fiscal year multiplied by the following excess cash flow percentages (such resulting payment an “Excess Cash Flow Payment”) based on our Net Leverage Ratio (as defined below) on the last day of such fiscal year: (a) 75% if the Net Leverage Ratio is greater than 3.75:1, (b) 50% if the Net Leverage Ratio is equal to or less than 3.75:1 but greater than 3.25:1 (c) 25% if the Net Leverage Ratio is equal to or less than 3.25:1 but greater than 2.75:1, and (d) 0% if the Net Leverage Ratio is equal to or less than 2.75:1
Net leverage ratio for next twelve month			5.75
Net leverage ratio in year two			5.25
Net leverage ratio thereafter			4.75
Net leverage ratio one			4.08
Credit Agreement \| Federal Funds Rate
Line Of Credit Facility [Line Items]
Basis spread on variable rate	0.50%
Credit Agreement \| One-Month LIBOR
Line Of Credit Facility [Line Items]
Basis spread on variable rate	1.00%
Credit Agreement \| Net Leverage Ratio Greater Than 3.75:1
Line Of Credit Facility [Line Items]
Excess cash flow percentage			75.00%
Net leverage ratio			375.00%
Credit Agreement \| Net Leverage Ratio Equal To or Less Than 3.75:1 but Greater Than 3.25:1
Line Of Credit Facility [Line Items]
Excess cash flow percentage			50.00%
Net leverage ratio			325.00%
Credit Agreement \| Net Leverage Ratio Equal To or Less Than 3.25:1 but Greater Than 2.75:1
Line Of Credit Facility [Line Items]
Excess cash flow percentage			25.00%
Net leverage ratio			275.00%
Credit Agreement \| Net Leverage Ratio Equal To or Less Than 2.75:1
Line Of Credit Facility [Line Items]
Excess cash flow percentage			0.00%
Credit Agreement \| Minimum
Line Of Credit Facility [Line Items]
Unused commitment fee percentage	0.25%
Credit Agreement \| Minimum \| LIBOR
Line Of Credit Facility [Line Items]
Variable rate basis	0.00%
Credit Agreement \| Maximum
Line Of Credit Facility [Line Items]
Unused commitment fee percentage	0.50%
Credit Agreement \| Revolving Credit Facility
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 125,000,000.0
Maturity date			Mar. 08, 2024
Credit Agreement \| Revolving Credit Facility \| Minimum \| LIBOR
Line Of Credit Facility [Line Items]
Margin rate	3.75%
Credit Agreement \| Revolving Credit Facility \| Minimum \| Base Rate
Line Of Credit Facility [Line Items]
Margin rate	2.75%
Credit Agreement \| Revolving Credit Facility \| Maximum \| LIBOR
Line Of Credit Facility [Line Items]
Margin rate	4.25%
Credit Agreement \| Revolving Credit Facility \| Maximum \| Base Rate
Line Of Credit Facility [Line Items]
Margin rate	3.25%
Credit Agreement \| Swingline Sub Facility
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 35,000,000.0
Maturity date			Mar. 08, 2024
Credit Agreement \| Letters of Credit Sub Facility
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	50,000,000.0
Credit Agreement \| Term Loan Facility A
Line Of Credit Facility [Line Items]
Debt instrument, face amount	$ 350,000,000.0
Periodic principal payment as percentage of aggregate principal amount	2.50%
Maturity date			Mar. 08, 2024
Credit Agreement \| Term Loan Facility A \| LIBOR
Line Of Credit Facility [Line Items]
Margin rate	4.25%
Credit Agreement \| Term Loan Facility A \| Base Rate
Line Of Credit Facility [Line Items]
Margin rate	3.25%
Credit Agreement \| Term Loan Facility B
Line Of Credit Facility [Line Items]
Debt instrument, face amount	$ 830,000,000.0
Periodic principal payment as percentage of aggregate principal amount	0.75%
Maturity date			Mar. 08, 2026
Credit Agreement \| Term Loan Facility B \| LIBOR
Line Of Credit Facility [Line Items]
Margin rate	5.25%
Credit Agreement \| Term Loan Facility B \| Base Rate
Line Of Credit Facility [Line Items]
Margin rate	4.25%
Credit Agreement \| Uncommitted Incremental Accordion Facility \| Minimum
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 125,000,000.0
Percentage of consolidated EBITDA requirement	50.00%
Credit Agreement \| Term Loans
Line Of Credit Facility [Line Items]
Payments on term loans				$ 125,000,000.0
Maturity date				Mar. 31, 2021

XML 68 R57.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information - (Details)	Nov. 06, 2017 Lawsuit $ / shares	Jun. 30, 2020 $ / shares	Dec. 31, 2019 $ / shares
Commitments And Contingencies Disclosure [Abstract]
Common stock, par value (in dollars per share) \| $ / shares	$ 0.001	$ 0.001	$ 0.001
Number of lawsuits filed	4
Number of lawsuits dismissed	3

XML 69 R58.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Interest Rate Swap Agreements \| Fair Value, Measurements, Recurring \| Level 2
Liabilities:
Liabilities measured at fair value	$ 44,407	$ 16,238

XML 70 R59.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Additional Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($) Tradename	Jun. 30, 2020 USD ($)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Impairment loss of goodwill	$ 0	$ 119,500,000	$ 119,500,000
Number of tradenames \| Tradename		2
Impairment loss of intangibles	0
Revolving Credit Facility
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Line of credit	0		0
Term Loans
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument fair value	921,200,000		921,200,000
Debt instrument carrying amount	1,012,300,000		1,012,300,000
Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash and cash equivalents	$ 60,300,000		60,300,000
Nutrition
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Impairment loss of goodwill		$ 119,500,000	119,500,000
Nutrisystem
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Impairment loss of goodwill			119,500,000
Nutrisystem \| Tradename
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Impairment loss of intangibles		$ 80,000,000.0	$ 80,000,000.0

XML 71 R60.htm IDEA: XBRL DOCUMENT

Derivative Instruments and Hedging Activities - Additional Information (Details) - Cash Flow Hedges - Derivatives Designated as Hedging Instruments - Interest Rate Swap Agreements	1 Months Ended
	May 31, 2019 Agreement	Jun. 30, 2020 USD ($)
Derivative [Line Items]
Number of amortizing interest rate swap agreements \| Agreement	8
Derivative maturity month and year	2024-05
Derivative, fixed interest rate	2.20%
Derivative, notional amount		$ 800,000,000.0
Derivative amount reclassify from accumulated OCI to interest expense within next 12 months		$ 15,800,000

XML 72 R61.htm IDEA: XBRL DOCUMENT

Derivative Instruments and Hedging Activities - Schedule of Estimated Gross Fair Values of Derivative Instruments and Their Classification on Consolidated Balance Sheet (Details) - Cash Flow Hedges - Derivatives Designated as Hedging Instruments - Interest Rate Swap Agreements - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Liabilities:
Derivative liabilities	$ 44,407	$ 16,238
Current Portion of Long-term Liabilities
Liabilities:
Current portion of long-term liabilities	15,664	4,947
Other Long-term Liabilities
Liabilities:
Other long-term liabilities	$ 28,743	$ 11,291

XML 73 R62.htm IDEA: XBRL DOCUMENT

Derivative Instruments and Hedging Activities - Schedule of Effect of Cash Flow Hedge Accounting on Accumulated OCI (Details) - Cash Flow Hedges - Derivatives Designated as Hedging Instruments - Interest Rate Swap Agreements - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Derivative Instruments Gain Loss [Line Items]
Loss related to effective portion of derivatives recognized in accumulated OCI, gross of tax effect	$ 5,020	$ 16,144	$ 32,772	$ 16,144
Interest Expense
Derivative Instruments Gain Loss [Line Items]
Gain (loss) related to effective portion of derivatives reclassified from accumulated OCI to interest expense, gross of tax effect	$ (3,482)	$ 160	$ (4,603)	$ 160

XML 74 R63.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per Share - Reconciliation of the Numerator and Denominator of Basic and Diluted Earnings (Loss) Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2020

Jun. 30, 2019

Numerator [Abstract]

Net income (loss)

$ 28,511

$ 18,137

$ (169,595)

$ 22,351

Net income allocated to unvested restricted stock

(20)

(93)

(77)

Net income (loss) allocated to shares of Common Stock

$ 28,491

$ 18,044

$ (169,595)

$ 22,274

Denominator [Abstract]

Shares used for basic income (loss) per share

48,711

47,790

48,662

45,165

Effect of dilutive stock options and restricted stock units outstanding [Abstract]

Shares used for diluted income (loss) per share

^[1]

48,794

48,461

48,662

45,719

Earnings (loss) per share, Basic

$ 0.59

$ 0.38

$ (3.49)

$ 0.49

Earnings (loss) per share, Diluted

^[1]

$ 0.58

$ 0.37

$ (3.49)

$ 0.49

Non-Qualified Stock Options

Effect of dilutive stock options and restricted stock units outstanding [Abstract]

Effect of dilutive stock options and restricted stock units outstanding (in shares)

110

Restricted Stock Units (RSUs)

Effect of dilutive stock options and restricted stock units outstanding [Abstract]

Effect of dilutive stock options and restricted stock units outstanding (in shares)

578

444

Market-based stock units

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]

Dilutive securities outstanding not included in the computation of earnings per share because their effect is anti-dilutive (in shares)

Non-Qualified Stock Options

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]

Dilutive securities outstanding not included in the computation of earnings per share because their effect is anti-dilutive (in shares)

235

202

Restricted Stock Units (RSUs)

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]

Dilutive securities outstanding not included in the computation of earnings per share because their effect is anti-dilutive (in shares)

750

288

544

172

Restricted Stock Awards

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]

Dilutive securities outstanding not included in the computation of earnings per share because their effect is anti-dilutive (in shares)

128

Performance-Based Stock Units

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]

Dilutive securities outstanding not included in the computation of earnings per share because their effect is anti-dilutive (in shares)

[1]	The impact of potentially dilutive securities for the six months ended June 30, 2020 was not considered because the impact would be anti-dilutive.

XML 75 R64.htm IDEA: XBRL DOCUMENT

Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Details) - Net Change in Fair Value of Interest Rate Swaps $ in Thousands	6 Months Ended
	Jun. 30, 2020 USD ($)
Changes in accumulated OCI, net of tax [Roll Forward]
Balance	$ (12,091)
Other comprehensive income (loss) before reclassifications, net	(24,402)
Amounts reclassified from accumulated OCI, net of tax	3,428
Balance	$ (33,065)

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)

+ Details

XML 76 R65.htm IDEA: XBRL DOCUMENT

Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Parenthetical) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020 USD ($)
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Other comprehensive income before reclassifications, tax	$ 8,370
Amounts reclassified from accumulated OCI, tax	$ 1,175

XML 77 R66.htm IDEA: XBRL DOCUMENT

Accumulated OCI - Schedule of Reclassifications Out of Accumulated OCI (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Interest expense	$ 21,235	$ 23,661	$ 42,898	$ 31,328
Income tax expense	$ (6,107)	$ (8,115)	9,038	$ (13,483)
Interest Rate Swap Agreements
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Net of tax			3,428
Reclassifications Out of Accumulate OCI
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Income tax expense			(1,175)
Net of tax			3,428
Reclassifications Out of Accumulate OCI \| Interest Rate Swap Agreements
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Interest expense			$ 4,603

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 78 R67.htm IDEA: XBRL DOCUMENT

Segment Disclosures and Concentrations of Risk - Additional Information (Details) $ in Millions		3 Months Ended	6 Months Ended
	Mar. 07, 2019 Segment	Jun. 30, 2020 USD ($)	Jun. 30, 2020 USD ($) Segment
Entity Wide Revenue Major Customer [Line Items]
Number of reportable segments \| Segment	1		2
Wisely Well
Entity Wide Revenue Major Customer [Line Items]
Intersegment revenues and costs \| $		$ 1.9	$ 1.9
SilverSneakers Senior Fitness
Entity Wide Revenue Major Customer [Line Items]
Percentage of concentration risk		19.00%	28.00%

XML 79 R68.htm IDEA: XBRL DOCUMENT

Segment Disclosures and Concentrations of Risk - Schedule of Reported Segment Revenues and Profit or Loss, Net of Intersegment Eliminations, and Reconciliation (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2020

Jun. 30, 2019

Segment Reporting Information [Line Items]

Revenue

^[1]

$ 262,598

$ 340,377

$ 600,253

$ 554,471

Income (loss) before income taxes

34,618

26,252

(178,633)

35,834

Acquisition and integration costs

2,049

8,999

4,844

26,049

Impairment loss

199,500

COVID-19 costs

1,260

Restructuring and related charges

1,009

2,352

1,752

3,943

Interest expense

21,235

23,661

42,898

31,328

Depreciation and amortization

12,919

9,084

27,682

12,666

Adjusted EBITDA

74,835

70,348

103,635

109,820

CEO

Segment Reporting Information [Line Items]

CEO transition costs

1,745

4,332

Healthcare

Segment Reporting Information [Line Items]

Revenue

81,923

157,481

241,615

314,008

Adjusted EBITDA

41,472

35,681

71,719

61,810

Nutrition

Segment Reporting Information [Line Items]

Revenue

180,675

182,896

358,638

240,463

Adjusted EBITDA

$ 33,363

$ 34,667

$ 31,916

$ 48,010

[1]	The figure for total segments equals the consolidated figure for such item.

XML 80 R69.htm IDEA: XBRL DOCUMENT

Segment Disclosures and Concentrations of Risk - Schedule of Total Assets by Segment (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Total assets	$ 1,381,170	$ 1,625,905
Healthcare
Segment Reporting Information [Line Items]
Total assets	527,353	526,013
Nutrition
Segment Reporting Information [Line Items]
Total assets	$ 853,817	$ 1,099,892

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

+ Details

EXCEL 81 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 83 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 84 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 249 345 1 true 72 0 false 13 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 100020 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnauditedParenthetical CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnauditedParenthetical CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) Statements 5 false false R6.htm 100050 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) Statements 6 false false R7.htm 100060 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnauditedParenthetical CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical) Statements 7 false false R8.htm 100070 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Statements 8 false false R9.htm 100080 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 9 false false R10.htm 100090 - Disclosure - Basis of Presentation and Recent Developments Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopments Basis of Presentation and Recent Developments Notes 10 false false R11.htm 100100 - Disclosure - Recent Relevant Accounting Standards Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRecentRelevantAccountingStandards Recent Relevant Accounting Standards Notes 11 false false R12.htm 100110 - Disclosure - Revenue Recognition Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognition Revenue Recognition Notes 12 false false R13.htm 100120 - Disclosure - Inventories Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureInventories Inventories Notes 13 false false R14.htm 100130 - Disclosure - Intangible Assets and Goodwill Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 14 false false R15.htm 100140 - Disclosure - Marketing Expenses Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureMarketingExpenses Marketing Expenses Notes 15 false false R16.htm 100150 - Disclosure - Share-Based Compensation Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensation Share-Based Compensation Notes 16 false false R17.htm 100160 - Disclosure - Income Taxes Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 17 false false R18.htm 100170 - Disclosure - Leases Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeases Leases Notes 18 false false R19.htm 100180 - Disclosure - Debt Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebt Debt Notes 19 false false R20.htm 100190 - Disclosure - Commitments and Contingencies Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 100200 - Disclosure - Fair Value Measurements Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 21 false false R22.htm 100210 - Disclosure - Derivative Instruments and Hedging Activities Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivities Derivative Instruments and Hedging Activities Notes 22 false false R23.htm 100220 - Disclosure - Earnings (Loss) Per Share Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShare Earnings (Loss) Per Share Notes 23 false false R24.htm 100230 - Disclosure - Accumulated OCI Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCI Accumulated OCI Notes 24 false false R25.htm 100240 - Disclosure - Segment Disclosures and Concentrations of Risk Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRisk Segment Disclosures and Concentrations of Risk Notes 25 false false R26.htm 100250 - Disclosure - Basis of Presentation and Recent Developments (Policies) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsPolicies Basis of Presentation and Recent Developments (Policies) Policies http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRecentRelevantAccountingStandards 26 false false R27.htm 100260 - Disclosure - Revenue Recognition (Tables) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognition 27 false false R28.htm 100270 - Disclosure - Intangible Assets and Goodwill (Tables) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillTables Intangible Assets and Goodwill (Tables) Tables http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill 28 false false R29.htm 100280 - Disclosure - Leases (Tables) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeases 29 false false R30.htm 100290 - Disclosure - Debt (Tables) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtTables Debt (Tables) Tables http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebt 30 false false R31.htm 100300 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurements 31 false false R32.htm 100310 - Disclosure - Derivative Instruments and Hedging Activities (Tables) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesTables Derivative Instruments and Hedging Activities (Tables) Tables http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivities 32 false false R33.htm 100320 - Disclosure - Earnings (Loss) Per Share (Tables) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareTables Earnings (Loss) Per Share (Tables) Tables http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShare 33 false false R34.htm 100330 - Disclosure - Accumulated OCI (Tables) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCITables Accumulated OCI (Tables) Tables http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCI 34 false false R35.htm 100340 - Disclosure - Segment Disclosures and Concentrations of Risk (Tables) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskTables Segment Disclosures and Concentrations of Risk (Tables) Tables http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRisk 35 false false R36.htm 100350 - Disclosure - Basis of Presentation and Recent Developments - Additional Information (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails Basis of Presentation and Recent Developments - Additional Information (Details) Details 36 false false R37.htm 100360 - Disclosure - Revenue Recognition - Additional Information (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails Revenue Recognition - Additional Information (Details) Details 37 false false R38.htm 100370 - Disclosure - Revenue Recognition - Summary of Revenue Disaggregated by Program (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramDetails Revenue Recognition - Summary of Revenue Disaggregated by Program (Details) Details 38 false false R39.htm 100380 - Disclosure - Revenue Recognition - Summary of Revenue Disaggregated by Program (Parenthetical) (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramParentheticalDetails Revenue Recognition - Summary of Revenue Disaggregated by Program (Parenthetical) (Details) Details 39 false false R40.htm 100390 - Disclosure - Revenue Recognition - Summary of Revenue Disaggregated by Source (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedBySourceDetails Revenue Recognition - Summary of Revenue Disaggregated by Source (Details) Details 40 false false R41.htm 100400 - Disclosure - Revenue Recognition - Summary of Information about Receivables, Contract Assets and Contract Liabilities from Contracts with Customers (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfInformationAboutReceivablesContractAssetsAndContractLiabilitiesFromContractsWithCustomersDetails Revenue Recognition - Summary of Information about Receivables, Contract Assets and Contract Liabilities from Contracts with Customers (Details) Details 41 false false R42.htm 100410 - Disclosure - Revenue Recognition - Summary of Significant Changes in Contract Liabilities (Deferred Revenue) Balance (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfSignificantChangesInContractLiabilitiesDeferredRevenueBalanceDetails Revenue Recognition - Summary of Significant Changes in Contract Liabilities (Deferred Revenue) Balance (Details) Details 42 false false R43.htm 100420 - Disclosure - Revenue Recognition - Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueFromPrepaidGiftCardsExpectedToBeRecognizedInFutureRelatedToPerformanceObligationUnsatisfiedOrPartiallySatisfiedDetails Revenue Recognition - Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied (Details) Details 43 false false R44.htm 100430 - Disclosure - Revenue Recognition - Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied (Details 1) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueFromPrepaidGiftCardsExpectedToBeRecognizedInFutureRelatedToPerformanceObligationUnsatisfiedOrPartiallySatisfiedDetails1 Revenue Recognition - Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied (Details 1) Details 44 false false R45.htm 100440 - Disclosure - Revenue Recognition - Additional Information (Details 1) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails1 Revenue Recognition - Additional Information (Details 1) Details 45 false false R46.htm 100450 - Disclosure - Inventories - Additional Information (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureInventoriesAdditionalInformationDetails Inventories - Additional Information (Details) Details 46 false false R47.htm 100460 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails Intangible Assets and Goodwill - Additional Information (Details) Details 47 false false R48.htm 100470 - Disclosure - Intangible Assets and Goodwill - Reconciliation of Goodwill Balance (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillReconciliationOfGoodwillBalanceDetails Intangible Assets and Goodwill - Reconciliation of Goodwill Balance (Details) Details 48 false false R49.htm 100480 - Disclosure - Marketing Expenses - Additional Information (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureMarketingExpensesAdditionalInformationDetails Marketing Expenses - Additional Information (Details) Details 49 false false R50.htm 100490 - Disclosure - Share-Based Compensation - Additional Information (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails Share-Based Compensation - Additional Information (Details) Details 50 false false R51.htm 100500 - Disclosure - Income Taxes- Additional Information (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes- Additional Information (Details) Details 51 false false R52.htm 100510 - Disclosure - Leases - Additional Information (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 52 false false R53.htm 100520 - Disclosure - Leases - Schedule of Components of Lease Expense (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails Leases - Schedule of Components of Lease Expense (Details) Details 53 false false R54.htm 100530 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details) Details 54 false false R55.htm 100540 - Disclosure - Debt - Summary of Debt, Net of Unamortized Deferred Loan Costs And Original Issue Discount (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails Debt - Summary of Debt, Net of Unamortized Deferred Loan Costs And Original Issue Discount (Details) Details 55 false false R56.htm 100560 - Disclosure - Debt - Credit Facility - Additional Information (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails Debt - Credit Facility - Additional Information (Details) Details 56 false false R57.htm 100570 - Disclosure - Commitments and Contingencies - Additional Information - (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information - (Details) Details 57 false false R58.htm 100580 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 58 false false R59.htm 100590 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 59 false false R60.htm 100600 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails Derivative Instruments and Hedging Activities - Additional Information (Details) Details 60 false false R61.htm 100610 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Estimated Gross Fair Values of Derivative Instruments and Their Classification on Consolidated Balance Sheet (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails Derivative Instruments and Hedging Activities - Schedule of Estimated Gross Fair Values of Derivative Instruments and Their Classification on Consolidated Balance Sheet (Details) Details 61 false false R62.htm 100620 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Effect of Cash Flow Hedge Accounting on Accumulated OCI (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails Derivative Instruments and Hedging Activities - Schedule of Effect of Cash Flow Hedge Accounting on Accumulated OCI (Details) Details 62 false false R63.htm 100630 - Disclosure - Earnings (Loss) Per Share - Reconciliation of the Numerator and Denominator of Basic and Diluted Earnings (Loss) Per Share (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails Earnings (Loss) Per Share - Reconciliation of the Numerator and Denominator of Basic and Diluted Earnings (Loss) Per Share (Details) Details http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareTables 63 false false R64.htm 100640 - Disclosure - Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIChangesInAccumulatedOCINetOfTaxDetails Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Details) Details 64 false false R65.htm 100650 - Disclosure - Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Parenthetical) (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIChangesInAccumulatedOCINetOfTaxParentheticalDetails Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Parenthetical) (Details) Details 65 false false R66.htm 100660 - Disclosure - Accumulated OCI - Schedule of Reclassifications Out of Accumulated OCI (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIScheduleOfReclassificationsOutOfAccumulatedOCIDetails Accumulated OCI - Schedule of Reclassifications Out of Accumulated OCI (Details) Details 66 false false R67.htm 100670 - Disclosure - Segment Disclosures and Concentrations of Risk - Additional Information (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskAdditionalInformationDetails Segment Disclosures and Concentrations of Risk - Additional Information (Details) Details 67 false false R68.htm 100680 - Disclosure - Segment Disclosures and Concentrations of Risk - Schedule of Reported Segment Revenues and Profit or Loss, Net of Intersegment Eliminations, and Reconciliation (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails Segment Disclosures and Concentrations of Risk - Schedule of Reported Segment Revenues and Profit or Loss, Net of Intersegment Eliminations, and Reconciliation (Details) Details 68 false false R69.htm 100690 - Disclosure - Segment Disclosures and Concentrations of Risk - Schedule of Total Assets by Segment (Details) Sheet http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfTotalAssetsBySegmentDetails Segment Disclosures and Concentrations of Risk - Schedule of Total Assets by Segment (Details) Details 69 false false All Reports Book All Reports tvty-10q_20200630.htm tvty-20200630.xsd tvty-20200630_cal.xml tvty-20200630_def.xml tvty-20200630_lab.xml tvty-20200630_pre.xml tvty-ex311_8.htm tvty-ex312_6.htm tvty-ex32_7.htm gs5ggmptrgcs000001.jpg http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 87 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tvty-10q_20200630.htm": { "axisCustom": 0, "axisStandard": 27, "contextCount": 249, "dts": { "calculationLink": { "local": [ "tvty-20200630_cal.xml" ] }, "definitionLink": { "local": [ "tvty-20200630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tvty-10q_20200630.htm" ] }, "labelLink": { "local": [ "tvty-20200630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "tvty-20200630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "tvty-20200630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 480, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 12, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 17 }, "keyCustom": 53, "keyStandard": 292, "memberCustom": 30, "memberStandard": 38, "nsprefix": "tvty", "nsuri": "http://www.tivityhealth.com/20200630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Basis of Presentation and Recent Developments", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopments", "shortName": "Basis of Presentation and Recent Developments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Recent Relevant Accounting Standards", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRecentRelevantAccountingStandards", "shortName": "Recent Relevant Accounting Standards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Revenue Recognition", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Inventories", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureInventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Intangible Assets and Goodwill", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "shortName": "Intangible Assets and Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "tvty:MarketingExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Marketing Expenses", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureMarketingExpenses", "shortName": "Marketing Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "tvty:MarketingExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Share-Based Compensation", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Income Taxes", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "tvty:LeasesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Leases", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "tvty:LeasesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Debt", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited", "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200630", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Commitments and Contingencies", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Fair Value Measurements", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Derivative Instruments and Hedging Activities", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivities", "shortName": "Derivative Instruments and Hedging Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Earnings (Loss) Per Share", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShare", "shortName": "Earnings (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Accumulated OCI", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCI", "shortName": "Accumulated OCI", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Segment Disclosures and Concentrations of Risk", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRisk", "shortName": "Segment Disclosures and Concentrations of Risk", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Basis of Presentation and Recent Developments (Policies)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsPolicies", "shortName": "Basis of Presentation and Recent Developments (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Revenue Recognition (Tables)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "tvty:ScheduleOfReconciliationOfOurGoodwill", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Intangible Assets and Goodwill (Tables)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillTables", "shortName": "Intangible Assets and Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "tvty:ScheduleOfReconciliationOfOurGoodwill", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "tvty:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Leases (Tables)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "tvty:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnauditedParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Debt (Tables)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Derivative Instruments and Hedging Activities (Tables)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesTables", "shortName": "Derivative Instruments and Hedging Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Earnings (Loss) Per Share (Tables)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareTables", "shortName": "Earnings (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Accumulated OCI (Tables)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCITables", "shortName": "Accumulated OCI (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Segment Disclosures and Concentrations of Risk (Tables)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskTables", "shortName": "Segment Disclosures and Concentrations of Risk (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20190307_20190307", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "U_tvtySegment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Basis of Presentation and Recent Developments - Additional Information (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "shortName": "Basis of Presentation and Recent Developments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200430", "decimals": "2", "lang": null, "name": "tvty:PercentageOfEmployeesFurloughed", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20190307_20190307", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "U_tvtySegment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Revenue Recognition - Additional Information (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "shortName": "Revenue Recognition - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_us-gaapStatementBusinessSegmentsAxis_us-gaapHealthCareMember_20200101_20200630", "decimals": "INF", "lang": null, "name": "tvty:NumberOfPrograms", "reportCount": 1, "unique": true, "unitRef": "U_tvtyProgram", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Revenue Recognition - Summary of Revenue Disaggregated by Program (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramDetails", "shortName": "Revenue Recognition - Summary of Revenue Disaggregated by Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_srtProductOrServiceAxis_tvtySilverSneakersMember_us-gaapStatementBusinessSegmentsAxis_us-gaapHealthCareMember_20200401_20200630", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Revenue Recognition - Summary of Revenue Disaggregated by Program (Parenthetical) (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramParentheticalDetails", "shortName": "Revenue Recognition - Summary of Revenue Disaggregated by Program (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "p", "link:footnote", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_srtProductOrServiceAxis_tvtyWellBeingProgramMember_20200401_20200630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Revenue Recognition - Summary of Revenue Disaggregated by Source (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedBySourceDetails", "shortName": "Revenue Recognition - Summary of Revenue Disaggregated by Source (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_srtProductOrServiceAxis_tvtyNutrisystemDirectToConsumerMember_us-gaapStatementBusinessSegmentsAxis_tvtyNutritionMember_20200401_20200630", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Revenue Recognition - Summary of Information about Receivables, Contract Assets and Contract Liabilities from Contracts with Customers (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfInformationAboutReceivablesContractAssetsAndContractLiabilitiesFromContractsWithCustomersDetails", "shortName": "Revenue Recognition - Summary of Information about Receivables, Contract Assets and Contract Liabilities from Contracts with Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Revenue Recognition - Summary of Significant Changes in Contract Liabilities (Deferred Revenue) Balance (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfSignificantChangesInContractLiabilitiesDeferredRevenueBalanceDetails", "shortName": "Revenue Recognition - Summary of Significant Changes in Contract Liabilities (Deferred Revenue) Balance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Revenue Recognition - Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueFromPrepaidGiftCardsExpectedToBeRecognizedInFutureRelatedToPerformanceObligationUnsatisfiedOrPartiallySatisfiedDetails", "shortName": "Revenue Recognition - Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2020-07-01_20200630", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Revenue Recognition - Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied (Details 1)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueFromPrepaidGiftCardsExpectedToBeRecognizedInFutureRelatedToPerformanceObligationUnsatisfiedOrPartiallySatisfiedDetails1", "shortName": "Revenue Recognition - Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied (Details 1)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Revenue Recognition - Additional Information (Details 1)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails1", "shortName": "Revenue Recognition - Additional Information (Details 1)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Inventories - Additional Information (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureInventoriesAdditionalInformationDetails", "shortName": "Inventories - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillImpairmentLoss", "span", "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails", "shortName": "Intangible Assets and Goodwill - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTradeNamesMember_20191231", "decimals": "-5", "lang": null, "name": "us-gaap:IndefiniteLivedTradeNames", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Intangible Assets and Goodwill - Reconciliation of Goodwill Balance (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillReconciliationOfGoodwillBalanceDetails", "shortName": "Intangible Assets and Goodwill - Reconciliation of Goodwill Balance (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "p", "tvty:MarketingExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Marketing Expenses - Additional Information (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureMarketingExpensesAdditionalInformationDetails", "shortName": "Marketing Expenses - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "tvty:MarketingExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_srtProductOrServiceAxis_us-gaapServiceMember_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnauditedParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_srtProductOrServiceAxis_us-gaapServiceMember_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": "INF", "first": true, "lang": null, "name": "tvty:ShareBasedCompensationArrangementByShareBasedPaymentAwardTypesOfShareBasedAwards", "reportCount": 1, "unique": true, "unitRef": "U_tvtyType", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Share-Based Compensation - Additional Information (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "shortName": "Share-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": "INF", "first": true, "lang": null, "name": "tvty:ShareBasedCompensationArrangementByShareBasedPaymentAwardTypesOfShareBasedAwards", "reportCount": 1, "unique": true, "unitRef": "U_tvtyType", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Income Taxes- Additional Information (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes- Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "tvty:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": "INF", "first": true, "lang": null, "name": "tvty:NumberOfSubleaseAgreements", "reportCount": 1, "unique": true, "unitRef": "U_tvtyAgreement", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Leases - Additional Information (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "tvty:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": "INF", "first": true, "lang": null, "name": "tvty:NumberOfSubleaseAgreements", "reportCount": 1, "unique": true, "unitRef": "U_tvtyAgreement", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "tvty:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails", "shortName": "Leases - Schedule of Components of Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "tvty:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "tvty:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "tvty:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails", "shortName": "Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "tvty:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "tvty:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200630", "decimals": "-3", "first": true, "lang": null, "name": "tvty:DebtNetOfUnamortizedOriginalIssueDiscount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Debt - Summary of Debt, Net of Unamortized Deferred Loan Costs And Original Issue Discount (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails", "shortName": "Debt - Summary of Debt, Net of Unamortized Deferred Loan Costs And Original Issue Discount (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200630", "decimals": "-3", "first": true, "lang": null, "name": "tvty:DebtNetOfUnamortizedOriginalIssueDiscount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Debt - Credit Facility - Additional Information (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "shortName": "Debt - Credit Facility - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_us-gaapDerivativeInstrumentRiskAxis_tvtyInterestRateSwapAgreementMember_20190531", "decimals": "INF", "lang": null, "name": "us-gaap:DerivativeNumberOfInstrumentsHeld", "reportCount": 1, "unique": true, "unitRef": "U_tvtyAgreement", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20171106", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Commitments and Contingencies - Additional Information - (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20171106", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapInterestRateSwapMember_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapInterestRateSwapMember_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200331", "decimals": "INF", "lang": null, "name": "tvty:NumberOfTradenames", "reportCount": 1, "unique": true, "unitRef": "U_tvtyTradename", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_us-gaapDerivativeInstrumentRiskAxis_us-gaapInterestRateSwapMember_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaapCashFlowHedgingMember_us-gaapHedgingDesignationAxis_us-gaapDesignatedAsHedgingInstrumentMember_20190531", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfInterestRateDerivativesHeld", "reportCount": 1, "unique": true, "unitRef": "U_tvtyAgreement", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails", "shortName": "Derivative Instruments and Hedging Activities - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_us-gaapDerivativeInstrumentRiskAxis_us-gaapInterestRateSwapMember_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaapCashFlowHedgingMember_us-gaapHedgingDesignationAxis_us-gaapDesignatedAsHedgingInstrumentMember_20190531", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfInterestRateDerivativesHeld", "reportCount": 1, "unique": true, "unitRef": "U_tvtyAgreement", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_us-gaapDerivativeInstrumentRiskAxis_us-gaapInterestRateSwapMember_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaapCashFlowHedgingMember_us-gaapHedgingDesignationAxis_us-gaapDesignatedAsHedgingInstrumentMember_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Estimated Gross Fair Values of Derivative Instruments and Their Classification on Consolidated Balance Sheet (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails", "shortName": "Derivative Instruments and Hedging Activities - Schedule of Estimated Gross Fair Values of Derivative Instruments and Their Classification on Consolidated Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_us-gaapDerivativeInstrumentRiskAxis_us-gaapInterestRateSwapMember_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaapCashFlowHedgingMember_us-gaapHedgingDesignationAxis_us-gaapDesignatedAsHedgingInstrumentMember_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_us-gaapDerivativeInstrumentRiskAxis_us-gaapInterestRateSwapMember_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaapCashFlowHedgingMember_us-gaapHedgingDesignationAxis_us-gaapDesignatedAsHedgingInstrumentMember_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Effect of Cash Flow Hedge Accounting on Accumulated OCI (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails", "shortName": "Derivative Instruments and Hedging Activities - Schedule of Effect of Cash Flow Hedge Accounting on Accumulated OCI (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_us-gaapDerivativeInstrumentRiskAxis_us-gaapInterestRateSwapMember_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaapCashFlowHedgingMember_us-gaapHedgingDesignationAxis_us-gaapDesignatedAsHedgingInstrumentMember_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Earnings (Loss) Per Share - Reconciliation of the Numerator and Denominator of Basic and Diluted Earnings (Loss) Per Share (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails", "shortName": "Earnings (Loss) Per Share - Reconciliation of the Numerator and Denominator of Basic and Diluted Earnings (Loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "lang": null, "name": "tvty:NetIncomeAllocatedToUnvestedRestrictedStock", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_us-gaapFinancialInstrumentAxis_us-gaapInterestRateSwapMember_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIChangesInAccumulatedOCINetOfTaxDetails", "shortName": "Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_us-gaapFinancialInstrumentAxis_us-gaapInterestRateSwapMember_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Parenthetical) (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIChangesInAccumulatedOCINetOfTaxParentheticalDetails", "shortName": "Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Accumulated OCI - Schedule of Reclassifications Out of Accumulated OCI (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIScheduleOfReclassificationsOutOfAccumulatedOCIDetails", "shortName": "Accumulated OCI - Schedule of Reclassifications Out of Accumulated OCI (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_20200101_20200630", "decimals": "-3", "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20190307_20190307", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "U_tvtySegment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Segment Disclosures and Concentrations of Risk - Additional Information (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskAdditionalInformationDetails", "shortName": "Segment Disclosures and Concentrations of Risk - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "tvty:IntersegmentRevenuesAndCosts", "p", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_srtProductOrServiceAxis_tvtyWiselyWellMember_20200401_20200630", "decimals": "-5", "lang": null, "name": "tvty:IntersegmentRevenuesAndCosts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Segment Disclosures and Concentrations of Risk - Schedule of Reported Segment Revenues and Profit or Loss, Net of Intersegment Eliminations, and Reconciliation (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails", "shortName": "Segment Disclosures and Concentrations of Risk - Schedule of Reported Segment Revenues and Profit or Loss, Net of Intersegment Eliminations, and Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationIntegrationRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Segment Disclosures and Concentrations of Risk - Schedule of Total Assets by Segment (Details)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfTotalAssetsBySegmentDetails", "shortName": "Segment Disclosures and Concentrations of Risk - Schedule of Total Assets by Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_us-gaapStatementBusinessSegmentsAxis_us-gaapHealthCareMember_20200630", "decimals": "-3", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnauditedParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited", "shortName": "CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "role": "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tvty-10q_20200630.htm", "contextRef": "C_0000704415_20200101_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } } }, "segmentCount": 72, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r503" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r504" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r505" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r505" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r505" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r506" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityNumberOfEmployees": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of persons employed by the Entity", "label": "Entity Number Of Employees", "terseLabel": "Number of employees" } } }, "localname": "EntityNumberOfEmployees", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r505" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r505" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r505" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r505" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r501" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r502" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r171" ], "lang": { "en-US": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "CEO" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r281", "r283", "r428", "r429", "r430", "r431", "r432", "r433", "r453", "r490", "r492" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r281", "r283", "r428", "r429", "r430", "r431", "r432", "r433", "r453", "r490", "r492" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r166", "r255", "r259", "r454", "r489", "r491" ], "lang": { "en-US": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramParentheticalDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedBySourceDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r166", "r255", "r259", "r454", "r489", "r491" ], "lang": { "en-US": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramParentheticalDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedBySourceDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r271", "r281", "r283", "r428", "r429", "r430", "r431", "r432", "r433", "r453", "r490", "r492" ], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r271", "r281", "r283", "r428", "r429", "r430", "r431", "r432", "r433", "r453", "r490", "r492" ], "lang": { "en-US": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r171", "r420" ], "lang": { "en-US": { "role": { "label": "Title Of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails" ], "xbrltype": "domainItemType" }, "tvty_AdjustedEarningBeforeInterestTaxDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails": { "order": 10080.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Adjusted earning before interest tax depreciation and amortization.", "label": "Adjusted Earning Before Interest Tax Depreciation And Amortization", "terseLabel": "Adjusted EBITDA" } } }, "localname": "AdjustedEarningBeforeInterestTaxDepreciationAndAmortization", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "tvty_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReplacementAwardsRelatedToMergerAndAttributableToPreCombinationServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Adjustments to additional paid in capital share-based compensation replacement awards related to merger and attributable to pre-combination services.", "label": "Adjustments To Additional Paid In Capital Share Based Compensation Replacement Awards Related To Merger And Attributable To Pre Combination Services", "terseLabel": "Share-based compensation replacement awards related to Merger and attributable to pre-combination services" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReplacementAwardsRelatedToMergerAndAttributableToPreCombinationServices", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "tvty_AmortizationAndWriteOffOfDeferredLoanCosts": { "auth_ref": [], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization and write-off of deferred loan costs.", "label": "Amortization And Write Off Of Deferred Loan Costs", "terseLabel": "Amortization and write-off of deferred loan costs" } } }, "localname": "AmortizationAndWriteOffOfDeferredLoanCosts", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "tvty_BasisOfPresentationAndRecentDevelopmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Basis of presentation and recent developments.", "label": "Basis Of Presentation And Recent Developments [Line Items]", "terseLabel": "Basis Of Presentation And Recent Developments [Line Items]" } } }, "localname": "BasisOfPresentationAndRecentDevelopmentsLineItems", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "tvty_BasisOfPresentationAndRecentDevelopmentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Basis of presentation and recent developments.", "label": "Basis Of Presentation And Recent Developments [Table]", "terseLabel": "Basis Of Presentation And Recent Developments [Table]" } } }, "localname": "BasisOfPresentationAndRecentDevelopmentsTable", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "tvty_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash paid for amounts included in the measurement of lease liabilities.", "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "stringItemType" }, "tvty_ChangeInDeferredTaxAssetTaxCredits": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Change in deferred tax asset, tax credits.", "label": "Change In Deferred Tax Asset Tax Credits", "terseLabel": "Reduction in deferred tax asset related to income tax credits" } } }, "localname": "ChangeInDeferredTaxAssetTaxCredits", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tvty_ContractWithCustomerInitialTerms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract with customer initial terms.", "label": "Contract With Customer Initial Terms", "terseLabel": "Contract with customer initial terms" } } }, "localname": "ContractWithCustomerInitialTerms", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "tvty_ContractWithCustomerNumberOfPerformanceObligations": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of performance obligations in contract with customer.", "label": "Contract With Customer Number Of Performance Obligations", "terseLabel": "Number of performance obligations" } } }, "localname": "ContractWithCustomerNumberOfPerformanceObligations", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "tvty_ContractWithCustomersNumberOfPerformanceObligationUnsatisfied": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract with customers, number of performance obligation unsatisfied.", "label": "Contract With Customers Number Of Performance Obligation Unsatisfied", "terseLabel": "Number of performance obligation unsatisfied" } } }, "localname": "ContractWithCustomersNumberOfPerformanceObligationUnsatisfied", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "tvty_CovidNineteenCosts": { "auth_ref": [], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails": { "order": 10040.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Covid nineteen costs.", "label": "Covid Nineteen Costs", "terseLabel": "COVID-19 costs" } } }, "localname": "CovidNineteenCosts", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "tvty_CovidNineteenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Covid nineteen.", "label": "Covid Nineteen [Member]", "terseLabel": "COVID-19" } } }, "localname": "CovidNineteenMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_CreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A credit facility agreement which includes revolving credit and term loan facility.", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement" } } }, "localname": "CreditAgreementMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_DebtInstrumentMarginRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Refers to the margin rate on the debt instrument.", "label": "Debt Instrument Margin Rate", "terseLabel": "Margin rate" } } }, "localname": "DebtInstrumentMarginRate", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tvty_DebtInstrumentPeriodicPaymentPercentageOfOriginalPrincipalAmount": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments expressed as a percent of the original principal amount of debt instrument.", "label": "Debt Instrument Periodic Payment Percentage Of Original Principal Amount", "terseLabel": "Periodic principal payment as percentage of aggregate principal amount" } } }, "localname": "DebtInstrumentPeriodicPaymentPercentageOfOriginalPrincipalAmount", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tvty_DebtInstrumentPrepaymentsDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument prepayments description.", "label": "Debt Instrument Prepayments Description", "verboseLabel": "Debt instrument, prepayments description" } } }, "localname": "DebtInstrumentPrepaymentsDescription", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "tvty_DebtInstrumentPrepaymentsExcessCashFlowPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument prepayments excess cash flow percentage.", "label": "Debt Instrument Prepayments Excess Cash Flow Percentage", "terseLabel": "Excess cash flow percentage" } } }, "localname": "DebtInstrumentPrepaymentsExcessCashFlowPercentage", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tvty_DebtInstrumentVariableRateBasis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.", "label": "Debt Instrument Variable Rate Basis", "terseLabel": "Variable rate basis" } } }, "localname": "DebtInstrumentVariableRateBasis", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tvty_DebtNetOfUnamortizedOriginalIssueDiscount": { "auth_ref": [], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails": { "order": 10010.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and before debt issuance costs, of debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper.", "label": "Debt Net Of Unamortized Original Issue Discount", "terseLabel": "Debt, net of unamortized original issue discount" } } }, "localname": "DebtNetOfUnamortizedOriginalIssueDiscount", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails" ], "xbrltype": "monetaryItemType" }, "tvty_DeferredLoanCostsAndOriginalIssueDiscount": { "auth_ref": [], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails": { "order": 10020.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred loan costs and original issue discount.", "label": "Deferred Loan Costs And Original Issue Discount", "negatedLabel": "Less: deferred loan costs and original issue discount" } } }, "localname": "DeferredLoanCostsAndOriginalIssueDiscount", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails" ], "xbrltype": "monetaryItemType" }, "tvty_DeferredTaxAssetChangeInIncomeTaxExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred tax asset, change in Income tax expense.", "label": "Deferred Tax Asset Change In Income Tax Expense", "terseLabel": "Increase in income tax expense" } } }, "localname": "DeferredTaxAssetChangeInIncomeTaxExpense", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tvty_DerivativeMaturityMonthYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derivative maturity month year.", "label": "Derivative Maturity Month Year", "terseLabel": "Derivative maturity month and year" } } }, "localname": "DerivativeMaturityMonthYear", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "tvty_ExecutiveOfficersAndOtherEmployeesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Executive officers and other employees.", "label": "Executive Officers And Other Employees [Member]", "terseLabel": "Executive Officers and Other Employees" } } }, "localname": "ExecutiveOfficersAndOtherEmployeesMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_FederalFundsRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The federal funds rate is the interest rate at which depository institutions actively trade balances held at the Federal Reserve, called federal funds, with each other, usually overnight, on an uncollateralized basis.", "label": "Federal Funds Rate [Member]", "terseLabel": "Federal Funds Rate" } } }, "localname": "FederalFundsRateMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_IncreaseDecreaseInContractWithCustomerLiabilityCashReceivedExcludingAmountRecognizedAsRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Customer liability increase due to cash received for prepaid gift cards sold or unshipped food excluding amounts recognized as revenue.", "label": "Increase Decrease In Contract With Customer Liability Cash Received Excluding Amount Recognized As Revenue", "terseLabel": "Increases due to cash received for prepaid gift cards sold or unshipped food, excluding amounts recognized as revenue, and (decreases) due to returns" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiabilityCashReceivedExcludingAmountRecognizedAsRevenue", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfSignificantChangesInContractLiabilitiesDeferredRevenueBalanceDetails" ], "xbrltype": "monetaryItemType" }, "tvty_IncrementalExpenseIncurredDueToShortageOfWorkers": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Incremental expense incurred due to shortage of workers.", "label": "Incremental Expense Incurred Due To Shortage Of Workers", "terseLabel": "Incremental expense incurred due to shortage of workers" } } }, "localname": "IncrementalExpenseIncurredDueToShortageOfWorkers", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tvty_InterestRateSwapAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate swap agreement.", "label": "Interest Rate Swap Agreement [Member]", "terseLabel": "Interest Rate Swap Agreements" } } }, "localname": "InterestRateSwapAgreementMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_IntersegmentRevenuesAndCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Intersegment revenues and costs.", "label": "Intersegment Revenues And Costs", "terseLabel": "Intersegment revenues and costs" } } }, "localname": "IntersegmentRevenuesAndCosts", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tvty_LeaseCostBeforeSubleases": { "auth_ref": [], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails": { "order": 10010.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Lease cost before subleases.", "label": "Lease Cost Before Subleases", "totalLabel": "Total lease cost before subleases" } } }, "localname": "LeaseCostBeforeSubleases", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "tvty_LeaseRemainingTermOfContract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease remaining term of contract.", "label": "Lease Remaining Term Of Contract", "terseLabel": "Remaining lease terms" } } }, "localname": "LeaseRemainingTermOfContract", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "tvty_LeasesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leases disclosure.", "label": "Leases Disclosure [Text Block]", "terseLabel": "Leases" } } }, "localname": "LeasesDisclosureTextBlock", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "tvty_LongTermLiabilitiesCurrentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term liabilities current.", "label": "Long Term Liabilities Current [Member]", "terseLabel": "Current Portion of Long-term Liabilities" } } }, "localname": "LongTermLiabilitiesCurrentMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "tvty_MarketStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shares or units awarded to employees for meeting certain market targets.", "label": "Market Stock Units [Member]", "terseLabel": "Market-based stock units" } } }, "localname": "MarketStockUnitsMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "tvty_MarketingExpenseDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Marketing expense disclosure.", "label": "Marketing Expense Disclosure [Text Block]", "terseLabel": "Marketing Expenses" } } }, "localname": "MarketingExpenseDisclosureTextBlock", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureMarketingExpenses" ], "xbrltype": "textBlockItemType" }, "tvty_NetIncomeAllocatedToUnvestedRestrictedStock": { "auth_ref": [], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails": { "order": 10020.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Net income allocated to unvested restricted stock.", "label": "Net Income Allocated To Unvested Restricted Stock", "negatedLabel": "Net income allocated to unvested restricted stock" } } }, "localname": "NetIncomeAllocatedToUnvestedRestrictedStock", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "tvty_NetLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net leverage ratio.", "label": "Net Leverage Ratio", "terseLabel": "Net leverage ratio" } } }, "localname": "NetLeverageRatio", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tvty_NetLeverageRatioForNextTwelveMonth": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net leverage ratio for next twelve month.", "label": "Net Leverage Ratio For Next Twelve Month", "terseLabel": "Net leverage ratio for next twelve month" } } }, "localname": "NetLeverageRatioForNextTwelveMonth", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "tvty_NetLeverageRatioInYearTwo": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net leverage ratio in year two.", "label": "Net Leverage Ratio In Year Two", "terseLabel": "Net leverage ratio in year two" } } }, "localname": "NetLeverageRatioInYearTwo", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "tvty_NetLeverageRatioOne": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net leverage ratio one.", "label": "Net Leverage Ratio One", "terseLabel": "Net leverage ratio one" } } }, "localname": "NetLeverageRatioOne", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "tvty_NetLeverageRatioThereafter": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net leverage ratio thereafter.", "label": "Net Leverage Ratio Thereafter", "terseLabel": "Net leverage ratio thereafter" } } }, "localname": "NetLeverageRatioThereafter", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "tvty_NonManagementMembersOfBoardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Non-management members of board.", "label": "Non Management Members Of Board [Member]", "terseLabel": "Non-management Members of Board" } } }, "localname": "NonManagementMembersOfBoardMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_NumberOfPrograms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Refers to number of programs under which the organization is carrying out its operations.", "label": "Number Of Programs", "terseLabel": "Number of programs" } } }, "localname": "NumberOfPrograms", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "tvty_NumberOfSourcesForRevenueRecognition": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of sources for revenue recognition.", "label": "Number Of Sources For Revenue Recognition", "terseLabel": "Number of sources for revenue recognition" } } }, "localname": "NumberOfSourcesForRevenueRecognition", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "tvty_NumberOfSubleaseAgreements": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of sublease agreements.", "label": "Number Of Sublease Agreements", "terseLabel": "Number of sublease agreements" } } }, "localname": "NumberOfSubleaseAgreements", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "tvty_NumberOfTradenames": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of tradenames.", "label": "Number Of Tradenames", "terseLabel": "Number of tradenames" } } }, "localname": "NumberOfTradenames", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "tvty_NutrisystemDirectToConsumerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nutrisystem direct to consumer.", "label": "Nutrisystem Direct To Consumer [Member]", "terseLabel": "Nutrisystem Direct to Consumer" } } }, "localname": "NutrisystemDirectToConsumerMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedBySourceDetails" ], "xbrltype": "domainItemType" }, "tvty_NutrisystemIncorporationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nutrisystem Incorporation.", "label": "Nutrisystem Incorporation [Member]", "verboseLabel": "Nutrisystem" } } }, "localname": "NutrisystemIncorporationMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_NutrisystemMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nutrisystem.", "label": "Nutrisystem [Member]", "terseLabel": "Nutrisystem" } } }, "localname": "NutrisystemMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_NutritionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nutrition.", "label": "Nutrition [Member]", "terseLabel": "Nutrition" } } }, "localname": "NutritionMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillReconciliationOfGoodwillBalanceDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedBySourceDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionTables", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfTotalAssetsBySegmentDetails" ], "xbrltype": "domainItemType" }, "tvty_OneMonthLondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market in a given month.", "label": "One Month London Interbank Offered Rate L I B O R [Member]", "terseLabel": "One-Month LIBOR" } } }, "localname": "OneMonthLondonInterbankOfferedRateLIBORMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_OtherLongTermLiabilitiesCurrentMaturities": { "auth_ref": [], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10220.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other long-term liabilities, classified as current.", "label": "Other Long Term Liabilities Current Maturities", "terseLabel": "Current portion of other long-term liabilities" } } }, "localname": "OtherLongTermLiabilitiesCurrentMaturities", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "tvty_PercentageOfAdditionalEmployeesFurloughed": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of additional employees furloughed.", "label": "Percentage Of Additional Employees Furloughed", "terseLabel": "Percentage of additional employees furloughed" } } }, "localname": "PercentageOfAdditionalEmployeesFurloughed", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tvty_PercentageOfConsolidatedEBITDA": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of consolidated EBITDA.", "label": "Percentage Of Consolidated E B I T D A", "terseLabel": "Percentage of consolidated EBITDA requirement" } } }, "localname": "PercentageOfConsolidatedEBITDA", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tvty_PercentageOfEmployeesFurloughed": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of employees furloughed.", "label": "Percentage Of Employees Furloughed", "terseLabel": "Percentage of employees furloughed" } } }, "localname": "PercentageOfEmployeesFurloughed", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tvty_PercentageOfEmployeesTerminated": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of employees terminated.", "label": "Percentage Of Employees Terminated", "terseLabel": "Percentage of employees terminated" } } }, "localname": "PercentageOfEmployeesTerminated", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tvty_PercentageOfFitnessPartnerLocationsHavingAtLeastOneVisit": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of fitness partner locations having at least one visit.", "label": "Percentage Of Fitness Partner Locations Having At Least One Visit", "terseLabel": "Percentage of fitness partner locations having at least one visit" } } }, "localname": "PercentageOfFitnessPartnerLocationsHavingAtLeastOneVisit", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tvty_PercentageOfReductionInAnnualCashRetainerAndAnnualCommitteeRetainersPayable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of reduction in annual cash retainer and annual committee retainers payable.", "label": "Percentage Of Reduction In Annual Cash Retainer And Annual Committee Retainers Payable", "terseLabel": "Percentage of reduction in annual cash retainer and annual committee retainers payable" } } }, "localname": "PercentageOfReductionInAnnualCashRetainerAndAnnualCommitteeRetainersPayable", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tvty_PercentageOfReductionInBaseSalary": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of reduction in base salary.", "label": "Percentage Of Reduction In Base Salary", "terseLabel": "Percentage of reduction in base salary" } } }, "localname": "PercentageOfReductionInBaseSalary", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tvty_PrepaymentsConditionFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prepayments condition four.", "label": "Prepayments Condition Four [Member]", "terseLabel": "Net Leverage Ratio Equal To or Less Than 2.75:1" } } }, "localname": "PrepaymentsConditionFourMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_PrepaymentsConditionOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prepayments condition one.", "label": "Prepayments Condition One [Member]", "terseLabel": "Net Leverage Ratio Greater Than 3.75:1" } } }, "localname": "PrepaymentsConditionOneMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_PrepaymentsConditionThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prepayments condition three.", "label": "Prepayments Condition Three [Member]", "terseLabel": "Net Leverage Ratio Equal To or Less Than 3.25:1 but Greater Than 2.75:1" } } }, "localname": "PrepaymentsConditionThreeMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_PrepaymentsConditionTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prepayments condition two.", "label": "Prepayments Condition Two [Member]", "terseLabel": "Net Leverage Ratio Equal To or Less Than 3.75:1 but Greater Than 3.25:1" } } }, "localname": "PrepaymentsConditionTwoMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_PrimeFitnessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prime Fitness is a fitness facility access program, through contracts with employers and with commercial health plans that allow their members to individually purchase the program.", "label": "Prime Fitness [Member]", "terseLabel": "Prime Fitness" } } }, "localname": "PrimeFitnessMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramDetails" ], "xbrltype": "domainItemType" }, "tvty_PurchaseOrderCanceledOfDeliveryPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase order canceled of delivery period.", "label": "Purchase Order Canceled Of Delivery Period", "terseLabel": "Purchase order canceled of delivery, period" } } }, "localname": "PurchaseOrderCanceledOfDeliveryPeriod", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "tvty_QVCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "QVC.", "label": "Q V C [Member]", "terseLabel": "QVC" } } }, "localname": "QVCMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedBySourceDetails" ], "xbrltype": "domainItemType" }, "tvty_ReductionPeriodOfAnnualCashRetainerAndAnnualCommitteeRetainersPayable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reduction period of annual cash retainer and annual committee retainers payable.", "label": "Reduction Period Of Annual Cash Retainer And Annual Committee Retainers Payable", "terseLabel": "Reduction period of annual cash retainer and annual committee retainers payable" } } }, "localname": "ReductionPeriodOfAnnualCashRetainerAndAnnualCommitteeRetainersPayable", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "tvty_ReturnOfPurchaseOrderToRefundPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Return of purchase order to refund period.", "label": "Return Of Purchase Order To Refund Period", "terseLabel": "Return of purchase order to refund or credit, period" } } }, "localname": "ReturnOfPurchaseOrderToRefundPeriod", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "tvty_RevenueFromContractWithCustomerProvisionForReturns": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Revenue from contract with customer provision for returns.", "label": "Revenue From Contract With Customer Provision For Returns", "terseLabel": "Provision for estimated returns" } } }, "localname": "RevenueFromContractWithCustomerProvisionForReturns", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tvty_RevenueFromContractWithCustomerReservesForSalesReturns": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue from contract with customer reserves for sales returns,", "label": "Revenue From Contract With Customer Reserves For Sales Returns", "terseLabel": "Reserve for estimated returns" } } }, "localname": "RevenueFromContractWithCustomerReservesForSalesReturns", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tvty_RevenuePerformanceObligationPeriodOfBillingInArrearsUponTimingOfServicesAreKnown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Refers to the period of billing in arrears once the timing of services to customers is known in contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Revenue Performance Obligation Period Of Billing In Arrears Upon Timing Of Services Are Known", "terseLabel": "Period of billing in arrears once timing of services to customers is known" } } }, "localname": "RevenuePerformanceObligationPeriodOfBillingInArrearsUponTimingOfServicesAreKnown", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "tvty_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of finite and indefinite lived intangible assets.", "label": "Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]", "terseLabel": "Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]" } } }, "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsLineItems", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "tvty_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of finite and indefinite lived intangible assets.", "label": "Schedule Of Finite And Indefinite Lived Intangible Assets [Table]", "terseLabel": "Schedule Of Finite And Indefinite Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "tvty_ScheduleOfReconciliationOfOurGoodwill": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of reconciliation of our goodwill.", "label": "Schedule Of Reconciliation Of Our Goodwill", "terseLabel": "Schedule of Reconciliation of Our Goodwill" } } }, "localname": "ScheduleOfReconciliationOfOurGoodwill", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillTables" ], "xbrltype": "textBlockItemType" }, "tvty_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of supplemental cash flow information related to leases.", "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]", "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases" } } }, "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "tvty_ShareBasedCompensationArrangementByShareBasedPaymentAwardTypesOfShareBasedAwards": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of types of share-based awards outstanding to employees and directors.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Types Of Share Based Awards", "terseLabel": "Types of share based awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTypesOfShareBasedAwards", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "tvty_SilverSneakersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Silver sneakers.", "label": "Silver Sneakers [Member]", "terseLabel": "SilverSneakers" } } }, "localname": "SilverSneakersMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramDetails" ], "xbrltype": "domainItemType" }, "tvty_SilverSneakersSeniorFitnessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "SilverSneakers senior fitness program is provided to members of Medicare Advantage, Medicare Supplement, and Group Retiree plans through contracts with such plans.", "label": "Silver Sneakers Senior Fitness [Member]", "terseLabel": "SilverSneakers Senior Fitness" } } }, "localname": "SilverSneakersSeniorFitnessMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_SouthBeachDietDirectToConsumerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "South Beach Diet direct to consumer.", "label": "South Beach Diet Direct To Consumer [Member]", "terseLabel": "South Beach Diet Direct to Consumer" } } }, "localname": "SouthBeachDietDirectToConsumerMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedBySourceDetails" ], "xbrltype": "domainItemType" }, "tvty_SupplementalNoncashInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supplemental noncash information.", "label": "Supplemental Noncash Information [Abstract]", "terseLabel": "Supplemental noncash information:" } } }, "localname": "SupplementalNoncashInformationAbstract", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "stringItemType" }, "tvty_SwinglineSubFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A large loan that a company may take out in order to repay other debts. A swingline loan is much like a line of credit or a demand loan, but differs in that it must be used to repay outstanding debt.", "label": "Swingline Sub Facility [Member]", "terseLabel": "Swingline Sub Facility" } } }, "localname": "SwinglineSubFacilityMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_TermForCustomerToMakePaymentAfterBeingInvoiced": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between invoice being sent to customer and when payment is due, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Term For Customer To Make Payment After Being Invoiced", "terseLabel": "Number of days for customer to make payment after being invoiced" } } }, "localname": "TermForCustomerToMakePaymentAfterBeingInvoiced", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "tvty_TermLoanFacilityAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A loan from a bank for a specified amount that has a specified repayment schedule and a floating interest rate.", "label": "Term Loan Facility A [Member]", "terseLabel": "Term Loan Facility A", "verboseLabel": "Term Loan A" } } }, "localname": "TermLoanFacilityAMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails" ], "xbrltype": "domainItemType" }, "tvty_TermLoanFacilityBMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term loan facility B.", "label": "Term Loan Facility B [Member]", "terseLabel": "Term Loan Facility B", "verboseLabel": "Term Loan B" } } }, "localname": "TermLoanFacilityBMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails" ], "xbrltype": "domainItemType" }, "tvty_TermLoansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term loans.", "label": "Term Loans [Member]", "terseLabel": "Term Loans" } } }, "localname": "TermLoansMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_TransitionCosts": { "auth_ref": [], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails": { "order": 10030.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Transition costs.", "label": "Transition Costs", "terseLabel": "CEO transition costs" } } }, "localname": "TransitionCosts", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "tvty_UncommittedIncrementalAccordionFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A type of option that a borrower can have inserted into a syndicated credit agreement at the outset of the transaction which allows it to increase the principal under the credit agreement, subject to there being no event of default. The interest, maturity and other terms applicable to the increased commitment will be identical to those applicable to the existing credit facility to which the increase relates. Companies typically purchase an accordion feature in anticipation of the need for more capital for possible expansion opportunities.", "label": "Uncommitted Incremental Accordion Facility [Member]", "terseLabel": "Uncommitted Incremental Accordion Facility" } } }, "localname": "UncommittedIncrementalAccordionFacilityMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_WellBeingProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Well-being program.", "label": "Well Being Program [Member]", "terseLabel": "Well-Being Program" } } }, "localname": "WellBeingProgramMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramParentheticalDetails" ], "xbrltype": "domainItemType" }, "tvty_WholeHealthLivingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "WholeHealth Living program is sold primarily to health plans.", "label": "Whole Health Living [Member]", "terseLabel": "WholeHealth Living" } } }, "localname": "WholeHealthLivingMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramDetails" ], "xbrltype": "domainItemType" }, "tvty_WiselyWellMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Wisely well.", "label": "Wisely Well [Member]", "terseLabel": "Wisely Well" } } }, "localname": "WiselyWellMember", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tvty_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Working capital deficit.", "label": "Working Capital Deficit", "terseLabel": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://www.tivityhealth.com/20200630", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r18", "r172", "r173" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10310.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable Net Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10160.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued Liabilities" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r26", "r211" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "terseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income Loss [Line Items]", "terseLabel": "Changes in accumulated OCI, net of tax [Roll Forward]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIChangesInAccumulatedOCINetOfTaxDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r49", "r51", "r52", "r477", "r497", "r500" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10130.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r392", "r393", "r394", "r395", "r396", "r398" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income Loss [Table]", "terseLabel": "Accumulated Other Comprehensive Income Loss [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIChangesInAccumulatedOCINetOfTaxDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r48", "r52", "r54", "r94", "r95", "r96", "r341", "r493", "r494" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19", "r299" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10100.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid In Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r94", "r95", "r96", "r295", "r296", "r297" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Adjustments Related To Tax Withholding For Share Based Compensation", "negatedLabel": "Tax withholding for share-based compensation" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments To Additional Paid In Capital Other", "terseLabel": "Other" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r284", "r286", "r301", "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Share-based employee compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r304" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Media expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureMarketingExpensesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r286", "r292", "r300" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Share-based compensation costs" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r71", "r85", "r401" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization Of Debt Discount Premium", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Dilutive securities outstanding not included in the computation of earnings per share because their effect is anti-dilutive (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r85", "r209" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails": { "order": 10020.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 }, "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 10100.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "positiveLabel": "Impairment of goodwill and intangible assets", "terseLabel": "Impairment loss" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r88", "r148", "r155", "r162", "r177", "r337", "r342", "r390", "r460", "r475" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets", "verboseLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfTotalAssetsBySegmentDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r10", "r41", "r88", "r177", "r337", "r342", "r390" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10230.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r287", "r293" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r355", "r360" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation and Recent Developments" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r280", "r282" ], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r280", "r282", "r331", "r332" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails": { "order": 10010.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination Integration Related Costs", "terseLabel": "Acquisition and integration costs" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostNet": { "auth_ref": [ "r195" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized Contract Cost Net", "terseLabel": "Capitalized costs" } } }, "localname": "CapitalizedContractCostNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r386", "r387" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Carrying Reported Amount Fair Value Disclosure [Member]", "terseLabel": "Carrying Value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r25", "r87" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10300.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash And Cash Equivalents Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r82", "r391" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r352" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedges" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r36", "r225", "r464", "r481" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingent liabilities" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r222", "r223", "r224", "r227" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r94", "r95" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r231" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10090.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common Stock $.001 par value, 120,000,000 shares authorized, 48,548,741 and 48,156,786 shares outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r56", "r58", "r59", "r66", "r469", "r485" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "verboseLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r56", "r58", "r65", "r336", "r346", "r468", "r484" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest", "terseLabel": "Comprehensive income (loss)", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r64", "r72", "r467", "r483" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income Note [Text Block]", "terseLabel": "Accumulated OCI" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCI" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r133", "r134", "r169", "r388", "r389" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage1", "terseLabel": "Percentage of concentration risk" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract With Customer Asset And Liability Table [Text Block]", "terseLabel": "Summary of Information about Contract Assets and Contract Liabilities from Contracts with Customers" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r239", "r241", "r256" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract With Customer Asset Net", "terseLabel": "Contract assets" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfInformationAboutReceivablesContractAssetsAndContractLiabilitiesFromContractsWithCustomersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r239", "r240", "r256" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract With Customer Liability", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfInformationAboutReceivablesContractAssetsAndContractLiabilitiesFromContractsWithCustomersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r239", "r240", "r256" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10170.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract With Customer Liability Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r257" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract With Customer Liability Revenue Recognized", "terseLabel": "Revenue recognized that was included in the contract liability (deferred revenue) balance on January 1, 2020" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfSignificantChangesInContractLiabilitiesDeferredRevenueBalanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": { "auth_ref": [ "r248" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.", "label": "Contract With Customer Performance Obligation Satisfied In Previous Period", "terseLabel": "Revenue recognized from performance obligations satisfied in prior period" } } }, "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r69", "r454" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 10060.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost Of Goods And Services Sold", "terseLabel": "Total cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSoldDepreciation": { "auth_ref": [ "r68", "r210" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service.", "label": "Cost Of Goods And Services Sold Depreciation", "terseLabel": "Depreciation" } } }, "localname": "CostOfGoodsAndServicesSoldDepreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.", "label": "Cost Of Goods And Services Sold Depreciation And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cost Of Revenue [Abstract]", "terseLabel": "Cost of revenue:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r13", "r14", "r15", "r461", "r462", "r474" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument Basis Spread On Variable Rate1", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r15", "r228", "r462", "r474" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Debt Instrument Carrying Amount", "terseLabel": "Debt instrument carrying amount" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r402", "r404" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument Face Amount", "terseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r385" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument Fair Value", "terseLabel": "Debt instrument fair value" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r33", "r380" ], "lang": { "en-US": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.", "label": "Debt Instrument Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r34", "r90", "r232", "r233", "r234", "r235", "r401", "r402", "r404", "r473" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Longterm And Shortterm Combined Amount [Abstract]" } } }, "localname": "DebtLongtermAndShorttermCombinedAmountAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r85", "r89", "r315", "r323", "r324", "r325" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense Benefit", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r305", "r306" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10050.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities Net", "terseLabel": "Long-term deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r85", "r143" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails": { "order": 10070.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 }, "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 10090.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation Depletion And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract Type [Domain]", "terseLabel": "Derivative Contract" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r42", "r45", "r358", "r435" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Fair Value Of Derivative Liability", "terseLabel": "Liabilities measured at fair value" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative Fixed Interest Rate", "terseLabel": "Derivative, fixed interest rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r356", "r359", "r364", "r367" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument Risk [Axis]", "terseLabel": "Derivative Instrument" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments And Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments And Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Instruments and Hedging Activities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r353", "r356", "r364" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Derivative Instruments Gain Loss By Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r353", "r356", "r364", "r367", "r368", "r371", "r373" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments Gain Loss By Hedging Relationship By Income Statement Location By Derivative Instrument Risk [Table]", "terseLabel": "Derivative Instruments Gain Loss By Hedging Relationship By Income Statement Location By Derivative Instrument Risk [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments Gain Loss [Line Items]", "terseLabel": "Derivative Instruments Gain Loss [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": { "auth_ref": [ "r363", "r366" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.", "label": "Derivative Instruments Gain Loss Reclassified From Accumulated O C I Into Income Effective Portion Net", "terseLabel": "Gain (loss) related to effective portion of derivatives reclassified from accumulated OCI to interest expense, gross of tax effect" } } }, "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r43", "r44", "r385" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liabilities", "totalLabel": "Derivative liabilities" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "DerivativeLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails": { "order": 10010.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liabilities Current", "terseLabel": "Current portion of long-term liabilities" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails": { "order": 10020.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liabilities Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r349", "r351" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative Notional Amount", "terseLabel": "Derivative, notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "auth_ref": [ "r349", "r351" ], "lang": { "en-US": { "role": { "documentation": "The number of derivative instruments of a particular group held by the entity.", "label": "Derivative Number Of Instruments Held", "terseLabel": "Number of agreements held for maturity" } } }, "localname": "DerivativeNumberOfInstrumentsHeld", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r348", "r350", "r351", "r353", "r354", "r361", "r364", "r369", "r370", "r373" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives Fair Value [Line Items]", "terseLabel": "Derivatives Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r353" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated As Hedging Instrument [Member]", "terseLabel": "Derivatives Designated as Hedging Instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation Of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramParentheticalDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedBySourceDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueFromPrepaidGiftCardsExpectedToBeRecognizedInFutureRelatedToPerformanceObligationUnsatisfiedOrPartiallySatisfiedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r255", "r259", "r260", "r261", "r262", "r263", "r264", "r265" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramParentheticalDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedBySourceDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueFromPrepaidGiftCardsExpectedToBeRecognizedInFutureRelatedToPerformanceObligationUnsatisfiedOrPartiallySatisfiedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue Table [Text Block]", "terseLabel": "Summary of Revenue Disaggregated" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarliestTaxYearMember": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Earliest identified tax year.", "label": "Earliest Tax Year [Member]", "terseLabel": "Earliest Tax Year" } } }, "localname": "EarliestTaxYearMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings (loss) per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r67", "r103", "r104", "r105", "r106", "r107", "r114", "r117", "r123", "r124", "r125", "r129", "r130", "r470", "r486" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share Basic", "terseLabel": "Basic", "verboseLabel": "Earnings (loss) per share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r67", "r103", "r104", "r105", "r106", "r107", "r117", "r123", "r124", "r125", "r129", "r130", "r470", "r486" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Diluted", "terseLabel": "Diluted", "verboseLabel": "Earnings (loss) per share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r126", "r127", "r128", "r131" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings (Loss) Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r391" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10040.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect Of Exchange Rate On Cash And Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Continuing Operations", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Accrued salaries and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "verboseLabel": "Non-Qualified Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Wide Revenue Major Customer [Line Items]", "terseLabel": "Entity Wide Revenue Major Customer [Line Items]" } } }, "localname": "EntityWideRevenueMajorCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r94", "r95", "r96", "r100", "r108", "r110", "r132", "r178", "r231", "r236", "r295", "r296", "r297", "r316", "r317", "r392", "r393", "r394", "r395", "r396", "r398", "r493", "r494", "r495" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]", "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r377", "r386", "r387" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value By Balance Sheet Grouping [Table]", "terseLabel": "Fair Value By Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r378", "r425", "r426", "r427" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r377", "r382" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Fair Value By Measurement Basis [Axis]", "terseLabel": "Measurement Basis" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r377", "r378", "r379", "r380", "r383" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Disclosure Item Amounts [Domain]", "terseLabel": "Fair Value Measurement" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r381" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r272", "r273", "r278", "r279", "r378", "r426" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r425", "r426", "r427" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r381", "r383" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r355", "r361", "r371" ], "lang": { "en-US": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table]", "terseLabel": "Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r407", "r412", "r419" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails": { "order": 10040.0, "parentTag": "tvty_LeaseCostBeforeSubleases", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease Interest Expense", "terseLabel": "Interest of lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r409", "r416" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease Interest Payment On Liability", "negatedLabel": "Operating cash flow attributable to finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r406" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10200.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease Liability Current", "verboseLabel": "Current portion of finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r406" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10040.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease Liability Noncurrent", "verboseLabel": "Long-term finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r408", "r416" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease Principal Payments", "negatedLabel": "Principal payments related to financing leases", "negatedTerseLabel": "Financing cash flow attributable to finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r405" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10260.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease Right Of Use Asset", "verboseLabel": "Right-of-use assets, finance leases" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r407", "r412", "r419" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails": { "order": 10030.0, "parentTag": "tvty_LeaseCostBeforeSubleases", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease Right Of Use Asset Amortization", "terseLabel": "Amortization of leased assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r175", "r176", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIChangesInAccumulatedOCINetOfTaxDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIScheduleOfReclassificationsOutOfAccumulatedOCIDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r196", "r198", "r459" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10280.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill, net" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillReconciliationOfGoodwillBalanceDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill And Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill And Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets and Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r85", "r197", "r199", "r201" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill Impairment Loss", "negatedLabel": "Impairment loss", "terseLabel": "Impairment loss of goodwill" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillReconciliationOfGoodwillBalanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillReconciliationOfGoodwillBalanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HealthCareMember": { "auth_ref": [ "r259" ], "lang": { "en-US": { "role": { "documentation": "Service provided for prevention, maintenance, diagnosis or treatment of physical and mental health.", "label": "Health Care [Member]", "terseLabel": "Healthcare" } } }, "localname": "HealthCareMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillReconciliationOfGoodwillBalanceDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionTables", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfTotalAssetsBySegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r353", "r368" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r353" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r353" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r85", "r207" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment Of Intangible Assets Indefinitelived Excluding Goodwill", "terseLabel": "Impairment loss of intangibles" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r62", "r148", "r154", "r158", "r161", "r164", "r458", "r465", "r472", "r487" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 10010.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r309", "r311", "r313", "r321", "r326", "r328", "r329", "r330" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r89", "r109", "r110", "r146", "r307", "r322", "r327", "r488" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIScheduleOfReclassificationsOutOfAccumulatedOCIDetails": { "order": 10020.0, "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "weight": 1.0 }, "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 10020.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "negatedLabel": "Income tax expense", "terseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIScheduleOfReclassificationsOutOfAccumulatedOCIDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r84" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Increase (decrease) in accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r84" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Decrease (increase) in accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r84" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10270.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase Decrease In Contract With Customer Liability", "terseLabel": "Increase (decrease) in deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r84" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase Decrease In Employee Related Liabilities", "terseLabel": "(Decrease) increase in accrued salaries and benefits" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r84" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase Decrease In Inventories", "negatedLabel": "Decrease in inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r84" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase Decrease In Other Current Assets", "negatedLabel": "Decrease in other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r84" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase Decrease In Other Current Liabilities", "terseLabel": "Decrease in other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r118", "r119", "r120", "r125" ], "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable To Share Based Payment Arrangements", "terseLabel": "Effect of dilutive stock options and restricted stock units outstanding (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r204", "r206" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite Lived Intangible Assets By Major Class [Axis]", "terseLabel": "Indefinite-lived Intangible Assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r204", "r206" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IndefiniteLivedTradeNames": { "auth_ref": [ "r206" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trade name to gain or protect exclusive use thereof for a projected indefinite period of benefit.", "label": "Indefinite Lived Trade Names", "terseLabel": "Intangible assets not subject to amortization" } } }, "localname": "IndefiniteLivedTradeNames", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r203", "r205" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10270.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets Net Excluding Goodwill", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r61", "r142", "r400", "r403", "r471" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIScheduleOfReclassificationsOutOfAccumulatedOCIDetails": { "order": 10010.0, "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "weight": 1.0 }, "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails": { "order": 10060.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 }, "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 10040.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIScheduleOfReclassificationsOutOfAccumulatedOCIDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r366" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r375" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain Loss To Be Reclassified During Next12 Months Net", "terseLabel": "Derivative amount reclassify from accumulated OCI to interest expense within next 12 months" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r365" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap Agreements", "verboseLabel": "Net Change in Fair Value of Interest Rate Swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIChangesInAccumulatedOCINetOfTaxDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIScheduleOfReclassificationsOutOfAccumulatedOCIDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureInventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r39" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10320.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r39", "r93", "r190" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Reserve for excess and obsolete inventory" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureInventoriesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r418", "r419" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease Cost", "totalLabel": "Total lease cost, net" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r418" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease Cost Table [Text Block]", "terseLabel": "Schedule of Components of Lease Expense" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee Lease Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r411" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee Lease Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter Of Credit [Member]", "terseLabel": "Letters of Credit Sub Facility" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r88", "r177", "r390", "r463", "r479" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r32", "r88", "r177", "r338", "r342", "r343", "r390" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r15", "r462", "r474" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line Of Credit", "terseLabel": "Line of credit", "verboseLabel": "Borrowed under revolving credit facility used to increase cash position" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInitiationDate1": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "Date the credit facility first became available, in CCYY-MM-DD format.", "label": "Line Of Credit Facility Initiation Date1", "terseLabel": "Initiation date" } } }, "localname": "LineOfCreditFacilityInitiationDate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line Of Credit Facility [Line Items]", "terseLabel": "Line Of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line Of Credit Facility Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payment applied to principal.", "label": "Line Of Credit Facility Periodic Payment Principal", "terseLabel": "Repayment of principal on the term loan" } } }, "localname": "LineOfCreditFacilityPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line Of Credit Facility Remaining Borrowing Capacity", "terseLabel": "Available borrowing capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r29", "r90" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line Of Credit Facility [Table]", "terseLabel": "Line Of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line Of Credit Facility Unused Capacity Commitment Fee Percentage", "terseLabel": "Unused commitment fee percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate L I B O R [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r15", "r229", "r462", "r476" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt", "positiveLabel": "Outstanding debt", "totalLabel": "Total debt", "verboseLabel": "Outstanding debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails2": { "order": 10010.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10210.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt Current", "negatedLabel": "Less: current portion", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails2": { "order": 10020.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt Noncurrent", "terseLabel": "Long-term debt", "verboseLabel": "Total non-current portion of debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyClaimsDismissedNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of claims dismissed.", "label": "Loss Contingency Claims Dismissed Number", "terseLabel": "Number of lawsuits dismissed" } } }, "localname": "LossContingencyClaimsDismissedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency New Claims Filed Number", "terseLabel": "Number of lawsuits filed" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MarketingAndAdvertisingExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Marketing And Advertising Expense [Abstract]" } } }, "localname": "MarketingAndAdvertisingExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_MarketingExpense": { "auth_ref": [ "r70" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 10070.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.", "label": "Marketing Expense", "terseLabel": "Marketing expenses" } } }, "localname": "MarketingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r82" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash flows (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r82" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash flows used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r82", "r83", "r86" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash flows provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r55", "r57", "r63", "r86", "r88", "r99", "r103", "r104", "r105", "r106", "r109", "r110", "r121", "r148", "r154", "r158", "r161", "r164", "r177", "r390", "r466", "r482" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails": { "order": 10010.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income Loss [Abstract]", "terseLabel": "Numerator [Abstract]" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r103", "r104", "r105", "r106", "r114", "r115", "r122", "r125", "r148", "r154", "r158", "r161", "r164" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income Loss Available To Common Stockholders Basic", "totalLabel": "Net income (loss) allocated to shares of Common Stock" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "New Accounting Pronouncements And Changes In Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r97", "r98", "r101", "r102", "r111", "r112", "r113", "r179", "r180", "r266", "r267", "r268", "r269", "r298", "r318", "r319", "r320", "r455", "r456", "r457", "r496", "r497", "r498", "r499", "r500" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "New Accounting Pronouncements And Changes In Accounting Principles [Text Block]", "terseLabel": "Recent Relevant Accounting Standards" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRecentRelevantAccountingStandards" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recent Relevant Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "auth_ref": [ "r349", "r351" ], "lang": { "en-US": { "role": { "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.", "label": "Number Of Interest Rate Derivatives Held", "terseLabel": "Number of amortizing interest rate swap agreements" } } }, "localname": "NumberOfInterestRateDerivativesHeld", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number Of Reportable Segments", "terseLabel": "Number of reportable segments", "verboseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OpenTaxYear": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Tax year that remains open to examination under enacted tax laws, in CCYY format.", "label": "Open Tax Year", "terseLabel": "Open tax year" } } }, "localname": "OpenTaxYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearListItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r148", "r154", "r158", "r161", "r164" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 10030.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Operating income (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r413", "r419" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails": { "order": 10050.0, "parentTag": "tvty_LeaseCostBeforeSubleases", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r406" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10190.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r406" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r410", "r416" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "negatedLabel": "Operating cash flow attributable to operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r405" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10250.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "verboseLabel": "Right-of-use assets, operating leases" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r314" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r347" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]", "terseLabel": "Basis of Presentation and Recent Developments" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopments" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10340.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10290.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r52", "r60", "r392", "r394", "r398" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income Loss Before Reclassifications Net Of Tax", "terseLabel": "Other comprehensive income (loss) before reclassifications, net" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIChangesInAccumulatedOCINetOfTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Other Comprehensive Income Loss Before Reclassifications Tax", "terseLabel": "Other comprehensive income before reclassifications, tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIChangesInAccumulatedOCINetOfTaxParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r46", "r49", "r357", "r362", "r372" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification And Tax", "negatedLabel": "Loss related to effective portion of derivatives recognized in accumulated OCI, gross of tax effect" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEffectOfCashFlowHedgeAccountingOnAccumulatedOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax": { "auth_ref": [ "r47", "r49", "r53" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) for adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease Adjustments Tax", "terseLabel": "Amounts reclassified from accumulated OCI, tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIChangesInAccumulatedOCINetOfTaxParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r46", "r49", "r374" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax", "terseLabel": "Net change in fair value of interest rate swaps, net of income tax benefit of $393, $4,068, $7,195, and $4,068, respectively" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax": { "auth_ref": [ "r46", "r50" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit), before reclassification adjustments, related to increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax", "negatedLabel": "Net change in fair value of interest rate swaps, income tax benefit" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10060.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Long-term Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesScheduleOfEstimatedGrossFairValuesOfDerivativeInstrumentsAndTheirClassificationOnConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10280.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities Cash Flow Statement", "terseLabel": "Other" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfLoanCosts": { "auth_ref": [ "r80" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for loan origination associated cost which is usually collected through escrow.", "label": "Payments Of Loan Costs", "negatedLabel": "Deferred loan costs" } } }, "localname": "PaymentsOfLoanCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r78" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payments Related To Tax Withholding For Share Based Compensation", "negatedLabel": "Payments related to tax withholding for share-based compensation" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r73" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments To Acquire Businesses Net Of Cash Acquired", "negatedLabel": "Business acquisitions, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r74" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Acquisition of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance-Based Stock Units", "verboseLabel": "Performance-Based Stock Units" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r384" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion At Fair Value Fair Value Disclosure [Member]", "terseLabel": "Fair Value Disclosure Item Amounts [Default]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r16" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred stock $.001 par value, 5,000,000 shares authorized, none outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidAdvertising": { "auth_ref": [ "r7", "r192", "r194" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration paid in advance for advertising that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Advertising", "terseLabel": "Prepaid for future advertisements and promotions" } } }, "localname": "PrepaidAdvertising", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureMarketingExpensesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r6", "r9", "r193", "r194" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10330.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r76" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds From Issuance Of Long Term Debt", "terseLabel": "Proceeds from issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r77", "r80", "r92" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds From Payments For Other Financing Activities", "terseLabel": "Change in cash overdraft and other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r75", "r294" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r259" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product And Service Other [Member]", "terseLabel": "Other" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramParentheticalDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedBySourceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r259" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Products" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r55", "r57", "r81", "r88", "r99", "r109", "r110", "r148", "r154", "r158", "r161", "r164", "r177", "r336", "r339", "r340", "r345", "r346", "r390", "r472" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r11", "r12", "r212", "r480" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10240.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net of accumulated depreciation of $53,525 and $42,510 respectively" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIScheduleOfReclassificationsOutOfAccumulatedOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r52", "r54", "r60", "r392", "r396", "r398" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIScheduleOfReclassificationsOutOfAccumulatedOCIDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax", "terseLabel": "Amounts reclassified from accumulated OCI, net of tax", "totalLabel": "Net of tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIChangesInAccumulatedOCINetOfTaxDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIScheduleOfReclassificationsOutOfAccumulatedOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification Out Of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIScheduleOfReclassificationsOutOfAccumulatedOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification Out Of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIScheduleOfReclassificationsOutOfAccumulatedOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification Out Of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassifications Out of Accumulate OCI" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIScheduleOfReclassificationsOutOfAccumulatedOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification Out Of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification Out Of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIScheduleOfReclassificationsOutOfAccumulatedOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification Out Of Accumulated Other Comprehensive Income Table [Text Block]", "terseLabel": "Schedule of Reclassifications Out of Accumulated OCI" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCITables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r155", "r158" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation Of Assets From Segment To Consolidated [Text Block]", "terseLabel": "Schedule of Total Assets by Segment" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "auth_ref": [ "r153", "r158" ], "lang": { "en-US": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation Of Revenue From Segments To Consolidated [Table]", "terseLabel": "Reconciliation Of Revenue From Segments To Consolidated [Table]" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r79", "r91" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments Of Lines Of Credit", "terseLabel": "Repayment of revolving credit facility", "verboseLabel": "Payments on term loans" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r79" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments Of Long Term Debt", "negatedLabel": "Payments of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "verboseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r85", "r215", "r218", "r219" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails": { "order": 10050.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 }, "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 10110.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring and related charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringChargesMember": { "auth_ref": [ "r216", "r218", "r220" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.", "label": "Restructuring Charges [Member]", "terseLabel": "Restructuring and Related Charges" } } }, "localname": "RestructuringChargesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetailMember": { "auth_ref": [ "r259" ], "lang": { "en-US": { "role": { "documentation": "Sale of product directly to consumer.", "label": "Retail [Member]", "terseLabel": "Retail" } } }, "localname": "RetailMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedBySourceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r236", "r299", "r478", "r496", "r500" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10110.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r94", "r95", "r96", "r100", "r108", "r110", "r178", "r295", "r296", "r297", "r316", "r317", "r493", "r495" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue From Contract With Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r139", "r140", "r153", "r159", "r160", "r166", "r167", "r169", "r254", "r255", "r454" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 10050.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Revenue", "verboseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramParentheticalDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedBySourceDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r242", "r243", "r244", "r245", "r246", "r247", "r251", "r252", "r258", "r270" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue From Contract With Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuePerformanceObligationDescriptionOfReturnsAndOtherSimilarObligations": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "Description of obligation for returns, refunds, and other similar obligations in contract with customer.", "label": "Revenue Performance Obligation Description Of Returns And Other Similar Obligations", "terseLabel": "Description of return of obligation" } } }, "localname": "RevenuePerformanceObligationDescriptionOfReturnsAndOtherSimilarObligations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuePracticalExpedientFinancingComponent": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "Indicates (true false) whether practical expedient was elected not to adjust consideration for effect of financing component when transfer and customer payment for product or service occurs within one year or less.", "label": "Revenue Practical Expedient Financing Component", "terseLabel": "Revenue, practical expedient, financing component [true false]" } } }, "localname": "RevenuePracticalExpedientFinancingComponent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails1" ], "xbrltype": "booleanItemType" }, "us-gaap_RevenuePracticalExpedientInitialApplicationAndTransitionQualitativeAssessment": { "auth_ref": [ "r266" ], "lang": { "en-US": { "role": { "documentation": "Description of assessment of estimated effect of practical expedients elected under initial application of retrospective method for completed contracts, completed contracts with variable consideration, modified contracts and disclosures of remaining performance obligation.", "label": "Revenue Practical Expedient Initial Application And Transition Qualitative Assessment", "terseLabel": "Revenue, Practical Expedient, Initial Application and Transition, Qualitative Assessment" } } }, "localname": "RevenuePracticalExpedientInitialApplicationAndTransitionQualitativeAssessment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r249" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue Remaining Performance Obligation", "terseLabel": "Revenue, remaining performance obligation, amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueFromPrepaidGiftCardsExpectedToBeRecognizedInFutureRelatedToPerformanceObligationUnsatisfiedOrPartiallySatisfiedDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueFromPrepaidGiftCardsExpectedToBeRecognizedInFutureRelatedToPerformanceObligationUnsatisfiedOrPartiallySatisfiedDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1", "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueFromPrepaidGiftCardsExpectedToBeRecognizedInFutureRelatedToPerformanceObligationUnsatisfiedOrPartiallySatisfiedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueFromPrepaidGiftCardsExpectedToBeRecognizedInFutureRelatedToPerformanceObligationUnsatisfiedOrPartiallySatisfiedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Table [Text Block]", "terseLabel": "Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtSummaryOfDebtNetOfUnamortizedDeferredLoanCostsAndOriginalIssueDiscountDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r417", "r419" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Finance Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for finance lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r417", "r419" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r52", "r397", "r398" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule Of Accumulated Other Comprehensive Income Loss Table [Text Block]", "terseLabel": "Changes in Accumulated OCI" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCITables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r363" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule Of Cash Flow Hedges Included In Accumulated Other Comprehensive Income Loss Table [Text Block]", "terseLabel": "Schedule of Effect of Cash Flow Hedge Accounting on Accumulated OCI" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule Of Debt Table [Text Block]", "terseLabel": "Summary of Debt, Net of Unamortized Deferred Loan Costs And Original Issue Discount" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule Of Derivative Instruments In Statement Of Financial Position Fair Value [Text Block]", "terseLabel": "Schedule of Estimated Gross Fair Values of Derivative Instruments and Their Classification on Consolidated Balance Sheet" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Reconciliation of the Numerator and Denominator of Basic and Diluted Earnings (Loss) Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.", "label": "Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table]", "terseLabel": "Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table]" } } }, "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r377", "r378" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]", "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r200", "r202" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule Of Goodwill [Table]", "terseLabel": "Schedule Of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillReconciliationOfGoodwillBalanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r148", "r151", "r157", "r200" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule Of Segment Reporting Information By Segment [Table]", "terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfTotalAssetsBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r148", "r151", "r157", "r200" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule Of Segment Reporting Information By Segment [Text Block]", "terseLabel": "Schedule of Reported Segment Revenues and Profit or Loss, Net of Intersegment Eliminations, and Reconciliation" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r287", "r293" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r135", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r153", "r154", "r155", "r156", "r158", "r159", "r160", "r161", "r162", "r164", "r169", "r489" ], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segment [Domain]", "terseLabel": "Segments" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillReconciliationOfGoodwillBalanceDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedBySourceDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionTables", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfTotalAssetsBySegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r135", "r137", "r138", "r148", "r152", "r158", "r162", "r163", "r164", "r165", "r166", "r168", "r169", "r170" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Disclosures and Concentrations of Risk" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRisk" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfTotalAssetsBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r70" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 10080.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling General And Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r259" ], "lang": { "en-US": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Services" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r84" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Share-based employee compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Each of share based awards, vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "auth_ref": [ "r285", "r288" ], "lang": { "en-US": { "role": { "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Description", "terseLabel": "Share based awards, description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r285", "r290" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShippingAndHandlingMember": { "auth_ref": [ "r259" ], "lang": { "en-US": { "role": { "documentation": "Packing and transport of product.", "label": "Shipping And Handling [Member]", "terseLabel": "Shipping and Handling Charges" } } }, "localname": "ShippingAndHandlingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r414", "r419" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails": { "order": 10060.0, "parentTag": "tvty_LeaseCostBeforeSubleases", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short Term Lease Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State And Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r135", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r153", "r154", "r155", "r156", "r158", "r159", "r160", "r161", "r162", "r164", "r169", "r200", "r214", "r217", "r221", "r489" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Statement Business Segments [Axis]", "terseLabel": "Segments" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillReconciliationOfGoodwillBalanceDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByProgramDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedBySourceDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionTables", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfReportedSegmentRevenuesAndProfitOrLossNetOfIntersegmentEliminationsAndReconciliationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureSegmentDisclosuresAndConcentrationsOfRiskScheduleOfTotalAssetsBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r38", "r94", "r95", "r96", "r100", "r108", "r110", "r132", "r178", "r231", "r236", "r295", "r296", "r297", "r316", "r317", "r392", "r393", "r394", "r395", "r396", "r398", "r493", "r494", "r495" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionTables", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Income And Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r94", "r95", "r96", "r132", "r454" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionTables", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r38", "r231", "r236" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period Value Acquisitions", "terseLabel": "Issuance of Common Stock in connection with Merger" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r38", "r231", "r236" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r22", "r23", "r88", "r174", "r177", "r390" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10070.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r88", "r94", "r95", "r96", "r100", "r108", "r177", "r178", "r236", "r295", "r296", "r297", "r316", "r317", "r334", "r335", "r344", "r390", "r392", "r393", "r398", "r494", "r495" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIChangesInAccumulatedOCINetOfTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r415", "r419" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails": { "order": 10020.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r399", "r421" ], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r399", "r421" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r399", "r421" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10180.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable Current", "terseLabel": "Income taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Tradename" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r175", "r176", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIChangesInAccumulatedOCINetOfTaxDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureAccumulatedOCIScheduleOfReclassificationsOutOfAccumulatedOCIDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r37", "r237" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r37", "r237" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock Shares", "terseLabel": "Treasury stock (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r37", "r237", "r238" ], "calculation": { "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited": { "order": 10120.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock Value", "negatedLabel": "Treasury stock, at cost, 2,254,953 shares in treasury" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnusualRiskOrUncertaintyByNatureAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by nature of risk and uncertainty, for example, but not limited to, threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.", "label": "Unusual Risk Or Uncertainty By Nature [Axis]", "terseLabel": "Unusual Risk or Uncertainty, Nature" } } }, "localname": "UnusualRiskOrUncertaintyByNatureAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualRiskOrUncertaintyNatureDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Describes the nature of the unusual risk or uncertainty, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.", "label": "Unusual Risk Or Uncertainty Nature [Domain]", "terseLabel": "Unusual Risk or Uncertainty, Nature" } } }, "localname": "UnusualRiskOrUncertaintyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureBasisOfPresentationAndRecentDevelopmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r312" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance Deferred Tax Asset Change In Amount", "terseLabel": "Increase in valuation allowance on deferred tax assets related to net operating loss carryforwards" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureDebtCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number Diluted Shares Outstanding Adjustment [Abstract]", "terseLabel": "Effect of dilutive stock options and restricted stock units outstanding [Abstract]" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r116", "r125" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number Of Diluted Shares Outstanding", "terseLabel": "Diluted", "verboseLabel": "Shares used for diluted income (loss) per share" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number Of Shares Outstanding [Abstract]", "terseLabel": "Weighted average common shares and equivalents:", "verboseLabel": "Denominator [Abstract]" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r114", "r125" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number Of Shares Outstanding Basic", "terseLabel": "Basic", "verboseLabel": "Shares used for basic income (loss) per share" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tivityhealth.com/20200630/taxonomy/role/DisclosureEarningsLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedEarningsLossPerShareDetails", "http://www.tivityhealth.com/20200630/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 13 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(c))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL108322424-203045" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130569-203045" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r347": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121558989&loc=d3e80720-113993" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r376": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r501": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r502": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r503": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r504": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r505": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r506": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(6)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" } }, "version": "2.1" } ZIP 88 0001564590-20-038169-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-038169-xbrl.zip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Θ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ñ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end